<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomolecules</journal-id><journal-id journal-id-type="iso-abbrev">Biomolecules</journal-id><journal-id journal-id-type="publisher-id">biomolecules</journal-id><journal-title-group><journal-title>Biomolecules</journal-title></journal-title-group><issn pub-type="epub">2218-273X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7922566</article-id><article-id pub-id-type="doi">10.3390/biom11020316</article-id><article-id pub-id-type="publisher-id">biomolecules-11-00316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2427-5482</contrib-id><name><surname>Hotinger</surname><given-names>Julia A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pendergrass</surname><given-names>Heather A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Aaron E.</given-names></name><xref rid="c1-biomolecules-11-00316" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>&#x0015a;wi&#x00119;tnicki</surname><given-names>Wies&#x00142;aw</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biomolecules-11-00316">Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23219, USA; <email>hotingerja@vcu.edu</email> (J.A.H.); <email>pendergrassha@vcu.edu</email> (H.A.P.)</aff><author-notes><corresp id="c1-biomolecules-11-00316"><label>*</label>Correspondence: <email>aemay@vcu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>11</volume><issue>2</issue><elocation-id>316</elocation-id><history><date date-type="received"><day>04</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The type III secretion system (T3SS) is a virulence apparatus used by many Gram-negative pathogenic bacteria to cause infections. Pathogens utilizing a T3SS are responsible for millions of infections yearly. Since many T3SS knockout strains are incapable of causing systemic infection, the T3SS has emerged as an attractive anti-virulence target for therapeutic design. The T3SS is a multiprotein molecular syringe that enables pathogens to inject effector proteins into host cells. These effectors modify host cell mechanisms in a variety of ways beneficial to the pathogen. Due to the T3SS&#x02019;s complex nature, there are numerous ways in which it can be targeted. This review will be focused on the direct targeting of components of the T3SS, including the needle, translocon, basal body, sorting platform, and effector proteins. Inhibitors will be considered a direct inhibitor if they have a binding partner that is a T3SS component, regardless of the inhibitory effect being structural or functional.</p></abstract><kwd-group><kwd>type III secretion system</kwd><kwd>anti-virulence</kwd><kwd>inhibition</kwd><kwd>antibacterials</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomolecules-11-00316"><title>1. Introduction</title><p>The discovery and use of antibiotics have contributed to the overall increase in life expectancy throughout the world [<xref rid="B1-biomolecules-11-00316" ref-type="bibr">1</xref>]. Notwithstanding the great success of antibiotic therapy, the over-prescription and misuse of broad-spectrum antibiotics have led to new challenges. Resistance to antibiotics threatens to make our current bacterial infection treatments ineffective [<xref rid="B2-biomolecules-11-00316" ref-type="bibr">2</xref>]. One solution to the resistance problem is the use of anti-virulence therapeutics. This involves targeting the ability of pathogens to cause and sustain infections. Anti-virulence drugs would stop or slow infection while exhibiting minimal selective pressure [<xref rid="B3-biomolecules-11-00316" ref-type="bibr">3</xref>]. One notable anti-virulence target is the type III secretion system (T3SS), a virulence factor used by pathogenic Gram-negative bacteria [<xref rid="B4-biomolecules-11-00316" ref-type="bibr">4</xref>,<xref rid="B5-biomolecules-11-00316" ref-type="bibr">5</xref>]. Some human pathogens that use T3SSs include, but are not limited to, <italic>Bordetella</italic> spp. [<xref rid="B6-biomolecules-11-00316" ref-type="bibr">6</xref>], <italic>Burkholderia</italic> spp. [<xref rid="B7-biomolecules-11-00316" ref-type="bibr">7</xref>], <italic>Chlamydia</italic> spp. [<xref rid="B8-biomolecules-11-00316" ref-type="bibr">8</xref>], enteropathogenic and enterohemorrhagic <italic>Escherichia coli</italic> (EPEC and EHEC, respectively) [<xref rid="B9-biomolecules-11-00316" ref-type="bibr">9</xref>,<xref rid="B10-biomolecules-11-00316" ref-type="bibr">10</xref>,<xref rid="B11-biomolecules-11-00316" ref-type="bibr">11</xref>], <italic>Pseudomonas aeruginosa</italic> [<xref rid="B4-biomolecules-11-00316" ref-type="bibr">4</xref>], <italic>Salmonella</italic> spp. [<xref rid="B5-biomolecules-11-00316" ref-type="bibr">5</xref>], <italic>Shigella</italic> spp. [<xref rid="B12-biomolecules-11-00316" ref-type="bibr">12</xref>], <italic>Vibrio cholerae</italic> [<xref rid="B13-biomolecules-11-00316" ref-type="bibr">13</xref>], and <italic>Yersinia</italic> spp. [<xref rid="B14-biomolecules-11-00316" ref-type="bibr">14</xref>,<xref rid="B15-biomolecules-11-00316" ref-type="bibr">15</xref>]. Pathogens targeting non-mammalian (<italic>Aeromonas</italic> spp. [<xref rid="B16-biomolecules-11-00316" ref-type="bibr">16</xref>], <italic>Edwardsiella</italic> spp. [<xref rid="B17-biomolecules-11-00316" ref-type="bibr">17</xref>], <italic>Vibrio</italic> spp. [<xref rid="B18-biomolecules-11-00316" ref-type="bibr">18</xref>]) and plant hosts (<italic>Erwinia</italic> spp. [<xref rid="B19-biomolecules-11-00316" ref-type="bibr">19</xref>], <italic>Pseudomonas syringae</italic> [<xref rid="B20-biomolecules-11-00316" ref-type="bibr">20</xref>,<xref rid="B21-biomolecules-11-00316" ref-type="bibr">21</xref>], <italic>Ralstonia</italic> spp. [<xref rid="B20-biomolecules-11-00316" ref-type="bibr">20</xref>], <italic>Xanthomonas</italic> spp. [<xref rid="B22-biomolecules-11-00316" ref-type="bibr">22</xref>]) are also found in nature. Given the conserved nature of the T3SS among pathogens, this target lends itself to the possible development of therapeutics capable of treating multiple infections, whether in human medical care, livestock upkeep, or agriculture.</p><p>The T3SS is a protein complex that secretes proteins directly from the cytosol of the bacterial pathogen into the host cell via a tube spanning the bacterial and host membranes. Any protein that has been secreted by the T3SS is considered an effector protein. Some include the T3SS needle and translocon components in this distinction due to their secondary effects as virulence factors or an outdated convention [<xref rid="B23-biomolecules-11-00316" ref-type="bibr">23</xref>,<xref rid="B24-biomolecules-11-00316" ref-type="bibr">24</xref>,<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>,<xref rid="B26-biomolecules-11-00316" ref-type="bibr">26</xref>], but in this review effector proteins will be considered any protein secreted by the completed T3SS. These molecular syringe-like injections have given the T3SS the nickname &#x0201c;the type III injectisome&#x0201d; [<xref rid="B2-biomolecules-11-00316" ref-type="bibr">2</xref>,<xref rid="B27-biomolecules-11-00316" ref-type="bibr">27</xref>,<xref rid="B28-biomolecules-11-00316" ref-type="bibr">28</xref>,<xref rid="B29-biomolecules-11-00316" ref-type="bibr">29</xref>,<xref rid="B30-biomolecules-11-00316" ref-type="bibr">30</xref>,<xref rid="B31-biomolecules-11-00316" ref-type="bibr">31</xref>]. The structure of the injectisome can be broken down into five major regions: the translocon, needle, basal body, export apparatus, and cytoplasmic complex (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>). The translocon (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, dark green) is a protein hexamer pore that is formed in the host cell membrane that binds to the needle tip and allows secreted proteins to pass into the host [<xref rid="B32-biomolecules-11-00316" ref-type="bibr">32</xref>,<xref rid="B33-biomolecules-11-00316" ref-type="bibr">33</xref>,<xref rid="B34-biomolecules-11-00316" ref-type="bibr">34</xref>,<xref rid="B35-biomolecules-11-00316" ref-type="bibr">35</xref>]. The needle tip protein (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, light green) is also considered the translocon component by some but will be considered part of the needle in this review. The needle itself is composed of helical monomers (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, yellow) that form a tube-like structure after polymerization [<xref rid="B31-biomolecules-11-00316" ref-type="bibr">31</xref>]. The needle differs in length from species to strain depending on the pathogen&#x02019;s target host [<xref rid="B36-biomolecules-11-00316" ref-type="bibr">36</xref>]. These variations will be discussed in the needle inhibition section.</p><p>The basal body is made of a dual ring system with the inner ring (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, light purple) spanning the inner bacterial membrane (IM) and the outer ring (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, dark purple) spanning the peptidoglycan layer (PG) and outer bacterial membrane (OM), anchoring the needle to the bacterial cell surface [<xref rid="B37-biomolecules-11-00316" ref-type="bibr">37</xref>]. The export apparatus (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, orange) works with the cytoplasmic complex (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, blue) to sort, guide, and power secretion, and together are called the sorting platform [<xref rid="B38-biomolecules-11-00316" ref-type="bibr">38</xref>]. The cytoplasmic complex contains an ATPase (<xref ref-type="fig" rid="biomolecules-11-00316-f001">Figure 1</xref>, dark blue) to power secretion. The sorting platform also functions as the recognition domain for effectors. It receives them from chaperone proteins and unfolds the effectors for secretion as folded proteins are too large to enter the needle (~2.5 nm inner diameter) [<xref rid="B39-biomolecules-11-00316" ref-type="bibr">39</xref>,<xref rid="B40-biomolecules-11-00316" ref-type="bibr">40</xref>,<xref rid="B41-biomolecules-11-00316" ref-type="bibr">41</xref>]. Once the secreted proteins pass into the host cell, they elicit specific responses to reprogram the host&#x02019;s machinery to enable colonization. In addition to reprogramming (<italic>Salmonella</italic> spp., <italic>Shigella</italic> spp.) [<xref rid="B29-biomolecules-11-00316" ref-type="bibr">29</xref>,<xref rid="B30-biomolecules-11-00316" ref-type="bibr">30</xref>], some effectors kill the target cells (<italic>Yersinia</italic> spp., <italic>Pseudomonas</italic> spp.) [<xref rid="B31-biomolecules-11-00316" ref-type="bibr">31</xref>,<xref rid="B39-biomolecules-11-00316" ref-type="bibr">39</xref>]. Individual pathogens can have upwards of 30 unique genes for effectors [<xref rid="B42-biomolecules-11-00316" ref-type="bibr">42</xref>,<xref rid="B43-biomolecules-11-00316" ref-type="bibr">43</xref>,<xref rid="B44-biomolecules-11-00316" ref-type="bibr">44</xref>].</p><p>Many T3SS knockout strains have attenuated or eliminated virulence, making the T3SS an attractive anti-virulence target [<xref rid="B32-biomolecules-11-00316" ref-type="bibr">32</xref>,<xref rid="B36-biomolecules-11-00316" ref-type="bibr">36</xref>,<xref rid="B40-biomolecules-11-00316" ref-type="bibr">40</xref>,<xref rid="B45-biomolecules-11-00316" ref-type="bibr">45</xref>,<xref rid="B46-biomolecules-11-00316" ref-type="bibr">46</xref>]. There have been no mammalian colonizing non-pathogenic bacteria found to use a T3SS, suggesting that agents targeting the T3SS will be selective for mammalian pathogens [<xref rid="B47-biomolecules-11-00316" ref-type="bibr">47</xref>,<xref rid="B48-biomolecules-11-00316" ref-type="bibr">48</xref>]. The highly conserved nature of the T3SS may also serve to provide a potential for cross-protection against multiple species of bacteria. There have been instances of inhibitors showing efficacy in vitro against multiple bacterial species and strains [<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>,<xref rid="B49-biomolecules-11-00316" ref-type="bibr">49</xref>,<xref rid="B50-biomolecules-11-00316" ref-type="bibr">50</xref>]. The extent of this cross-protection has yet to be investigated. This is potentially due to the high homology of the T3SS with the bacterial flagella. With this in mind, a general T3SS inhibitor may prevent the motility of commensal bacteria, resulting in a loss of many benefits to a pathogen-specific treatment. A common theme among T3SS inhibitor screening assays is a lack of toxicity to the pathogen [<xref rid="B51-biomolecules-11-00316" ref-type="bibr">51</xref>,<xref rid="B52-biomolecules-11-00316" ref-type="bibr">52</xref>]. This means the inhibitors do not exert selective pressure, potentially reducing the rate of resistance formation to these agents [<xref rid="B53-biomolecules-11-00316" ref-type="bibr">53</xref>]. T3SS inhibitors are usually discovered through in vitro assays and are known as compounds that inhibit the secretion phenotype. Given the complex nature of the needle apparatus, the molecular targets of discovered inhibitors are often unclear. Although the importance of T3SS inhibitors for plant-targeting bacteria is of high importance and has many potential applications [<xref rid="B54-biomolecules-11-00316" ref-type="bibr">54</xref>], the examples given in this review will focus on pathogens clinically relevant to veterinary and medical care. This review covers known and potential targets and strategies for direct inhibition of T3SS components.</p></sec><sec id="sec2-biomolecules-11-00316"><title>2. Needle and Translocon</title><p>The type of needle presented in the T3SS complex depends on the target organism and the colonization style of the pathogen [<xref rid="B55-biomolecules-11-00316" ref-type="bibr">55</xref>]. For example, T3SSs of plant pathogens, like <italic>P. syringae</italic>, have much longer needles (up to several &#x000b5;m) as they need to puncture through cell walls, while those infecting animals, like <italic>Yersinia enterocolitica</italic>, have shorter needles (~58 nm). Most T3SSs, however, have similar needle outer diameters, approx. 7 nm [<xref rid="B56-biomolecules-11-00316" ref-type="bibr">56</xref>]. There are seven major groups of the T3SS, the five most common are shown in <xref ref-type="fig" rid="biomolecules-11-00316-f002">Figure 2</xref> [<xref rid="B55-biomolecules-11-00316" ref-type="bibr">55</xref>,<xref rid="B56-biomolecules-11-00316" ref-type="bibr">56</xref>]. The four eukaryotic-targeting T3SS groups are Ysc, Inv-Mxi-Spa, Esc-Ssa, and Chlamydiales. They have similar needle lengths and base structure, but effectors and needle tip structure differ based upon their virulence needs. The plant pathogen groups, Hrp1, Hrp2, and RHIZ, are nearly identical in structure but vary in regulation and effectors more significantly [<xref rid="B56-biomolecules-11-00316" ref-type="bibr">56</xref>]. Some pathogens encode multiple T3SS, often from different groups, with each having separate effectors. <italic>S. enterica</italic> uses two unique T3SSs encoded by <italic>Salmonella</italic> pathogenicity islands 1 and 2 (SPI1 and SPI 2, respectively). SPI1 encodes an Inv-Mxi-Spa group T3SS for invasion, and SPI2 encodes an Esc-Ssa group T3SS for intracellular survival [<xref rid="B57-biomolecules-11-00316" ref-type="bibr">57</xref>]. The differences in T3SS group structure are essential to understand when inhibiting specific pathogens, especially when targeting the needle and tip as they are the most variable between the groups.</p><p>Ysc group T3SSs are seen in the largest variety of eukaryotic pathogens, including <italic>Yersinia</italic> spp. [<xref rid="B14-biomolecules-11-00316" ref-type="bibr">14</xref>,<xref rid="B15-biomolecules-11-00316" ref-type="bibr">15</xref>], <italic>P. aeruginosa</italic> [<xref rid="B4-biomolecules-11-00316" ref-type="bibr">4</xref>], <italic>Bordetella pertussis</italic> [<xref rid="B6-biomolecules-11-00316" ref-type="bibr">6</xref>], <italic>Photorhabdus luminescens</italic> [<xref rid="B58-biomolecules-11-00316" ref-type="bibr">58</xref>], <italic>Aeromonas</italic> spp. [<xref rid="B16-biomolecules-11-00316" ref-type="bibr">16</xref>], and <italic>Vibrio</italic> spp. [<xref rid="B13-biomolecules-11-00316" ref-type="bibr">13</xref>,<xref rid="B18-biomolecules-11-00316" ref-type="bibr">18</xref>] (<xref ref-type="fig" rid="biomolecules-11-00316-f002">Figure 2</xref>A). The group is named after the Ysc pathogenicity island of <italic>Y. pestis</italic>, the causative agent of bubonic plague. It has a distinctive needle tip in each of its pathogens, creating a highly selective target for anti-virulence therapies. The Ysc group T3SS secretes effectors that assist in adhesion, resist phagocytosis, and prevent inflammatory responses.</p><p>The Inv-Mxi-Spa group is named after the Inv-Spa T3SS of <italic>Salmonella enterica</italic> and the Inv-Mxi T3SS of <italic>Shigella</italic> spp. [<xref rid="B5-biomolecules-11-00316" ref-type="bibr">5</xref>,<xref rid="B12-biomolecules-11-00316" ref-type="bibr">12</xref>] (<xref ref-type="fig" rid="biomolecules-11-00316-f002">Figure 2</xref>B). This needle type is involved in secreting effectors that trigger bacterial uptake and cellular invasion and correlates with these pathogens being intracellular. The SPI1 T3SS of <italic>S. enterica</italic> was the first to be observed and is often considered the prototypical T3SS [<xref rid="B5-biomolecules-11-00316" ref-type="bibr">5</xref>]. Other notable pathogens utilizing this T3SS are <italic>Y. enterocolitica</italic> biogroup 1B [<xref rid="B60-biomolecules-11-00316" ref-type="bibr">60</xref>], <italic>Sodalis glossinidus</italic> [<xref rid="B61-biomolecules-11-00316" ref-type="bibr">61</xref>], <italic>Burkholderia</italic> spp. [<xref rid="B62-biomolecules-11-00316" ref-type="bibr">62</xref>], and <italic>Chromobacterium violaceum</italic> [<xref rid="B63-biomolecules-11-00316" ref-type="bibr">63</xref>].</p><p>Esc-Ssa characteristically has a needle tip longer than the needle itself, often called the filament due to its length (<xref ref-type="fig" rid="biomolecules-11-00316-f002">Figure 2</xref>C). The archetypal T3SS for this group is the Esc T3SS expressed in EPEC and EHEC, used primarily for adhesion and persistence [<xref rid="B9-biomolecules-11-00316" ref-type="bibr">9</xref>,<xref rid="B10-biomolecules-11-00316" ref-type="bibr">10</xref>,<xref rid="B11-biomolecules-11-00316" ref-type="bibr">11</xref>]. In these pathogens, the filament is hollow, with an interior diameter of ~25&#x000c5;, which is only large enough to allow passage of linear or partially unfolded proteins [<xref rid="B64-biomolecules-11-00316" ref-type="bibr">64</xref>]. It has been proposed the filament evolved to help EPEC/EHEC reach their target intestinal epithelial through a mucus layer that lines the intestine The SPI2 encoded T3SS of <italic>S. enterica</italic> is Esc-Ssa group and is used after the invasion has occurred and used to prevent endocytic trafficking and phagosome maturation, thus allowing <italic>S. enterica</italic> to survive within macrophages [<xref rid="B57-biomolecules-11-00316" ref-type="bibr">57</xref>]. Other pathogens encoding an Esc-Ssa group T3SS include <italic>Edwardsiella</italic> spp. [<xref rid="B17-biomolecules-11-00316" ref-type="bibr">17</xref>], <italic>Citrobacter rodentium</italic> [<xref rid="B65-biomolecules-11-00316" ref-type="bibr">65</xref>], and <italic>Yersinia</italic> spp. (nonfunctional) [<xref rid="B66-biomolecules-11-00316" ref-type="bibr">66</xref>].</p><p>The Chlamydiales group T3SS (not pictured) is the last eukaryotic pathogen T3SS and is not well studied in comparison to the Ysc, Inv-Mxi-Spa, and Esc-Ssa groups. It is only present in <italic>Chlamydia</italic> spp. and has highly specific expression and secretion conditions, making it difficult to study in vitro [<xref rid="B8-biomolecules-11-00316" ref-type="bibr">8</xref>]. The Chlamydiales T3SS is also not encoded on a single pathogenicity island like the other T3SS, making it difficult to study genetically as well. It differs from the other eukaryotic-targeting groups structurally by extra length in the N-terminus of both basal body rings and possibly lacking a stalk protein. This group secretes effectors that assist in intracellular lifestyles [<xref rid="B8-biomolecules-11-00316" ref-type="bibr">8</xref>].</p><p>Hrp1 and Hrp2 groups are the prototypical plant pathogen T3SSs, each having a long, flexible pilus instead of a rigid needle (<xref ref-type="fig" rid="biomolecules-11-00316-f002">Figure 2</xref>D,E). They are highly similar in structure and as such are separated based mainly upon loci organization and regulatory systems, but the distinction is also visible phylogenetically [<xref rid="B67-biomolecules-11-00316" ref-type="bibr">67</xref>]. Regardless of the structural similarities, each pathogen varies widely in effector number and composition and is highly specialized to its specific host. The Hrp1 T3SS found in <italic>Erwinia</italic> spp. [<xref rid="B19-biomolecules-11-00316" ref-type="bibr">19</xref>] and <italic>P. syringae</italic> [<xref rid="B20-biomolecules-11-00316" ref-type="bibr">20</xref>,<xref rid="B21-biomolecules-11-00316" ref-type="bibr">21</xref>] is activated by HrpL, a sigma factor of the extracytoplasmic function subfamily. On the other hand, the Hrp2 T3SS of <italic>Ralstonia</italic> spp. [<xref rid="B20-biomolecules-11-00316" ref-type="bibr">20</xref>] and <italic>Xanthomonas</italic> spp. [<xref rid="B22-biomolecules-11-00316" ref-type="bibr">22</xref>] is activated by HrpB, a member of the AraC family [<xref rid="B68-biomolecules-11-00316" ref-type="bibr">68</xref>]. Hrp1 and Hrp2 T3SSs also appear as secondary or tertiary T3SS in eukaryotic-targeting bacteria such as <italic>Vibrio parahaemolyticus</italic> and <italic>Burkholderia</italic> spp. [<xref rid="B69-biomolecules-11-00316" ref-type="bibr">69</xref>,<xref rid="B70-biomolecules-11-00316" ref-type="bibr">70</xref>]. Although the function of this secondary T3SS is unknown, it has been proposed that it has a role in cell-cell interaction within a bacterial population [<xref rid="B69-biomolecules-11-00316" ref-type="bibr">69</xref>].</p><p>The Rhizobiales (RHIZ) group T3SS (not pictured) is highly similar to the other plant-pathogen T3SSs in structure, but not in function. The RHIZ T3SS is found only in <italic>Rhizobium</italic> spp., <italic>Mesorhizobium loti</italic>, and <italic>Bradyrhizobium japonicum</italic> [<xref rid="B71-biomolecules-11-00316" ref-type="bibr">71</xref>]. Rhizobiales form a symbiotic relationship with their plant host through the formation of root nodules. These RHIZ T3SS can assist in nodule formation or favor the host&#x02019;s defensive reaction and prevent colonization [<xref rid="B72-biomolecules-11-00316" ref-type="bibr">72</xref>].</p><sec id="sec2dot1-biomolecules-11-00316"><title>2.1. Needle Formation Inhibition</title><p>The length of a T3SS needle is essential to its function and as such is regulated by a specific mechanism; one accepted mechanism is an &#x0201c;infrequent ruler model,&#x0201d; proposed by Moriya et al. [<xref rid="B73-biomolecules-11-00316" ref-type="bibr">73</xref>]. This involves the &#x0201c;ruler protein&#x0201d;, SctP, measuring the length of the needle as it polymerizes (<xref ref-type="fig" rid="biomolecules-11-00316-f003">Figure 3</xref>). SctP has an N-terminal unfolded &#x0201c;length sensing&#x0201d; (LS) domain that is recognized by SctU, the autoprotease, that determines the length of the needle. This length is specific to each pathogen&#x02019;s need. For example, in EHEC EscP is ~140 amino acids while in <italic>Yersinia</italic> spp. YscP is &#x0003e;500 amino acids [<xref rid="B74-biomolecules-11-00316" ref-type="bibr">74</xref>]. The globular C-terminus is called the substrate-switching (SS) domain and interacts with extracellularly exposed SctC, the basal body upper ring, initiating needle formation [<xref rid="B74-biomolecules-11-00316" ref-type="bibr">74</xref>].</p><p>To start the needle formation process, oligomers of protein SctI form an inner rod structure sometimes called the needle adaptor, which is essential to type III secretion [<xref rid="B75-biomolecules-11-00316" ref-type="bibr">75</xref>]. It interacts with the SctC and SctU [<xref rid="B76-biomolecules-11-00316" ref-type="bibr">76</xref>]. The needle itself is composed of oligomerized SctF and is required for the successful secretion of effectors and the rest of the structural components of the T3SS [<xref rid="B77-biomolecules-11-00316" ref-type="bibr">77</xref>,<xref rid="B78-biomolecules-11-00316" ref-type="bibr">78</xref>]. As SctF is secreted and begins to polymerize it pushes up the SS domain of SctP, which then acts as a cap to the growing needle (<xref ref-type="fig" rid="biomolecules-11-00316-f003">Figure 3</xref>A). Through direct interaction with SctF monomers, SctP moves through the interior of the needle complex, and secretion of SctF stops after the needle reaches the same length as SctP. At this point, there is an interaction between SctU and SctP result in the secretion of SctP (<xref ref-type="fig" rid="biomolecules-11-00316-f003">Figure 3</xref>B). This interaction is proposed to cause the conformational change in the SctU proteins responsible for changing the specificity of effector binding to allow middle and late-stage secretion [<xref rid="B73-biomolecules-11-00316" ref-type="bibr">73</xref>,<xref rid="B74-biomolecules-11-00316" ref-type="bibr">74</xref>].</p><p>After the needle is assembled, the secretion of the final structural components begins. SctA is the needle tip of the T3SS and varies widely among different pathogens. For example, most needle tips are pentamers of SctA [<xref rid="B79-biomolecules-11-00316" ref-type="bibr">79</xref>], while EPEC SctA monomers interact through a coiled-coil domain to form a homo-oligomer filamentous structure, which builds from interactions with the needle, EscF [<xref rid="B77-biomolecules-11-00316" ref-type="bibr">77</xref>,<xref rid="B80-biomolecules-11-00316" ref-type="bibr">80</xref>,<xref rid="B81-biomolecules-11-00316" ref-type="bibr">81</xref>]. Some consider the needle tip to be the hydrophilic component of the translocon due to this important adhesion to the hydrophobic translocon components, SctE and SctB. Deletion of SctA inhibits bacterial attachment, making it integral to the T3SS [<xref rid="B82-biomolecules-11-00316" ref-type="bibr">82</xref>]. SctE and SctB are then secreted and form a hetero-oligomeric donut-shaped structure within the eukaryotic host cell membrane, called the translocon [<xref rid="B83-biomolecules-11-00316" ref-type="bibr">83</xref>]. SctA serves as a scaffold for pore formation by SctE and SctB [<xref rid="B84-biomolecules-11-00316" ref-type="bibr">84</xref>]. SctE acts as the major subunit, able to form pores within the host membrane itself, while SctB is the minor subunit, unable to form pores alone [<xref rid="B82-biomolecules-11-00316" ref-type="bibr">82</xref>]. The pore formation of SctE and SctB to create the translocon is the final step in the construction of the T3SS.</p><p>A needle length that is too long could inhibit intimate attachment and/or internalization processes. A stunted needle length can prevent attachment due to mucosal lining or host extracellular proteins physically blocking the bacteria from coming close enough. In the case of plant pathogens, a stunted needle can prevent the needle from reaching the cytoplasm of the host. The simplest method of needle inhibition is the prevention of needle subunit polymerization. This can be done by physically preventing the needle subunits from binding to each other, inducing incorrect folding of the subunits, or modulation of conditions required for correct needle polymerization.</p><p>It is common for there to be a coiled-coil domain in the needle tip and translocon, a structure composed of an amphipathic secondary &#x003b1;-helix. The presence of this domain is hypothesized to play a role in multimeric oligomerization, molecule recognition, and potential interaction between bacterial and eukaryotic proteins upon translocation. In pathogenic <italic>E. coli</italic>, the proteins responsible for forming the filament (EspA) and needle (EscF) have coiled-coil domains, as does the chaperone for EspA (CesA). To analyze the potential inhibitory effects of these domains on T3SS function, coiled-coil mimetics were synthesized based on the amino acid (AA) sequences of EspA, EscF, and CesA (<xref rid="biomolecules-11-00316-t001" ref-type="table">Table 1</xref>). The ability of these peptides to inhibit T3SS activity was quantified based on hemolysis of red blood cells (RBCs) in the presence of EPEC [<xref rid="B85-biomolecules-11-00316" ref-type="bibr">85</xref>]. T3SS-mediated hemolysis was inhibited by 95% in the presence of Coil A or Coil B at 0.16 mM. Coil AB1 and Coil AB2 showed less potent inhibition of between 10% and 20% at 0.14 mM. Coil C and Coil D did not exhibit inhibitory effects to a major extent. CesA1 did not inhibit hemolysis, but CesA2 inhibited hemolysis by ~50% at 0.23 mM. With the growing prevalence of peptide drugs approved by the FDA [<xref rid="B86-biomolecules-11-00316" ref-type="bibr">86</xref>], and given that these coiled peptides target extracellular proteins, they show promise for use as pharmaceutical agents.</p><p>The salicylidene acylhydrazides (SAs) are a well-characterized structural class of small molecule T3SS inhibitors. They were originally discovered as inhibitors of the <italic>Y. pestis</italic> T3SS [<xref rid="B87-biomolecules-11-00316" ref-type="bibr">87</xref>] but have since been implicated as T3SS inhibitors for <italic>Chlamydia</italic> spp. [<xref rid="B88-biomolecules-11-00316" ref-type="bibr">88</xref>,<xref rid="B89-biomolecules-11-00316" ref-type="bibr">89</xref>], <italic>Salmonella enterica</italic> serovar Typhimurium (<italic>S</italic>. Typhimurium) [<xref rid="B90-biomolecules-11-00316" ref-type="bibr">90</xref>]. <italic>Shigella</italic> spp. [<xref rid="B91-biomolecules-11-00316" ref-type="bibr">91</xref>], EHEC [<xref rid="B92-biomolecules-11-00316" ref-type="bibr">92</xref>], <italic>Xanthomonas oryzae</italic> [<xref rid="B93-biomolecules-11-00316" ref-type="bibr">93</xref>,<xref rid="B94-biomolecules-11-00316" ref-type="bibr">94</xref>], and <italic>Erwinia amylovora</italic> [<xref rid="B95-biomolecules-11-00316" ref-type="bibr">95</xref>]. Veenendaal et al. investigated whether a group of SAs prevented expression of or destabilized the inner lower ring and/or the needle subunit of the T3SS in whole-cell extracts of bacteria exposed to the compounds. Western blotting showed that the levels of these proteins remained in all samples and controls [<xref rid="B91-biomolecules-11-00316" ref-type="bibr">91</xref>]. However, they noted a possibility that the compounds affected the assembly of the T3SS without affecting the levels of its protein components. Electron microscopy was used to visualize the macromolecular T3SS in <italic>Shigella</italic> cells from cultures grown in the presence of the inhibitors after cytoplasm removal. There was a 30-40% decrease in injectisomes per cell in all compound-treated samples, as well as an increased number of injectisomes without needles or with truncated needles, giving strength to the needle subunit-related inhibition mechanism theory [<xref rid="B91-biomolecules-11-00316" ref-type="bibr">91</xref>].</p><p>In a screen of over 80,000 compounds done by Aiello et al., the phenoxyacetamide scaffold was discovered as a potent T3SS inhibitor class [<xref rid="B49-biomolecules-11-00316" ref-type="bibr">49</xref>]. The assay allowed for visualization of inhibitory effects on ExoT expression, a <italic>P. aeruginosa</italic> effector, using a fused <italic>luxCDABE</italic> operon to the <italic>exoT</italic> gene. The inhibition of secretion of an ExoS-&#x003b2;-lactamase fusion, an effector in <italic>P. aeruginosa</italic>, as well as native ExoS was observed via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [<xref rid="B49-biomolecules-11-00316" ref-type="bibr">49</xref>]. The same research group later did mutational studies using five phenoxyacetamide analogs, including MBX 2359 (<xref ref-type="fig" rid="biomolecules-11-00316-f004">Figure 4</xref>), to determine the target of these inhibitors. They selected gentamicin-resistant clones of ethyl methanesulfonate-mutagenized MDM1710 in the presence of MBX 2359. Mutations in the <italic>pscF</italic> gene, the needle subunit in <italic>P. aeruginosa</italic>, were sufficient to rescue T3SS activity in the presence of MBX 2359, while still susceptible to other classes of inhibitors [<xref rid="B96-biomolecules-11-00316" ref-type="bibr">96</xref>]. MBX 2359 has since been used in vivo to show that T3SS inhibition protects against <italic>P. aeruginosa</italic> abscess formation in mice [<xref rid="B34-biomolecules-11-00316" ref-type="bibr">34</xref>]. This inhibitor class is also active against <italic>Yersinia</italic> and <italic>Chlamydia</italic> T3SS [<xref rid="B49-biomolecules-11-00316" ref-type="bibr">49</xref>].</p><p>In 2014, Duncan et al. performed a high throughput screen to discover new inhibitors of the <italic>Y. pseudotuberculosis</italic> T3SS and uncovered piericidin A&#x02019;s inhibitory activity (<xref ref-type="fig" rid="biomolecules-11-00316-f004">Figure 4</xref>) [<xref rid="B97-biomolecules-11-00316" ref-type="bibr">97</xref>]. SDS-PAGE analysis indicated that secretion of YopE was decreased by 65% at 71 &#x003bc;M piericidin A. Piericidin A was also shown to potently inhibit translocation of YopM into Chinese hamster ovary (CHO) cells at 75% at 71 &#x003bc;M. Although piericidin has a known antibacterial target (Complex I), an alternative Complex I inhibitor, rotenone, has no TTSS inhibitory activity, indicating the TTSS inhibitory activity of piericidin A may be independent of complex I inhibition [<xref rid="B98-biomolecules-11-00316" ref-type="bibr">98</xref>]. The mechanism of action of piericidin A as a TTSS inhibitor is not known, but evidence suggesting inhibition of needle formation has recently been discovered [<xref rid="B99-biomolecules-11-00316" ref-type="bibr">99</xref>]. Inhibition of the T3SS by piericidin A decreased formation of Ysc-type needle units on the surface of <italic>Y. pseudotuberculosis</italic> without interfering with gene expression, indicating the mechanism is directly related to needle assembly [<xref rid="B99-biomolecules-11-00316" ref-type="bibr">99</xref>]. Further work to identify the exact T3SS inhibition target of piericidin A would aid in the rational design of more potent analogs that selectively inhibit the T3SS without antibiotic effects related to Complex I binding.</p></sec><sec id="sec2dot2-biomolecules-11-00316"><title>2.2. Needle Tip and Translocon Inhibition</title><p>Inhibitors, whether small molecule or antibody, targeting the T3SS needle tip will likely adopt the secretion blockade mechanism of pathogenesis prevention [<xref rid="B100-biomolecules-11-00316" ref-type="bibr">100</xref>]. Secretion blockades have two variations: true secretion blockades and translocation blockades (<xref ref-type="fig" rid="biomolecules-11-00316-f005">Figure 5</xref>). Concerning the T3SS, translocation is defined as secretion directly into a host cell while secretion is the expulsion of protein through the T3SS needle [<xref rid="B101-biomolecules-11-00316" ref-type="bibr">101</xref>]. True secretion blockades occur when the inhibitor physically prevents the secreted proteins from exiting the needle either with itself blocking the pore or changing the conformation of the tip protein (<xref ref-type="fig" rid="biomolecules-11-00316-f005">Figure 5</xref>B). When designing anti-needle tip inhibitors, a true blockade style inhibition is desirable because the secreted proteins are not released.</p><p>When an inhibitor binds to the needle tip without blocking the pore it can still prevent binding of the tip to the translocon, creating a translocation blockade [<xref rid="B102-biomolecules-11-00316" ref-type="bibr">102</xref>]. Many effector proteins cannot pass through the membrane after secretion, allowing them to stay within the host [<xref rid="B26-biomolecules-11-00316" ref-type="bibr">26</xref>]. When the needle tip is prevented from binding from the translocon by an antibody or small molecule, then effectors are secreted into the intercellular space where they can no longer enter the host cell (<xref ref-type="fig" rid="biomolecules-11-00316-f005">Figure 5</xref>). The translocation blockade is considered a cause of unproductive use of effectors or &#x0201c;wasting effectors&#x0201d; that results in less virulence.</p><p>In 1958 researchers noticed that V antigen was present in pathogenic strains of <italic>Yersinia</italic>, but not in non-pathogenic strains [<xref rid="B103-biomolecules-11-00316" ref-type="bibr">103</xref>]. V antigen was later determined to be LcrV, the needle tip protein of the <italic>Y. pestis</italic> T3SS [<xref rid="B104-biomolecules-11-00316" ref-type="bibr">104</xref>,<xref rid="B105-biomolecules-11-00316" ref-type="bibr">105</xref>]. Antibodies targeting LcrV were sufficient to prevent translocation of effector proteins by the <italic>Y. pestis</italic> T3SS [<xref rid="B106-biomolecules-11-00316" ref-type="bibr">106</xref>]. Ivanov et al. confirmed that anti-LcrV mAbs were sufficient to directly prevent the secretion of Yop effector proteins [<xref rid="B107-biomolecules-11-00316" ref-type="bibr">107</xref>]. Their work provided a foundation to show that anti-needle tip Abs were acting as a secretion blockade and not a translocation blockade (<xref ref-type="fig" rid="biomolecules-11-00316-f005">Figure 5</xref>) [<xref rid="B100-biomolecules-11-00316" ref-type="bibr">100</xref>]. One example of this phenomenon is a specific anti-LcrV Ab blocking the apoptotic action of LcrV, the <italic>Yersinia</italic> spp. needle tip, against human T-cells [<xref rid="B108-biomolecules-11-00316" ref-type="bibr">108</xref>].</p><p>Some inhibitors of the needle tip have gone into human trials. One of these therapies, a bi-functional anti-PcrV and anti-Psl mAb for the treatment of <italic>P. aeruginosa</italic> infections called MEDI3902, showed a dose-dependent survival increase and a decrease in bacterial load in both rabbit and mouse <italic>P. aeruginosa</italic> challenge models. MEDI3902 also reduced lung inflammation caused by bacterial colonization [<xref rid="B109-biomolecules-11-00316" ref-type="bibr">109</xref>,<xref rid="B110-biomolecules-11-00316" ref-type="bibr">110</xref>,<xref rid="B111-biomolecules-11-00316" ref-type="bibr">111</xref>,<xref rid="B112-biomolecules-11-00316" ref-type="bibr">112</xref>]. MEDI3902 performed well in phase I clinical trials for the treatment of chronic airway <italic>P. aeruginosa</italic> infections but did not show high enough effectivity in phase II trials in the US [<xref rid="B113-biomolecules-11-00316" ref-type="bibr">113</xref>,<xref rid="B114-biomolecules-11-00316" ref-type="bibr">114</xref>]. Despite this setback, work on MEDI3902 has continued. Le et al. showed MEDI3902 was effective as a treatment and prophylactic for acute blood and acute lung <italic>P. aeruginosa</italic> infections. Combination therapy with a subtherapeutic dose of the antibiotic meropenem enhanced effectivity of MEDI3902 [<xref rid="B115-biomolecules-11-00316" ref-type="bibr">115</xref>].</p><p>As the needle tip protein is essential to the T3SS, Dey et al. screened nearly 300 compounds via surface plasmon resonance to identify small-molecules that bind to IpaD, the needle tip in <italic>Shigella</italic> spp. [<xref rid="B116-biomolecules-11-00316" ref-type="bibr">116</xref>]. Four small molecules were identified that have scaffolds based on quinoline, pyrrolidine aniline, hydroxyindole, and morpholinoaniline (<xref ref-type="fig" rid="biomolecules-11-00316-f006">Figure 6</xref>, termed Dey 1-4, respectively, in this review for brevity and clarity). They further validated their findings by determining the residues and surfaces of IpaD interacting with the compounds by saturation transfer difference (STD) and titration NMR methods. Three potential binding pockets were discovered, all of which are involved in protein-protein interactions of IpaD with other T3SS components [<xref rid="B116-biomolecules-11-00316" ref-type="bibr">116</xref>]. Before their screen, the only small molecules known to bind to IpaD were the bile salt sterols deoxycholate, cholate, chenodeoxycholate, and taurodeoxycholate [<xref rid="B117-biomolecules-11-00316" ref-type="bibr">117</xref>,<xref rid="B118-biomolecules-11-00316" ref-type="bibr">118</xref>,<xref rid="B119-biomolecules-11-00316" ref-type="bibr">119</xref>]. The bile salt compounds have been shown to bind in one of the binding pockets identified in the Dey study [<xref rid="B116-biomolecules-11-00316" ref-type="bibr">116</xref>]. When bound, they induce a conformational change in IpaD that allows interactions with IpaB during translocon assembly [<xref rid="B120-biomolecules-11-00316" ref-type="bibr">120</xref>].</p><p>Jessen et al. have shown that the T3SS inhibitor compound D (termed cmpdD in this review for brevity and clarity, <xref ref-type="fig" rid="biomolecules-11-00316-f006">Figure 6</xref>) inhibits T3SS secretion in <italic>Y. pestis</italic>, <italic>Y. pseudotuberculosis</italic>, and <italic>P. aeruginosa</italic>, via interaction with a translocon component [<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>]. They found YopD, the minor translocon component in <italic>Yersinia</italic> spp., was specifically implicated in cmpdD&#x02019;s inhibition mechanism. The effector and structural proteins YopB, YopD, YopK, YopM, YopE, and LcrV secretion were inhibited, except for LcrV, indicating that an intact needle was present before inhibition took place. They then tested YopB and YopD null strains of <italic>Y. pestis</italic> for cmpdD-mediated inhibition of Yop secretion and found that YopD plays a role in cmpdD&#x02019;s inhibition mechanism. Secretion assays in the presence and absence of calcium were performed. Interestingly, cmpdD was only effective as an inhibitor in a calcium-depleted environment. This enhances the theory that cmpdD-mediated inhibition occurs after the needle is complete [<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>], suggesting the formation of a secretion blockade by cmpdD.</p><p>The SAs are a broad category of T3SS inhibitors that are promiscuous binders [<xref rid="B121-biomolecules-11-00316" ref-type="bibr">121</xref>]. Zambelloni et al. designed a new class of SAs using MED055 (<xref ref-type="fig" rid="biomolecules-11-00316-f007">Figure 7</xref>) as a scaffold and incorporating the imine moiety into two different hydrazine-containing heterocycles, 1,4,5,6-tetrahydropyridazine (THP) and 1,2-dihydrophthalazine (DHP) [<xref rid="B122-biomolecules-11-00316" ref-type="bibr">122</xref>]. Of the eight new compounds, the sulfonyl di-hydroxyl derivatives (RCZ12 and RCZ20, <xref ref-type="fig" rid="biomolecules-11-00316-f007">Figure 7</xref>) had the strongest EHEC T3SS secretion inhibition profile with multiple effectors undetectable when in the presence of 200 &#x000b5;M of either compound. They performed pull-down assays to determine the molecular target of RCZ12 and RCZ20. EspD was the only T3SS-related protein to show affinity to the compounds, although some off-target cellular targets, notably 2-oxoglutarate dehydrogenase and elongation factor Tu, were identified. The selectivity of the two compounds was, however, significantly better than MED055 [<xref rid="B121-biomolecules-11-00316" ref-type="bibr">121</xref>]. The affinity data was further supported by mechanistic studies that determined the coiled-coil domain 1 of EspD as a binding site of both RCZ12 and RCZ20 [<xref rid="B122-biomolecules-11-00316" ref-type="bibr">122</xref>].</p></sec><sec id="sec2dot3-biomolecules-11-00316"><title>2.3. Structural Chaperone Inhibition</title><p>Chaperone proteins are classified as proteins that help with conformational changes and/or folding of proteins after transcription. A pilot protein assists in the localization of proteins. In the case of T3SS chaperones, they perform both duties, prevention of folding the protein and then localizing it to the T3SS to be secreted [<xref rid="B123-biomolecules-11-00316" ref-type="bibr">123</xref>,<xref rid="B124-biomolecules-11-00316" ref-type="bibr">124</xref>]. Most chaperones function as dimers [<xref rid="B124-biomolecules-11-00316" ref-type="bibr">124</xref>,<xref rid="B125-biomolecules-11-00316" ref-type="bibr">125</xref>]. Associations between a chaperone and its substrate are dependent on a specific AA sequence present on the N-terminus of the substrate called the chaperone binding domain (CBD) [<xref rid="B123-biomolecules-11-00316" ref-type="bibr">123</xref>,<xref rid="B126-biomolecules-11-00316" ref-type="bibr">126</xref>]. The CBD is recognized by the sorting platform and then the substrate is released, allowing secretion. The chaperone is then free to receive another protein and continue the cycle [<xref rid="B127-biomolecules-11-00316" ref-type="bibr">127</xref>].</p><p>There are three classes of chaperones, class I, class II, and class III. The first class is dedicated to chaperones that transport effector proteins and are further separated into IA and IB. These chaperones will be discussed in more detail in the effector inhibition section of this review. The second and third classes of chaperones are involved in transporting structural protein components of the T3SS including the needle subunit, needle tip, and translocon components (<xref rid="biomolecules-11-00316-t002" ref-type="table">Table 2</xref>). Class II chaperones contain tetratricopeptide (TPR) repeats that are required to bind and secrete the translocon components. Homodimerization allows for these TPR to form a &#x0201c;cupped palm&#x0201d; groove that the translocon components then bind to [<xref rid="B128-biomolecules-11-00316" ref-type="bibr">128</xref>].</p><p>Class III chaperones are heterodimeric, working in pairs, and bind to the needle protein subunits, typically in a 1:1:1 ratio. This is done to prevent polymerization of the needle within the bacteria before secretion [<xref rid="B128-biomolecules-11-00316" ref-type="bibr">128</xref>]. For example, EscF, the needle subunit in EPEC, is transported to the T3SS by co-chaperones EscE and EscG, which form interactions with the bacterial membrane while in complex with EscF. Null mutants of EscE and EscG do not secrete multiple T3SS proteins, further implementing EscF and its chaperones as a necessity for type III secretion [<xref rid="B129-biomolecules-11-00316" ref-type="bibr">129</xref>]. Of note, some bacterial species have subunits of a differing conformation such as EspA, the needle tip in EPEC, that require only one chaperone, CesA in this case, to prevent polymerization within the cytosol [<xref rid="B130-biomolecules-11-00316" ref-type="bibr">130</xref>,<xref rid="B131-biomolecules-11-00316" ref-type="bibr">131</xref>,<xref rid="B132-biomolecules-11-00316" ref-type="bibr">132</xref>]. Needle tip proteins of the Inv-Mxi-Spa family contain a chaperone-like domain and are proposed to be self-chaperoning [<xref rid="B133-biomolecules-11-00316" ref-type="bibr">133</xref>].</p><p>Inhibiting the chaperones of structural components of the T3SS will have similar effects to inhibition of the structural component itself. Class II chaperone inhibitors will prevent the translocon from entering the injectisome. This will cause an unproductive use of effectors as there will be no translocon pore for the effectors to translocate through. Phenotypically distinguishing between a component inhibitor or an inhibitor of its chaperone is very difficult, meaning many class II and III chaperone inhibitors will go unidentified [<xref rid="B153-biomolecules-11-00316" ref-type="bibr">153</xref>]. In one study, a small molecule T3SS inhibitor, cmpdD (<xref ref-type="fig" rid="biomolecules-11-00316-f006">Figure 6</xref>), was thought to be interacting with YopD, a translocon component, directly to prevent secretion [<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>]. This hypothesis was brought into question, however, when the expression of YopD in the &#x00394;yopD <italic>Y. pestis</italic> strain did not restore secretion inhibition in the presence of cmpdD. Only co-expression of yopD and LcrH, the class IA chaperone of YopD, was able to restore cmpdD&#x02019;s ability to inhibit secretion. Together these results suggest the YopD/LcrH complex may be involved in the mechanism of cmpdD [<xref rid="B25-biomolecules-11-00316" ref-type="bibr">25</xref>].</p><p>Recently, the co-chaperone nature of class III chaperones has been exploited by Ngo et al. to design protein-protein interface inhibitors. They chemically linked two smaller bioactive molecules to design inhibitors that will disrupt the interaction between the co-chaperones, PscG and PscE, that stabilize PscF, the <italic>P. aeruginosa</italic> needle subunit protein [<xref rid="B154-biomolecules-11-00316" ref-type="bibr">154</xref>]. They found two compounds, 12(4,6) and 12(6,4) (<xref ref-type="fig" rid="biomolecules-11-00316-f008">Figure 8</xref>) that were able to disrupt the interaction between PscG and PscE as well as prevent the secretion of effectors ExoT, ExoS, and translocon component PopD in a dose-dependent manner. The compounds also did not affect growth, flagellar movement, or biofilm formation, indicating specificity to the T3SS. 12(4,6) and 12(6,4) also provided partial protection from <italic>P. aeruginosa</italic> infection in a <italic>Galleria mellonella</italic> model [<xref rid="B154-biomolecules-11-00316" ref-type="bibr">154</xref>].</p></sec></sec><sec id="sec3-biomolecules-11-00316"><title>3. T3SS Base: Basal Body, Export Apparatus, and Cytoplasmic Complex</title><p>The base of the needle assembly anchors the T3SS into the inner and outer membranes (IM and OM, respectively) of the bacterial cell. The basal body of the T3SS contains two major components, the lower ring attached to the IM and the upper ring spanning the periplasm and OM (<xref ref-type="fig" rid="biomolecules-11-00316-f009">Figure 9</xref>, Purple). The export apparatus is also occasionally included in the basal body as it is located within the lower ring (<xref ref-type="fig" rid="biomolecules-11-00316-f009">Figure 9</xref>, Orange). In this review, however, it will be considered a separate component due to its function as a filter; determining the order of effectors to be secreted. The cytoplasmic complex (<xref ref-type="fig" rid="biomolecules-11-00316-f009">Figure 9</xref>, blue) contains an ATPase (<xref ref-type="fig" rid="biomolecules-11-00316-f009">Figure 9</xref>, dark blue) that powers secretion. The cytoplasmic complex and export apparatus together are often called the sorting platform as they determine order and rate of secretion as well as power it with the ATPase.</p><p>One notable downside to targeting the base of the T3SS is that it is highly conserved among other secretion systems and flagella [<xref rid="B155-biomolecules-11-00316" ref-type="bibr">155</xref>,<xref rid="B156-biomolecules-11-00316" ref-type="bibr">156</xref>]. One particularly poignant example of this is the export apparatus components, all of which have an <italic>E</italic> &#x0003c; 10<sup>&#x02212;5</sup> with their flagellar counterparts (<xref ref-type="fig" rid="biomolecules-11-00316-f009">Figure 9</xref>) [<xref rid="B155-biomolecules-11-00316" ref-type="bibr">155</xref>]. The expectation or E-value is <italic>E</italic>(<italic>b</italic>) &#x02264; <italic>p</italic>(<italic>b</italic>)<italic>D</italic>, where <italic>D</italic> is the number of sequences in the database and <italic>p(b)</italic> is the probability of two sequences being aligned [<xref rid="B157-biomolecules-11-00316" ref-type="bibr">157</xref>]. Other than direct correlation to flagellar components, there are also issues with relation to other secretion systems. SctC belongs to a family of pore-forming proteins called secretin. Secretins are also found in type IV pili (T4P), type II secretion systems (T2SS), Flp pili encoded by the tight adherence (Tad) system, and the extrusion machinery of filamentous phages [<xref rid="B158-biomolecules-11-00316" ref-type="bibr">158</xref>,<xref rid="B159-biomolecules-11-00316" ref-type="bibr">159</xref>]. In each group of T3SS, the SctC has developed from the secretin of different secretion systems. For example, the majority of T3SS groups obtained their SctC from the T4P, while Chlamydial T3SS obtained their SctC from the T2SS [<xref rid="B156-biomolecules-11-00316" ref-type="bibr">156</xref>]. These similarities can lead to off-target effects on commensal bacteria. Multiple T3SS inhibitors are known to affect flagella [<xref rid="B160-biomolecules-11-00316" ref-type="bibr">160</xref>,<xref rid="B161-biomolecules-11-00316" ref-type="bibr">161</xref>,<xref rid="B162-biomolecules-11-00316" ref-type="bibr">162</xref>].</p><sec id="sec3dot1-biomolecules-11-00316"><title>3.1. Formation Inhibition</title><p>The formation of the T3SS base occurs in three steps, the first two, export apparatus and cytoplasmic complex formation, happen simultaneously while the third, basal body formation, is sequential (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>). The inhibition of any one of the steps in the T3SS base formation could prevent the completion of a functional needle and therefore the secretion of effectors into the host cell. This implies the design of protein-protein interaction inhibitors may be the best fit for this purpose. Genetic modulators that reduce the number of a particular component, thereby reducing the number of functional T3SS, are also a valid strategy, but outside the scope of this review. The components of the T3SS base are also the most conserved among T3SS proteins, making them an attractive target if a multi-species T3SS inhibitor is desired.</p><p>The export apparatus is formed in a highly ordered manner, from the most internal components to the more exterior: SctR, SctT, SctS, SctU, then SctV (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>A) [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>]. SctR is the central component of the export apparatus and initiates the assembly of the rest of the T3SS through interactions with other structural components [<xref rid="B164-biomolecules-11-00316" ref-type="bibr">164</xref>]. The role of SctT is not well understood, but it has been identified as a T3SS protein based on sequence homology among multiple bacterial species [<xref rid="B165-biomolecules-11-00316" ref-type="bibr">165</xref>]. When either of the two putative transmembrane domains of SctS are replaced by hydrophobic residues, the T3SS becomes non-functional, indicating SctS may play a role in adjustments of protein orientation within the base [<xref rid="B166-biomolecules-11-00316" ref-type="bibr">166</xref>]. SctU is an autoprotease often called the switch of the export apparatus. The self-cleavage of SctU is necessary for infection of host cells [<xref rid="B167-biomolecules-11-00316" ref-type="bibr">167</xref>]. In addition, an absence of SctU cleavage resulted in a decreased accumulation of chaperones on the IM. This suggests that the autoprotease activity of SctU contributes to the successful docking of effector/chaperone complexes [<xref rid="B167-biomolecules-11-00316" ref-type="bibr">167</xref>]. SctV, the gate protein, is the largest of the export apparatus proteins and is homologous with flagellar protein FlhA, which facilitates the transport of sodium ions and protons [<xref rid="B168-biomolecules-11-00316" ref-type="bibr">168</xref>]. SctV is proposed to function as a proton/protein antiporter [<xref rid="B169-biomolecules-11-00316" ref-type="bibr">169</xref>]. Once the export apparatus is complete, the basal body will begin to form around the apparatus (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>C) [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>].</p><p>The cytoplasmic complex is not formed in any particular order and the components, SctK, SctQ, SctL and SctN, can associate at will (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>B). This has the exception of the stalk protein, SctO, that associates last and can even associate after the cytoplasmic domain has bound to the basal body [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>]. SctO stabilizes the oligomerization of the ATPase and helps prevent ATP-mediated dissociation. SctL mediates interactions between the ATPase, SctN, and the cytoplasmic ring, SctQ [<xref rid="B170-biomolecules-11-00316" ref-type="bibr">170</xref>,<xref rid="B171-biomolecules-11-00316" ref-type="bibr">171</xref>]. In plant pathogens, such as <italic>P. syringae</italic>, there are two proteins, termed HrcQ<sub>A</sub> and HrcQ<sub>B</sub>, that interact to form the cytoplasmic ring [<xref rid="B172-biomolecules-11-00316" ref-type="bibr">172</xref>]. Pull-down studies indicate that SctL, the linker, binds to the needle tip, SctA, and stabilizes it in the bacterial cytosol as a secondary function [<xref rid="B132-biomolecules-11-00316" ref-type="bibr">132</xref>]. The final component, SctK, binds within the inner diameter of the cytoplasmic ring [<xref rid="B171-biomolecules-11-00316" ref-type="bibr">171</xref>]. While the function of SctK is thought to be primarily structural, functional analysis of an SctK knockout indicates it is critical for effector secretion [<xref rid="B171-biomolecules-11-00316" ref-type="bibr">171</xref>].</p><p>After export apparatus completion, first the inner lower ring, SctJ, and then the outer lower ring, SctD, will oligomerize to form a ring around the export apparatus and span the bacterial membrane (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>C) [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>,<xref rid="B173-biomolecules-11-00316" ref-type="bibr">173</xref>]. Simultaneously, a lytic glycosylase (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>, light green) is employed to cleave bonds within the PG layer, allowing base subunits to assemble. Overexpression of lytic glycosylase leads to cell lysis, and mutation in its catalytic residues results in a non-functional T3SS [<xref rid="B174-biomolecules-11-00316" ref-type="bibr">174</xref>]. The lower ring components are necessary for the assembly of the upper ring, as null mutations result in decreased oligomerization SctC, the monomer of the upper ring, and a member of the secretin family of proteins [<xref rid="B159-biomolecules-11-00316" ref-type="bibr">159</xref>]. After the lower ring is complete, the completed cytoplasmic complex can bind at any time. Pilotin (<xref ref-type="fig" rid="biomolecules-11-00316-f010">Figure 10</xref>, dark green) then assists in upper ring binding and pore formation before leaving [<xref rid="B159-biomolecules-11-00316" ref-type="bibr">159</xref>]. Once all of these have been correctly assembled, the needle formation process can begin [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>,<xref rid="B175-biomolecules-11-00316" ref-type="bibr">175</xref>,<xref rid="B176-biomolecules-11-00316" ref-type="bibr">176</xref>].</p><p>In the absence of the export apparatus, there is a marked decrease in the base assembly, leading to an overall reduction in functional T3SSs [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>]. In a study by Martinez-Argudo et al., <italic>S</italic>. Typhimurium mutants were isolated that were resistant to the SA inhibitors, INP0404, and INP0405 (<xref ref-type="fig" rid="biomolecules-11-00316-f011">Figure 11</xref>), allowing the determination of their target [<xref rid="B162-biomolecules-11-00316" ref-type="bibr">162</xref>]. The mutants contained mutations affecting the gate protein (SctU), <italic>fadB</italic> (the &#x003b3;-subunit of fatty acid oxidation complex), and the ATPase. One mutation to the ATPase caused the deletion of the first five amino acids, resulting in an inability to bind effectively to other components of the cytoplasmic complex. This mutation was also found to affect flagellar formation and motility. The point mutation affecting SctU was insufficient to cause disruptions in flagellar function, implying it is more specific to the T3SS inhibitory effect of INP0404 and INP0405. The overall expression levels of SctU were unchanged in the presence of the mutation, but the mutation did lead to a decrease in protein in the periplasm. Together these imply these inhibitors&#x02019; mechanism is directly interacting with the base of the T3SS, possibly binding to multiple components [<xref rid="B162-biomolecules-11-00316" ref-type="bibr">162</xref>].</p></sec><sec id="sec3dot2-biomolecules-11-00316"><title>3.2. Basal Body: The Periplasmic Gate</title><p>When mentioning the &#x0201c;gate&#x0201d; of the T3SS, there are two possible meanings. The major export apparatus protein, SctV, is often called the gate due to its function while the T3SS is operational. The other &#x0201c;gate&#x0201d; in question is called the periplasmic gate and is located within the upper ring, SctC, of the basal body and is involved in needle formation. The periplasmic gate has three conformations: closed, unlocked, and open (<xref ref-type="fig" rid="biomolecules-11-00316-f012">Figure 12</xref>) [<xref rid="B177-biomolecules-11-00316" ref-type="bibr">177</xref>]. SctC is natively in the closed conformation as it associates with the lower ring of the basal body. The gate is locked via N3 domain &#x003b2;-hairpin stabilizing interactions. Needle adaptor proteins enter the canal of SctC and remain collapsed without lateral packing. After the subunits enter the canal, the &#x003b2;-hairpin interactions are destabilized, &#x0201c;unlocking&#x0201d; the gate and allowing it to partially open. Polymerization of needle subunits begins, and subsequent polymerization pushes the arms of the gate open and into the sides of the canal [<xref rid="B177-biomolecules-11-00316" ref-type="bibr">177</xref>].</p><p>An effective mechanism to preventing secretion could be a conformational change in SctC that prevents periplasmic gate opening, ultimately resulting in no needle formation. As most inhibitors are discovered in phenotypic screens, there are no current inhibitors known to produce this effect via this mechanism. These inhibitors, however, could easily be mistaken as those interacting with needle subunit proteins as the phenotype would be similar. Notwithstanding this setback, there have been multiple inhibitors shown to interact with SctC and inhibit the functionality of the T3SS. One inhibitor class that may be interacting with periplasmic gate function is the salicylidene acylhydrazides.</p><p>Inhibition of the T3SS with SAs results in a decrease in injectisomes per cell as well as an increased number of injectisomes without needles or with truncated needles [<xref rid="B91-biomolecules-11-00316" ref-type="bibr">91</xref>]. Recent studies have shown that a group of nine SAs inhibit both the T3SS-1 and T3SS-2 of <italic>S</italic>. Typhimurium, as well as decreasing flagellar motility [<xref rid="B161-biomolecules-11-00316" ref-type="bibr">161</xref>]. The most potent SA that showed dose-dependent inhibition was INP0010 (<xref ref-type="fig" rid="biomolecules-11-00316-f013">Figure 13</xref>). This suggests that SAs if acting on a T3SS component directly, will be binding to a conserved factor among all three of these structures. Although export apparatus components may seem the likely target due to their high homology with flagellar components [<xref rid="B155-biomolecules-11-00316" ref-type="bibr">155</xref>], the upper ring of the basal body has been identified as the potential target. This is because the N-terminus of SctC/secretin in the T3SS-1, T3SS-2, and flagella in <italic>S</italic>. Typhimurium share even higher homology [<xref rid="B161-biomolecules-11-00316" ref-type="bibr">161</xref>].</p><p>The thiazolidinones have also been shown to interact with SctC. 2-Imino-5-arylidene thiazolidinone (<xref ref-type="fig" rid="biomolecules-11-00316-f013">Figure 13</xref>) was first discovered in a virtual screen to discover inhibitors of <italic>S</italic>. Typhimurium T3SS [<xref rid="B178-biomolecules-11-00316" ref-type="bibr">178</xref>]. From this point onward termed HBF1, this inhibitor prevented the secretion of effectors SipA and SspH1 while not inhibiting bacterial growth or flagellar motility. HBF1 was proposed to bind to PrgH, the outer lower ring of the basal body in a way that prevented its alkaline phosphatase activity as well as binging to the upper ring. This was due to a lack of T3SS protein expression changes, examined via western blot, but a significant decrease in functional basal body and needle formation was observed [<xref rid="B178-biomolecules-11-00316" ref-type="bibr">178</xref>]. Felise et al. found HBF1 was able to inhibit secretion of Yop effectors in <italic>Y. enterocolitica</italic>, indicating again that a highly conserved structural T3SS protein was involved in its mechanism of action. They also proved HBF1&#x02032;s ability to prevent T3SS-dependent <italic>S.</italic> Typhimurium macrophage cytotoxicity and <italic>P. syringae</italic>&#x02019;s hypersensitivity response (HR) in tobacco, furthering its applicability as a broad spectrum T3SS inhibitor [<xref rid="B178-biomolecules-11-00316" ref-type="bibr">178</xref>]. There has also been work detailing the structure-activity relationship (SAR) of thiazolidinones, indicating that although HBF1 has broad activity, it can be designed to specifically act on pathogens of interest [<xref rid="B178-biomolecules-11-00316" ref-type="bibr">178</xref>,<xref rid="B179-biomolecules-11-00316" ref-type="bibr">179</xref>].</p></sec><sec id="sec3dot3-biomolecules-11-00316"><title>3.3. Cytoplasmic Complex: Prevention of ATPase Function</title><p>The ATPase of the cytoplasmic complex powers secretion of effector proteins through the T3SS [<xref rid="B38-biomolecules-11-00316" ref-type="bibr">38</xref>,<xref rid="B169-biomolecules-11-00316" ref-type="bibr">169</xref>,<xref rid="B180-biomolecules-11-00316" ref-type="bibr">180</xref>]. It is a hexamer arranged into a pore that has a diameter of approximately 20 &#x000c5;. Of the six ATP binding sites on the hexamer, two are filled with ATP, two with ADP, and two are empty. The ATPase powers secretion by tilting upwards at the empty binding sites and rotating this tilt as the ATP is dephosphorylated creating a &#x0201c;screwing&#x0201d; motion (<xref ref-type="fig" rid="biomolecules-11-00316-f014">Figure 14</xref>). This causes the unfolded effectors to then be pushed upwards through the channel and into the export apparatus, then the needle [<xref rid="B38-biomolecules-11-00316" ref-type="bibr">38</xref>]. The ATPase of the <italic>Salmonella</italic> T3SS-1, InvC, has been implicated as an &#x0201c;unfold-ase&#x0201d; that serves to linearize effectors in an ATP and substrate-dependent manner [<xref rid="B125-biomolecules-11-00316" ref-type="bibr">125</xref>,<xref rid="B181-biomolecules-11-00316" ref-type="bibr">181</xref>]. The conserved structure of the T3SS family of ATPases suggests this may be a universal role for SctN [<xref rid="B182-biomolecules-11-00316" ref-type="bibr">182</xref>]. Without the ATPase, the T3SS is nonfunctional as seen in ATPase knockouts [<xref rid="B183-biomolecules-11-00316" ref-type="bibr">183</xref>,<xref rid="B184-biomolecules-11-00316" ref-type="bibr">184</xref>,<xref rid="B185-biomolecules-11-00316" ref-type="bibr">185</xref>]. It is so necessary for virulence that one <italic>Y. pestis</italic> ATPase knockout strain has been tested as a potential live, attenuated vaccine candidate. The <italic>YscN</italic> mutant strain was shown to prevent the secretion of LcrV, the needle tip, as well as showing dose-dependent protection against <italic>Y. pestis</italic> challenge in mice [<xref rid="B185-biomolecules-11-00316" ref-type="bibr">185</xref>].</p><p>The development of T3SS inhibitors that target the ATPase is one of the best-studied targets. Inhibitors have been found against multiple species of bacteria, including <italic>Burkholderia</italic> spp. [<xref rid="B187-biomolecules-11-00316" ref-type="bibr">187</xref>], <italic>Chlamydia</italic> spp. [<xref rid="B188-biomolecules-11-00316" ref-type="bibr">188</xref>,<xref rid="B189-biomolecules-11-00316" ref-type="bibr">189</xref>], EPEC [<xref rid="B190-biomolecules-11-00316" ref-type="bibr">190</xref>], <italic>Pseudomonas</italic> spp. [<xref rid="B191-biomolecules-11-00316" ref-type="bibr">191</xref>,<xref rid="B192-biomolecules-11-00316" ref-type="bibr">192</xref>,<xref rid="B193-biomolecules-11-00316" ref-type="bibr">193</xref>], <italic>Shigella</italic> spp. [<xref rid="B194-biomolecules-11-00316" ref-type="bibr">194</xref>,<xref rid="B195-biomolecules-11-00316" ref-type="bibr">195</xref>], and <italic>Yersinia</italic> spp. [<xref rid="B184-biomolecules-11-00316" ref-type="bibr">184</xref>,<xref rid="B196-biomolecules-11-00316" ref-type="bibr">196</xref>]. Of these inhibitors, one class of small molecule, hydroxyquinolines, has been shown to inhibit the ATPase of T3SS in multiple species. Compound INP1750, an 8-hydroxyquinoline derivative (<xref ref-type="fig" rid="biomolecules-11-00316-f015">Figure 15</xref>), was originally thought to inhibit the needle tip of <italic>Y. pseudotuberculosis</italic> and <italic>C. trachomatis</italic> but has since been shown to act on the ATPase in <italic>P. aeruginosa</italic>, <italic>Y. pseudotuberculosis,</italic> and <italic>C. trachomatis</italic> [<xref rid="B50-biomolecules-11-00316" ref-type="bibr">50</xref>,<xref rid="B116-biomolecules-11-00316" ref-type="bibr">116</xref>,<xref rid="B191-biomolecules-11-00316" ref-type="bibr">191</xref>,<xref rid="B193-biomolecules-11-00316" ref-type="bibr">193</xref>].</p><p>Swietnicki et al. performed a virtual screen of approximately 2,000,000 compounds to determine their binding potential to the <italic>Y. pestis</italic> ATPase, YscN. From this screen, they purchased 50 compounds to test in vitro. Compounds 7146 and 1504 (<xref ref-type="fig" rid="biomolecules-11-00316-f015">Figure 15</xref>) were able to inhibit YscN&#x02019;s ATPase activity at IC<sub>50</sub> with 16.5 and 18.2 &#x000b5;M concentrations, respectively [<xref rid="B184-biomolecules-11-00316" ref-type="bibr">184</xref>]. They also tested the ability of these compounds to inhibit <italic>Burkholderia mallei</italic>&#x02019;s ATPase, BscN, as it shares 40% identity with YscN [<xref rid="B184-biomolecules-11-00316" ref-type="bibr">184</xref>,<xref rid="B185-biomolecules-11-00316" ref-type="bibr">185</xref>,<xref rid="B187-biomolecules-11-00316" ref-type="bibr">187</xref>]. Compound 7146 had a lower IC<sub>50</sub>, 7.4 &#x000b5;M, while compound 1504&#x02032;s IC<sub>50</sub> was increased at 28.4 &#x000b5;M [<xref rid="B184-biomolecules-11-00316" ref-type="bibr">184</xref>]. This demonstrates the high specificity of ATPase binding sites and the possibility to design inhibitors of specific ATPases. Compound 939 from the virtual screen was later tested by Gong et al. in <italic>B. pseudomallei</italic> and it inhibited the secretion of <italic>Burkholderia</italic> effector, BopE, and reduced intracellular survival in RAW 264.7 cells (murine macrophages) [<xref rid="B187-biomolecules-11-00316" ref-type="bibr">187</xref>].</p><p>The WEN compounds, a new class of small-molecule inhibitors derived from compound <bold>54</bold> (<xref ref-type="fig" rid="biomolecules-11-00316-f016">Figure 16</xref>), were discovered using a virtual screen for potential compounds to target the EPEC ATPase, EscN [<xref rid="B190-biomolecules-11-00316" ref-type="bibr">190</xref>]. The screening campaign was conducted using the ATP binding site of EscN (PDB code: 2OMB) and compounds from the ZINC database. The initial 3000 compounds were filtered for predicted cytotoxicity, and the remaining top 70 compounds were purchased for ATP hydrolysis screening using recombinant EscN. Next, compounds were screened for their cytotoxicity toward HeLa cells. Finally, five compounds were screened for their ability to inhibit the T3SS based on the relative secretion of effector EspG1 according to Western blot results. Analogs of one compound were designed based on the predicted binding pose within the EscN active site. The most efficacious compound was WEN05-03, with a K<sub>i</sub> = 16 &#x000b1; 2 &#x003bc;M (<xref ref-type="fig" rid="biomolecules-11-00316-f016">Figure 16</xref>) [<xref rid="B190-biomolecules-11-00316" ref-type="bibr">190</xref>].</p><p>Grishin et al. performed a virtual screen to discover compounds that bind to the ATPase of <italic>C. trachomatis</italic>, CdsN. From the 221,574 compounds screened, 16 were purchased for in vitro testing, having eliminated compounds for poor binding scores as well as non-favorable Lipinski characteristics, a set of common rules used in the small molecule drug discovery process (including guidelines on parameters such as the number of hydrogen bond donors and molecular weight) [<xref rid="B197-biomolecules-11-00316" ref-type="bibr">197</xref>]. The most potent compounds, W1227933 and W1774182 (<xref ref-type="fig" rid="biomolecules-11-00316-f016">Figure 16</xref>) decreased the number of chlamydial inclusions in McCoy cells by 70% and 90%, respectively, when incubated at 50 &#x000b5;M. The inclusions that were present were also much smaller in size compared to control inclusions. When McCoy cells infected with <italic>C. trachomatis</italic> were incubated with either inhibitor at 25 &#x000b5;M for 24 h, they reduced the secretion of effector IncA to undetectable levels [<xref rid="B188-biomolecules-11-00316" ref-type="bibr">188</xref>]. Disruption of the interaction between CdsN and the linker protein, CdsL, by peptide mimetics has also been shown to act as an effective secretion inhibitor. W1227933 and W1774182 also inhibited <italic>C. pneumoniae</italic> invasion of HeLa cells dose-dependently [<xref rid="B189-biomolecules-11-00316" ref-type="bibr">189</xref>]. This indicates inhibition of ATPase binding can be similarly potent as ATPase activity inhibition.</p></sec></sec><sec id="sec4-biomolecules-11-00316"><title>4. Inhibition of Effectors</title><p>T3SS inhibitors have a vast array of possible activities and targets, the most common of which are placed into four larger categories: interference with the host cytoskeleton, cellular trafficking, cell death and/or survival pathways, and NF-&#x003ba;B/MAPK pathways [<xref rid="B67-biomolecules-11-00316" ref-type="bibr">67</xref>]. Each of these categories can be either up or downregulated to varying degrees based upon the pathogen in question. The prospect of inhibiting a single inhibitor can also seem reductive as many effectors have redundancy in their activity and a singular knockout will not cause complete attenuation of virulence. Notwithstanding this, there are exceptions in which a particular effector is responsible for most of the virulence or host-wide symptoms [<xref rid="B198-biomolecules-11-00316" ref-type="bibr">198</xref>]. In these cases, targeting effector proteins is a possible course of action.</p><p>The T3SS effector ExoU is a cytotoxin associated with up to 90% of severe cases of <italic>P. aeruginosa</italic> infections [<xref rid="B198-biomolecules-11-00316" ref-type="bibr">198</xref>]. ExoU&#x02019;s phospholipase A2 activity is tied to pathogenicity via its interaction with host cell superoxide dismutase 1 inducing cell lysis of the target cell, as well as attenuating particular cellular signaling pathways [<xref rid="B199-biomolecules-11-00316" ref-type="bibr">199</xref>,<xref rid="B200-biomolecules-11-00316" ref-type="bibr">200</xref>]. 9H-fluorene-4-carboxamide, designated pseudolipasin A (<xref ref-type="fig" rid="biomolecules-11-00316-f017">Figure 17</xref>), is a specific inhibitor for the phospholipase A2 activity of <italic>P. aeruginosa</italic> ExoU. It was shown to not have any effect on T3SS secretion or formation, but rather inhibited the activity of the cytotoxin [<xref rid="B201-biomolecules-11-00316" ref-type="bibr">201</xref>]. Arylsulfonamides were identified as ExoU inhibitors during a screen to identify compounds inhibiting ExoU-dependent cytotoxicity in yeast [<xref rid="B202-biomolecules-11-00316" ref-type="bibr">202</xref>]. A small SAR was performed and although none of the arylsulfonamide derivatives were as potent as pseudolipasin A, it indicated this scaffold could be used to develop inhibitors [<xref rid="B200-biomolecules-11-00316" ref-type="bibr">200</xref>].</p><p>ExoS is another important T3SS effector/toxin in <italic>P. aeruginosa</italic>. It contains a membrane localization domain to assist in delivery to the membrane in a cholesterol-dependent manner. The ADP-ribosyltransferase activity of ExoS can inhibit Rab 5 and Ras2p function [<xref rid="B203-biomolecules-11-00316" ref-type="bibr">203</xref>,<xref rid="B204-biomolecules-11-00316" ref-type="bibr">204</xref>]. ExoS also contains a GAP domain whose action disrupts the actin cytoskeleton, inhibits bacterial internalization into macrophages, induces host cell rounding, and prevents wound healing [<xref rid="B199-biomolecules-11-00316" ref-type="bibr">199</xref>]. Key mutations in ExoS&#x02019;s binding domain significantly affect its ability to cause death in a mouse model of pneumonia, making it an attractive inhibitory target [<xref rid="B198-biomolecules-11-00316" ref-type="bibr">198</xref>]. Exosin (<xref ref-type="fig" rid="biomolecules-11-00316-f017">Figure 17</xref>) has been identified as a competitive inhibitor of ExoS ADP-ribosyltransferase activity. It, as well as multiple derivatives, confers protection of CHO cells from ExoS-induced cytotoxicity with the most potent analog giving nearly 40% recovery [<xref rid="B204-biomolecules-11-00316" ref-type="bibr">204</xref>].</p><sec id="sec4dot1-biomolecules-11-00316"><title>4.1. Adhesion Inhibition</title><p>The T3SS is a contributor to the ability of bacterial cells to adhere to eukaryotic host cells, primarily in the translocon-needle tip interaction. There are, however, numerous other mechanisms, both T3SS-dependent and independent, that contribute to the majority of the adhesion process. Using pathogenic <italic>E. coli</italic> as an example, we will discuss the T3SS-dependent adhesion mechanism, called intimate attachment, to then show examples of intimate adhesion inhibition as it is the best characterized. As mentioned, there are other methods of attachment related to the T3SS and its effector proteins in different species of bacteria. These methods/mechanisms can be inhibited with similar overall outcomes [<xref rid="B87-biomolecules-11-00316" ref-type="bibr">87</xref>,<xref rid="B89-biomolecules-11-00316" ref-type="bibr">89</xref>,<xref rid="B205-biomolecules-11-00316" ref-type="bibr">205</xref>,<xref rid="B206-biomolecules-11-00316" ref-type="bibr">206</xref>,<xref rid="B207-biomolecules-11-00316" ref-type="bibr">207</xref>,<xref rid="B208-biomolecules-11-00316" ref-type="bibr">208</xref>,<xref rid="B209-biomolecules-11-00316" ref-type="bibr">209</xref>,<xref rid="B210-biomolecules-11-00316" ref-type="bibr">210</xref>,<xref rid="B211-biomolecules-11-00316" ref-type="bibr">211</xref>].</p><p>Some analyses into the ability of compounds to inhibit cellular adhesion have been performed to complement screens of potential T3SS inhibitors. These assays typically involve fluorescence microscopy to visualize the adherence of the bacteria to the cell surface. Since EPEC, EHEC, and <italic>C. rodentium</italic> (a well-adopted mouse model for EPEC/EHEC infection) [<xref rid="B212-biomolecules-11-00316" ref-type="bibr">212</xref>] are attaching and effacing pathogens, pedestal formation and changes in eukaryotic morphology may also be noted. It is noteworthy that although these compounds inhibit adhesion, and therefore the systemic infection, they don&#x02019;t inhibit T3SS secretion. The effectors are still secreted into the extracellular matrix and can cause minor effects to the host cells.</p><p>The translocated intimin receptor (Tir) is one of the first effector proteins translocated by <italic>E. coli</italic>&#x02019;s T3SS into host cells and is involved in the intimate binding process [<xref rid="B213-biomolecules-11-00316" ref-type="bibr">213</xref>,<xref rid="B214-biomolecules-11-00316" ref-type="bibr">214</xref>,<xref rid="B215-biomolecules-11-00316" ref-type="bibr">215</xref>]. There are multiple other effector proteins, including EspB, EspG, EspH, EspM2, EspT, Map, and TccP, that assist in adhesion via cytoskeleton rearrangement in redundant or similar mechanisms to Tir (<xref ref-type="fig" rid="biomolecules-11-00316-f018">Figure 18</xref>). Knockouts of these effectors are not as attenuated as Tir knockouts indicating the interaction between intimin and Tir is the most important for intimate attachment. Mutational studies confirm that changes to the receptor recognition domain abolish attachment capabilities [<xref rid="B216-biomolecules-11-00316" ref-type="bibr">216</xref>]. Tir integrates into the host membrane after translocation and its N- and C-terminal tyrosines are phosphorylated by host kinases [<xref rid="B27-biomolecules-11-00316" ref-type="bibr">27</xref>]. As intimin binds to the extracellular loops of Tir, the phosphorylated tyrosines act upon focal adhesion proteins, including &#x003b1;-actinin [<xref rid="B217-biomolecules-11-00316" ref-type="bibr">217</xref>], host pathways (Ex. Nck and IRTKS/IRSp53), and effectors (Ex. EspF) [<xref rid="B218-biomolecules-11-00316" ref-type="bibr">218</xref>,<xref rid="B219-biomolecules-11-00316" ref-type="bibr">219</xref>,<xref rid="B220-biomolecules-11-00316" ref-type="bibr">220</xref>,<xref rid="B221-biomolecules-11-00316" ref-type="bibr">221</xref>]. This results in pedestal formation and intimate attachment [<xref rid="B213-biomolecules-11-00316" ref-type="bibr">213</xref>,<xref rid="B215-biomolecules-11-00316" ref-type="bibr">215</xref>,<xref rid="B217-biomolecules-11-00316" ref-type="bibr">217</xref>].</p><p>Due to Tir&#x02019;s extracellular localization, inhibitors can bind without having to cross the eukaryotic membrane. Girard et al. found that anti-Tir IgY was effective at preventing bacterial adhesion to porcine ileal in vitro organ culture against both porcine and human strains of enteropathogenic <italic>E. coli</italic> (EPEC). Ruano-Gallego et al. assessed the potential of an anti-Tir nanobody, TD4, as a treatment or prophylactic for EHEC infections. TD4 inhibits the attachment of EHEC to HeLa cells and reduces adherence to human colonic mucosa [<xref rid="B222-biomolecules-11-00316" ref-type="bibr">222</xref>]. The Tir-binding domain of intimin has also been investigated as an indirect way to inhibit Tir adhesion. Anti-intimin IgY was effective at reducing the adherence of both EPEC strains to host gut epithelial tissue in an ileal loop assay as well as in oral administration of the IgY [<xref rid="B223-biomolecules-11-00316" ref-type="bibr">223</xref>]. Saberianfar et al. investigated the Tir-binding domain of intimin as a target to isolate sdAbs from tobacco leaves. These sdAbs were used to design a chimeric Ab, V<sub>H</sub>H10-IgA. This Ab inhibited four strains of EHEC from adhering to host cells, with three of the four completely inhibited [<xref rid="B224-biomolecules-11-00316" ref-type="bibr">224</xref>]. V<sub>H</sub>H10-IgA&#x02019;s cross-serotype inhibition of bacterial adhesion is highly promising for future studies.</p><p>Multiple other small molecule and antibody inhibitors of adhesion targeting the intimate attachment of pathogenic <italic>E. coli</italic> have been discovered through the years [<xref rid="B102-biomolecules-11-00316" ref-type="bibr">102</xref>,<xref rid="B122-biomolecules-11-00316" ref-type="bibr">122</xref>,<xref rid="B225-biomolecules-11-00316" ref-type="bibr">225</xref>,<xref rid="B226-biomolecules-11-00316" ref-type="bibr">226</xref>,<xref rid="B227-biomolecules-11-00316" ref-type="bibr">227</xref>,<xref rid="B228-biomolecules-11-00316" ref-type="bibr">228</xref>,<xref rid="B229-biomolecules-11-00316" ref-type="bibr">229</xref>,<xref rid="B230-biomolecules-11-00316" ref-type="bibr">230</xref>,<xref rid="B231-biomolecules-11-00316" ref-type="bibr">231</xref>]. Quercetin (<xref ref-type="fig" rid="biomolecules-11-00316-f019">Figure 19</xref>) was recently implicated as an inhibitor by Xue et al. while observing <italic>E. coli</italic> O157:H7, the EHEC strain most commonly causing outbreaks, adhesion to human colon adenocarcinoma-2 (Caco-2) cells. Quercetin attenuated the association of multiple focal adhesion proteins, implying a mechanism of action associated with the N-terminus of Tir [<xref rid="B232-biomolecules-11-00316" ref-type="bibr">232</xref>]. Lin et al. tested quercetin&#x02019;s ability to reduce infection in a <italic>C. rodentium</italic> mouse model. They found that quercetin reduced colitis severity in infected mice, but the cause could not be confidently attributed to its adhesion inhibitory properties. This is because the populations of commensal bacteria such as <italic>Bacteroides</italic>, <italic>Bifidobacterium</italic>, <italic>Lactobacillus</italic>, and <italic>Clostridia</italic>, were increased in quercetin-treated mice. These commensals were likely able to out-compete the <italic>C. rodentium</italic> in the colon [<xref rid="B233-biomolecules-11-00316" ref-type="bibr">233</xref>].</p></sec><sec id="sec4dot2-biomolecules-11-00316"><title>4.2. Internalization Inhibition</title><p>Internalization is not the mechanism employed by all T3SS encoding bacterium, but it is essential for those that do. As with adhesion, one pathogen will be used to explain and exemplify the possible outcomes of internalization inhibition. <italic>S</italic>. Typhimurium is notorious for its ability to invade multiple mammalian and plant cell types [<xref rid="B234-biomolecules-11-00316" ref-type="bibr">234</xref>,<xref rid="B235-biomolecules-11-00316" ref-type="bibr">235</xref>,<xref rid="B236-biomolecules-11-00316" ref-type="bibr">236</xref>]. <italic>S</italic>. Typhimurium has multiple redundant mechanisms for adhesion and invasion, some T3SS-dependent, and some T3SS-independent. The only internalization via the T3SS allows for intracellular proliferation [<xref rid="B237-biomolecules-11-00316" ref-type="bibr">237</xref>,<xref rid="B238-biomolecules-11-00316" ref-type="bibr">238</xref>].</p><p>First, the T3SS-1 makes contact with the host cell and injects multiple effector proteins including SipA, SopE, SopE2, SopB, and SptP (<xref ref-type="fig" rid="biomolecules-11-00316-f020">Figure 20</xref>A). SipA binds to fimbrin, promoting actin rearrangement and polymerization as well as stabilizing the new actin filaments [<xref rid="B239-biomolecules-11-00316" ref-type="bibr">239</xref>,<xref rid="B240-biomolecules-11-00316" ref-type="bibr">240</xref>,<xref rid="B241-biomolecules-11-00316" ref-type="bibr">241</xref>,<xref rid="B242-biomolecules-11-00316" ref-type="bibr">242</xref>]. The minor translocon component, SipC, nucleates the actin filaments that grow out from the pore and create the membrane ruffles [<xref rid="B238-biomolecules-11-00316" ref-type="bibr">238</xref>,<xref rid="B243-biomolecules-11-00316" ref-type="bibr">243</xref>]. SopE activates Rac which eventually leads to upregulation of Arp2/3 and branching of the new actin filaments [<xref rid="B240-biomolecules-11-00316" ref-type="bibr">240</xref>,<xref rid="B244-biomolecules-11-00316" ref-type="bibr">244</xref>]. SopB upregulates the conversion of PIP<sub>2</sub> to PIP<sub>x</sub>, thereby increasing activation of RhoG and membrane ruffling, called the trigger response [<xref rid="B245-biomolecules-11-00316" ref-type="bibr">245</xref>,<xref rid="B246-biomolecules-11-00316" ref-type="bibr">246</xref>]. Once the host membrane ruffles have engulfed the bacterial cell into a <italic>Salmonella</italic> containing vesicle (SCV), SptP then downregulates Rac and Cdc42 via GAP activity to reduce host membrane ruffling (<xref ref-type="fig" rid="biomolecules-11-00316-f020">Figure 20</xref>B, faded) [<xref rid="B247-biomolecules-11-00316" ref-type="bibr">247</xref>,<xref rid="B248-biomolecules-11-00316" ref-type="bibr">248</xref>]. <italic>S. Typhimurium</italic> then expresses its T3SS-2 to proliferate and maintain its intracellular lifestyle (<xref ref-type="fig" rid="biomolecules-11-00316-f020">Figure 20</xref>D).</p><p>Quinine, an FDA-approved anti-malaria drug (<xref ref-type="fig" rid="biomolecules-11-00316-f021">Figure 21</xref>), was shown to inhibit the invasion process of <italic>S. Typhimurium</italic> and <italic>Shigella flexneri</italic> [<xref rid="B249-biomolecules-11-00316" ref-type="bibr">249</xref>]. Wolf et al. analyzed the ability of these pathogens to invade Caco-2 cells in the presence of 50 and 100 &#x000b5;M quinine sulfate. Extracellular bacteria were destroyed via gentamicin addition and intracellular bacterial were enumerated after lysis of the infected Caco-2 cells. Both pathogens were inhibited in a dose-dependent manner, although the highest concentration was only one order of magnitude smaller than the control. Cytotoxicity and growth inhibition tests showed that inhibition was occurring and not cell death. These results have been called into question, however, by the work of Kharal et al. who showed quinine was bactericidal to multiple species of bacteria, including <italic>P. aeruginosa</italic> and <italic>S. enterica</italic> serovar Typhi [<xref rid="B250-biomolecules-11-00316" ref-type="bibr">250</xref>].</p><p>The mechanism of host cell invasion and adhesion by pathogenic bacteria are often related. Inhibitors of the internalization process will potentially be adhesion inhibitors and vice versa. EGCG (<xref ref-type="fig" rid="biomolecules-11-00316-f021">Figure 21</xref>) has been shown to inhibit T3SS-mediated adhesion and internalization of multiple organisms including EPEC and EHEC, <italic>S.</italic> Typhimurium, and <italic>Y. pestis</italic> [<xref rid="B251-biomolecules-11-00316" ref-type="bibr">251</xref>,<xref rid="B252-biomolecules-11-00316" ref-type="bibr">252</xref>]. EGCG was analyzed for its ability to inhibit adherence of EPEC to human epithelial type 2 (Hep-2) cells. In this assay, EPEC was cultured with the Hep-2 cells and incubated for 2 h in the presence and absence of EGCG. The Hep-2 cells were then affixed to a microscope slide and stained with Giemsa to determine the number of adhered bacteria. EGCG at concentrations of 100 &#x003bc;M reduced adherence by ~50% [<xref rid="B251-biomolecules-11-00316" ref-type="bibr">251</xref>]. Tsou et al. evaluated EGCG&#x02019;s ability to inhibit <italic>S</italic>. Typhimurium invasion into HeLa cells via flow cytometry and immunofluorescence imaging using anti-<italic>Salmonella</italic> antibody staining. <italic>S</italic>. Typhimurium grown in the presence of 100 &#x000b5;M EGCG showed a significant reduction in its ability to invade the cultured HeLa cells. The level of reduction was similar to that of <italic>S</italic>. Typhimurium strain with a nonfunctional InvA. They demonstrated that EGCG did not affect bacterial growth but was inhibiting SPI1 T3SS-dependent <italic>S</italic>. Typhimurium invasion of host cells [<xref rid="B252-biomolecules-11-00316" ref-type="bibr">252</xref>].</p></sec><sec id="sec4dot3-biomolecules-11-00316"><title>4.3. Effector Chaperone Inhibition</title><p>Effector chaperones come in two varieties, class IA and class IB. Both IA and IB chaperones typically bind to the N-terminus of the effector by winding the unfolded effector around itself. There has also been some research showing the C-terminus of the effector retaining a globular conformation. This is commonly referred to as &#x0201c;threading the needle&#x0201d; [<xref rid="B128-biomolecules-11-00316" ref-type="bibr">128</xref>]. Class IA chaperones also typically only have one binding partner, while class IB chaperones have multiple unique effectors. Another differentiating factor between class IA and IB is that genes for IA chaperones are encoded adjacent to their binding partner, while IB chaperones are encoded near structural components.</p><p>The chaperone holds the effector and prevents the CBD from folding as it is transcribed by the ribosome. The chaperone carries the effector until it deposits it into the sorting platform of the basal body, allowing for a successful secretion of the linear effector. The chaperone then returns to the ribosome to cycle through the process again. In the case of a class IB chaperone, the cycle can continue with the same or an altogether different effector (<xref ref-type="fig" rid="biomolecules-11-00316-f022">Figure 22</xref>A). Knockouts of these multi-substrate chaperones, such as CesT, can drastically reduce or even eliminate the virulence capabilities of the pathogen. In the case of CesT, Runte et al. showed mutations in either tyrosine 152 or tyrosine 153 to phenylalanine had delayed colonization and the strains were more easily cleared from the intestine in a <italic>C. rodentium</italic> model of infection [<xref rid="B253-biomolecules-11-00316" ref-type="bibr">253</xref>].</p><p>Similar to structural chaperone inhibition, the inhibition of effector chaperones will have similar effects to inhibiting the effector itself. This comes with the caveat that class IB chaperones can have multiple effectors as binding partners [<xref rid="B254-biomolecules-11-00316" ref-type="bibr">254</xref>]. In essence, this leads to the inhibition of multiple effectors with one inhibitor. For example, the EPEC chaperone CesT has at least 13 known substrates: Tir, Map, EscJ, EscC, EspF, NleA, NleG, NleH1, NleH2, NleF, EspH, EspZ, &#x00026; EspG, making it an attractive target for inhibition [<xref rid="B127-biomolecules-11-00316" ref-type="bibr">127</xref>,<xref rid="B253-biomolecules-11-00316" ref-type="bibr">253</xref>,<xref rid="B255-biomolecules-11-00316" ref-type="bibr">255</xref>,<xref rid="B256-biomolecules-11-00316" ref-type="bibr">256</xref>,<xref rid="B257-biomolecules-11-00316" ref-type="bibr">257</xref>,<xref rid="B258-biomolecules-11-00316" ref-type="bibr">258</xref>,<xref rid="B259-biomolecules-11-00316" ref-type="bibr">259</xref>,<xref rid="B260-biomolecules-11-00316" ref-type="bibr">260</xref>]. As with the effector inhibition, there is the complication that even if you inhibit all effector chaperones within a pathogen then there will still be some effectors that are self-chaperoning and/or membrane-permeable (<xref ref-type="fig" rid="biomolecules-11-00316-f022">Figure 22</xref>B) [<xref rid="B133-biomolecules-11-00316" ref-type="bibr">133</xref>,<xref rid="B261-biomolecules-11-00316" ref-type="bibr">261</xref>]. They are often &#x0201c;floppy&#x0201d; or less structured proteins. An example of this would be the membrane-permeable effector from <italic>Y. pestis</italic>, YopM [<xref rid="B262-biomolecules-11-00316" ref-type="bibr">262</xref>,<xref rid="B263-biomolecules-11-00316" ref-type="bibr">263</xref>].</p><p>Targeting the protein-protein interaction between SctU and the CBD of chaperones is an attractive notion. In the absence of a correctly folded SctU, there was an increase of chaperone accumulation on the bacterial inner membrane, suggesting the interaction between the chaperone and SctU is necessary for T3SS secretion, making it an attractive interaction to target [<xref rid="B167-biomolecules-11-00316" ref-type="bibr">167</xref>]. Also, targeting the CBD will potentially inhibit self-chaperoning proteins as well as chaperones as they share a common motif [<xref rid="B133-biomolecules-11-00316" ref-type="bibr">133</xref>]. To date, there have been no inhibitors shown to interact at this site, likely due to the lack of mechanistic studies on effector secretion inhibitors.</p></sec></sec><sec sec-type="conclusions" id="sec5-biomolecules-11-00316"><title>5. Conclusions</title><p>The number of identified inhibitors of the T3SS has steadily increased over the years, but they are often discovered in phenotypic assays. This results in a lack of knowledge regarding their mechanism of action and the binding partners of the inhibitors. The current minimalistic approach to determining the mechanism of action of T3SS inhibitors can lead to incorrect assumptions about the target. The SAs are the perfect example of this effect. They have been shown to inhibit many structural features of the T3SS, but it is not yet confirmed if this is due to the small structural changes in the compounds screened, or due to bias of the phenotypic screen. Many SAs have also been shown to modulate the expression or genetic regulation of T3SS components and effectors &#x02013; a possible explanation for the disparity in phenotypic results. Although these inhibitors, like INP0341 [<xref rid="B264-biomolecules-11-00316" ref-type="bibr">264</xref>], have shown recent successes in vitro and in vivo, they were excluded from this review as they have yet to be shown as direct inhibitors of the T3SS.</p><p>This review covered direct inhibitors of T3SS components, whether structural or functional in mechanism. Inhibition of needle and translocon components, and/or their regulatory proteins, reduces the number of functional needles and increases truncated needle prevalence, resulting in little to no effector translocation into host cells, but can allow for secretion into the intracellular matrix. Inhibitors binding to any components of the T3SS base, including the basal body, export apparatus, and cytoplasmic complex, tend to prevent the formation of functional T3SS apparatuses, thereby stopping effector secretion. While this a more complete method of inhibition, inhibitors using this method are susceptible to off-target effects as base components of the T3SS are more conserved with other secretion systems. Effector inhibition, while not highly effective for most T3SS-utilizing pathogens, is very effective when a specific effector is responsible for a majority of symptoms or pathogenesis initiation. Collectively, this knowledge can be used for the rational design and improvement of T3SS inhibitors.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Writing&#x02014;original draft preparation, J.A.H., H.A.P., and A.E.M.; writing&#x02014;review and editing, J.A.H., H.A.P., and A.E.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by startup funds from the School of Pharmacy at Virginia Commonwealth University (VCU). This work was also supported by VCU&#x02019;s CTSA (UL1TR002649 from the National Center for Advancing Translational Sciences) and the CCTR Endowment Fund of Virginia Commonwealth University.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biomolecules-11-00316"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>CDC National Centre for Health Statistics</collab></person-group><article-title>Expectancy</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/fastats/life-expectancy.htm">https://www.cdc.gov/nchs/fastats/life-expectancy.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-12">(accessed on 12 October 2019)</date-in-citation></element-citation></ref><ref id="B2-biomolecules-11-00316"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munita</surname><given-names>J.M.</given-names></name><name><surname>Arias</surname><given-names>C.A.</given-names></name></person-group><article-title>Mechanisms of antibiotic resistance</article-title><source>Microbiol. Spectr.</source><year>2016</year><volume>4</volume><pub-id pub-id-type="doi">10.1128/microbiolspec.VMBF-0016-2015</pub-id><?supplied-pmid 27227291?><pub-id pub-id-type="pmid">27227291</pub-id></element-citation></ref><ref id="B3-biomolecules-11-00316"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyser</surname><given-names>P.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Rosell</surname><given-names>S.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name></person-group><article-title>Virulence blockers as alternatives to antibiotics: Type III secretion inhibitors against Gram-negative bacteria</article-title><source>J. Intern. Med.</source><year>2008</year><volume>264</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2008.01941.x</pub-id><pub-id pub-id-type="pmid">18393958</pub-id></element-citation></ref><ref id="B4-biomolecules-11-00316"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelis</surname><given-names>G.R.</given-names></name><name><surname>Van Gijsegem</surname><given-names>F.</given-names></name></person-group><article-title>Assembly and Function of Type III Secretory Systems</article-title><source>Annu. Rev. Microbiol.</source><year>2000</year><volume>54</volume><fpage>735</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.54.1.735</pub-id><pub-id pub-id-type="pmid">11018143</pub-id></element-citation></ref><ref id="B5-biomolecules-11-00316"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmond</surname><given-names>G.P.</given-names></name><name><surname>Reeves</surname><given-names>P.J.</given-names></name></person-group><article-title>Membrance traffic wardens and protein secretion in Gram-negative bacteria</article-title><source>Trends Biochem. Sci.</source><year>1993</year><volume>18</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(93)90080-7</pub-id><pub-id pub-id-type="pmid">8438237</pub-id></element-citation></ref><ref id="B6-biomolecules-11-00316"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaillard</surname><given-names>M.E.</given-names></name><name><surname>Bottero</surname><given-names>D.</given-names></name><name><surname>Castuma</surname><given-names>C.E.</given-names></name><name><surname>Basile</surname><given-names>L.A.</given-names></name><name><surname>Hozbor</surname><given-names>D.</given-names></name></person-group><article-title>Laboratory adaptation of <italic>Bordetella pertussis</italic> is associated with the loss of type three secretion system functionality&#x01c14;</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>3677</fpage><lpage>3682</lpage><pub-id pub-id-type="doi">10.1128/IAI.00136-11</pub-id><pub-id pub-id-type="pmid">21730086</pub-id></element-citation></ref><ref id="B7-biomolecules-11-00316"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>M.P.</given-names></name><name><surname>Wood</surname><given-names>M.W.</given-names></name><name><surname>Taylor</surname><given-names>L.A.</given-names></name><name><surname>Monaghan</surname><given-names>P.</given-names></name><name><surname>Hawes</surname><given-names>P.</given-names></name><name><surname>Jones</surname><given-names>P.W.</given-names></name><name><surname>Wallis</surname><given-names>T.S.</given-names></name><name><surname>Galyov</surname><given-names>E.E.</given-names></name></person-group><article-title>An Inv/Mxi-Spa-like type III protein secretion system in <italic>Burkholderia pseudomallei</italic> modulates intracellular behaviour of the pathogen</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>46</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.03190.x</pub-id><?supplied-pmid 12410823?><pub-id pub-id-type="pmid">12410823</pub-id></element-citation></ref><ref id="B8-biomolecules-11-00316"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>Conserved type III secretion system exerts important roles in <italic>Chlamydia trachomatis</italic></article-title><source>Int. J. Clin. Exp. Pathol.</source><year>2014</year><volume>7</volume><fpage>5404</fpage><lpage>5414</lpage><pub-id pub-id-type="pmid">25337183</pub-id></element-citation></ref><ref id="B9-biomolecules-11-00316"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croxen</surname><given-names>M.A.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Molecular mechanisms of <italic>Escherichia coli</italic> pathogenicity</article-title><source>Nat. Rev. Genet.</source><year>2009</year><volume>8</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2265</pub-id><?supplied-pmid 19966814?><pub-id pub-id-type="pmid">19966814</pub-id></element-citation></ref><ref id="B10-biomolecules-11-00316"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzin</surname><given-names>F.M.</given-names></name><name><surname>Sircili</surname><given-names>M.P.</given-names></name></person-group><article-title>Locus of enterocyte effacement: A pathogenicity island involved in the virulence of enteropathogenic and enterohemorrhagic <italic>Escherichia coli</italic> subjected to a complex network of gene regulation</article-title><source>Biomed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>534738</fpage><pub-id pub-id-type="doi">10.1155/2015/534738</pub-id><pub-id pub-id-type="pmid">25710006</pub-id></element-citation></ref><ref id="B11-biomolecules-11-00316"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>K.G.</given-names></name><name><surname>Giron</surname><given-names>J.A.</given-names></name><name><surname>Jerse</surname><given-names>A.E.</given-names></name><name><surname>McDaniel</surname><given-names>T.K.</given-names></name><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name><name><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>Enteropathogenic <italic>Escherichia coli</italic> contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>7996</fpage><lpage>8000</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.17.7996</pub-id><?supplied-pmid 7644527?><pub-id pub-id-type="pmid">7644527</pub-id></element-citation></ref><ref id="B12-biomolecules-11-00316"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontaine</surname><given-names>A.</given-names></name><name><surname>Arondel</surname><given-names>J.</given-names></name><name><surname>Sansonetti</surname><given-names>P.J.</given-names></name></person-group><article-title>Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of <italic>Shigella dysenteriae</italic> 1</article-title><source>Infect. Immun.</source><year>1988</year><volume>56</volume><fpage>3099</fpage><lpage>3109</lpage><pub-id pub-id-type="doi">10.1128/IAI.56.12.3099-3109.1988</pub-id><pub-id pub-id-type="pmid">3053452</pub-id></element-citation></ref><ref id="B13-biomolecules-11-00316"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Tam</surname><given-names>V.</given-names></name><name><surname>Hamilton</surname><given-names>E.</given-names></name><name><surname>Dziejman</surname><given-names>M.</given-names></name></person-group><article-title>VttR A and vttR B encode ToxR family proteins that mediate bile-induced expression of type three secretion system genes in a Non-O1/Non-O139 <italic>Vibrio cholerae</italic> strain</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>2554</fpage><lpage>2570</lpage><pub-id pub-id-type="doi">10.1128/IAI.01073-09</pub-id><pub-id pub-id-type="pmid">20385759</pub-id></element-citation></ref><ref id="B14-biomolecules-11-00316"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marketon</surname><given-names>M.M.</given-names></name><name><surname>DePaolo</surname><given-names>R.W.</given-names></name><name><surname>Debord</surname><given-names>K.L.</given-names></name><name><surname>Jabri</surname><given-names>B.</given-names></name><name><surname>Schneewind</surname><given-names>O.</given-names></name></person-group><article-title>Plague bacteria target immune cells during infection</article-title><source>Sci.</source><year>2005</year><volume>309</volume><fpage>1739</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1126/science.1114580</pub-id></element-citation></ref><ref id="B15-biomolecules-11-00316"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartra</surname><given-names>S.S.</given-names></name><name><surname>Lorica</surname><given-names>C.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Bahnan</surname><given-names>W.</given-names></name><name><surname>Barreras</surname><given-names>H.B.</given-names><suffix>Jr.</suffix></name><name><surname>Hernandez</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Plano</surname><given-names>G.V.</given-names></name><name><surname>Schesser</surname><given-names>K.</given-names></name></person-group><article-title>Chromosomally-encoded <italic>Yersinia pestis</italic> type III secretion effector proteins promote infection in cells and in mice</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00023</pub-id><pub-id pub-id-type="pmid">30854334</pub-id></element-citation></ref><ref id="B16-biomolecules-11-00316"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fast</surname><given-names>M.D.</given-names></name><name><surname>Tse</surname><given-names>B.</given-names></name><name><surname>Boyd</surname><given-names>J.M.</given-names></name><name><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>Mutations in the <italic>Aeromonas salmonicida</italic> subsp. salmonicida type III secretion system affect Atlantic salmon leucocyte activation and downstream immune responses</article-title><source>Fish Shellfish. Immunol.</source><year>2009</year><volume>27</volume><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2009.09.009</pub-id><pub-id pub-id-type="pmid">19751835</pub-id></element-citation></ref><ref id="B17-biomolecules-11-00316"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Tan</surname><given-names>Y.P.</given-names></name><name><surname>Sivaraman</surname><given-names>J.</given-names></name><name><surname>Mok</surname><given-names>Y.-K.</given-names></name><name><surname>Mo</surname><given-names>Z.L.</given-names></name><name><surname>Leung</surname><given-names>K.Y.</given-names></name></person-group><article-title>EscC is a chaperone for the <italic>Edwardsiella tarda</italic> type III secretion system putative translocon components EseB and EseD</article-title><source>Microbiology</source><year>2007</year><volume>153</volume><fpage>1953</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2006/004952-0</pub-id><pub-id pub-id-type="pmid">17526852</pub-id></element-citation></ref><ref id="B18-biomolecules-11-00316"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liverman</surname><given-names>A.D.B.</given-names></name><name><surname>Cheng</surname><given-names>H.C.</given-names></name><name><surname>Trosky</surname><given-names>J.E.</given-names></name><name><surname>Leung</surname><given-names>D.W.</given-names></name><name><surname>Yarbrough</surname><given-names>M.L.</given-names></name><name><surname>Burdette</surname><given-names>D.L.</given-names></name><name><surname>Rosen</surname><given-names>M.K.</given-names></name><name><surname>Orth</surname><given-names>K.</given-names></name></person-group><article-title>Arp2/3-independent assembly of actin by <italic>Vibrio</italic> type III effector VopL</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>17117</fpage><lpage>17122</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703196104</pub-id><?supplied-pmid 17942696?><pub-id pub-id-type="pmid">17942696</pub-id></element-citation></ref><ref id="B19-biomolecules-11-00316"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdanove</surname><given-names>A.J.</given-names></name><name><surname>Wei</surname><given-names>Z.M.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Beer</surname><given-names>S.V.</given-names></name></person-group><article-title><italic>Erwinia amylovora</italic> secretes harpin via a type III pathway and contains a homolog of yopN of <italic>Yersinia</italic> spp.</article-title><source>J. Bacteriol.</source><year>1996</year><volume>178</volume><fpage>1720</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1128/JB.178.6.1720-1730.1996</pub-id><?supplied-pmid 8626302?><pub-id pub-id-type="pmid">8626302</pub-id></element-citation></ref><ref id="B20-biomolecules-11-00316"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hueck</surname><given-names>C.J.</given-names></name></person-group><article-title>Type III protein secretion systems in bacterial pathogens of animals and plants</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>1998</year><volume>62</volume><fpage>379</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/MMBR.62.2.379-433.1998</pub-id><?supplied-pmid 9618447?><pub-id pub-id-type="pmid">9618447</pub-id></element-citation></ref><ref id="B21-biomolecules-11-00316"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badel</surname><given-names>J.L.</given-names></name><name><surname>Nomura</surname><given-names>K.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name><name><surname>Shimizu</surname><given-names>R.</given-names></name><name><surname>Collmer</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>S.Y.</given-names></name></person-group><article-title><italic>Pseudomonas syringae</italic> pv. tomato DC3000 HopPtoM (CEL ORF3) is important for lesion formation but not growth in tomato and is secreted and translocated by the Hrp type III secretion system in a chaperone-dependent manner</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>49</volume><fpage>1239</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03647.x</pub-id><pub-id pub-id-type="pmid">12940984</pub-id></element-citation></ref><ref id="B22-biomolecules-11-00316"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossier</surname><given-names>O.</given-names></name><name><surname>Wengelnik</surname><given-names>K.</given-names></name><name><surname>Hahn</surname><given-names>K.</given-names></name><name><surname>Bonas</surname><given-names>U.</given-names></name></person-group><article-title>The <italic>Xanthomonas</italic> Hrp type III system secretes proteins from plant and mammalian bacterial pathogens</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>9368</fpage><lpage>9373</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.16.9368</pub-id><pub-id pub-id-type="pmid">10430949</pub-id></element-citation></ref><ref id="B23-biomolecules-11-00316"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Diepold</surname><given-names>A.</given-names></name></person-group><article-title>A unified nomenclature for injectisome-type type III secretion systems</article-title><source>Curr. Topics Microbiol. Immunol.</source><year>2020</year><volume>427</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/82_2020_210</pub-id><?supplied-pmid 32415388?><pub-id pub-id-type="pmid">32415388</pub-id></element-citation></ref><ref id="B24-biomolecules-11-00316"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jessen Condry</surname><given-names>D.L.</given-names></name><name><surname>Nilles</surname><given-names>M.L.</given-names></name></person-group><article-title>Identification of the targets of type III secretion system inhibitors</article-title><source>Methods in Molecular Biology</source><publisher-name>Humana Press Inc.</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2017</year><volume>Volume 1531</volume><fpage>203</fpage><lpage>211</lpage></element-citation></ref><ref id="B25-biomolecules-11-00316"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>D.L.</given-names></name><name><surname>Bradley</surname><given-names>D.S.</given-names></name><name><surname>Nilles</surname><given-names>M.L.</given-names></name></person-group><article-title>A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of <italic>Yersinia pestis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1128/AAC.01170-13</pub-id><pub-id pub-id-type="pmid">24247143</pub-id></element-citation></ref><ref id="B26-biomolecules-11-00316"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>P.</given-names></name></person-group><article-title>Functional domains and motifs of bacterial type III effector proteins and their roles in infection</article-title><source>FEMS Microbiol. Rev.</source><year>2011</year><volume>35</volume><fpage>1100</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2011.00271.x</pub-id><pub-id pub-id-type="pmid">21517912</pub-id></element-citation></ref><ref id="B27-biomolecules-11-00316"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Grado</surname><given-names>M.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>Gauthier</surname><given-names>A.</given-names></name><name><surname>Steele-Mortimer</surname><given-names>O.</given-names></name><name><surname>DeVinney</surname><given-names>R.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Identification of the intimin-binding domain of Tir of enteropathogenic <italic>Escherichia coli</italic></article-title><source>Cell. Microbiol.</source><year>1999</year><volume>1</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.1999.00001.x</pub-id><?supplied-pmid 11207537?><pub-id pub-id-type="pmid">11207537</pub-id></element-citation></ref><ref id="B28-biomolecules-11-00316"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendergrass</surname><given-names>H.A.</given-names></name><name><surname>May</surname><given-names>A.E.</given-names></name></person-group><article-title>Natural product type III secretion system inhibitors</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8040162</pub-id></element-citation></ref><ref id="B29-biomolecules-11-00316"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hume</surname><given-names>P.J.</given-names></name><name><surname>Singh</surname><given-names>V.</given-names></name><name><surname>Davidson</surname><given-names>A.C.</given-names></name><name><surname>Koronakis</surname><given-names>V.</given-names></name></person-group><article-title>Swiss army pathogen: The <italic>Salmonella</italic> entry toolkit</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2017</year><volume>7</volume><fpage>348</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00348</pub-id><?supplied-pmid 28848711?><pub-id pub-id-type="pmid">28848711</pub-id></element-citation></ref><ref id="B30-biomolecules-11-00316"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattock</surname><given-names>E.</given-names></name><name><surname>Blocker</surname><given-names>A.J.</given-names></name></person-group><article-title>How do the virulence factors of <italic>Shigella</italic> work together to cause disease?</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2017</year><volume>7</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00064</pub-id><?supplied-pmid 28393050?><pub-id pub-id-type="pmid">28393050</pub-id></element-citation></ref><ref id="B31-biomolecules-11-00316"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Mei</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Yi</surname><given-names>L.</given-names></name></person-group><article-title>The functions of effector proteins in <italic>Yersinia</italic> virulence</article-title><source>Pol. J. Microbiol.</source><year>2016</year><volume>65</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.5604/17331331.1197324</pub-id><pub-id pub-id-type="pmid">27281989</pub-id></element-citation></ref><ref id="B32-biomolecules-11-00316"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissim-Eliraz</surname><given-names>E.</given-names></name><name><surname>Nir</surname><given-names>E.</given-names></name><name><surname>Shoval</surname><given-names>I.</given-names></name><name><surname>Marsiano</surname><given-names>N.</given-names></name><name><surname>Nissan</surname><given-names>I.</given-names></name><name><surname>Shemesh</surname><given-names>H.</given-names></name><name><surname>Nagy</surname><given-names>N.</given-names></name><name><surname>Goldstein</surname><given-names>A.M.</given-names></name><name><surname>Gutnick</surname><given-names>M.</given-names></name><name><surname>Rosenshine</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Microvascular thrombosis and ischemic enteritis in human gut xenografts infected with enteropathogenic <italic>E. Coli</italic></article-title><source>Infect. Immun.</source><year>2017</year><volume>85</volume><fpage>e00558-17</fpage><pub-id pub-id-type="doi">10.1128/IAI.00558-17</pub-id><?supplied-pmid 28784929?><pub-id pub-id-type="pmid">28784929</pub-id></element-citation></ref><ref id="B33-biomolecules-11-00316"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>S.H.</given-names></name><name><surname>Hasegawa</surname><given-names>P.</given-names></name><name><surname>Okamoto</surname><given-names>S.</given-names></name><name><surname>Fierer</surname><given-names>J.</given-names></name><name><surname>Guiney</surname><given-names>D.G.</given-names></name></person-group><article-title>Identification of <italic>Salmonella</italic> SPI-2 secretion system components required for SpvB-mediated cytotoxicity in macrophages and virulence in mice</article-title><source>FEMS</source><year>2008</year><volume>1</volume><fpage>194</fpage><lpage>201</lpage></element-citation></ref><ref id="B34-biomolecules-11-00316"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berube</surname><given-names>B.J.</given-names></name><name><surname>Murphy</surname><given-names>K.R.</given-names></name><name><surname>Torhan</surname><given-names>M.C.</given-names></name><name><surname>Bowlin</surname><given-names>N.O.</given-names></name><name><surname>Williams</surname><given-names>J.D.</given-names></name><name><surname>Bowlin</surname><given-names>T.L.</given-names></name><name><surname>Moir</surname><given-names>D.T.</given-names></name><name><surname>Hauser</surname><given-names>A.R.</given-names></name></person-group><article-title>Impact of type III secretion effectors and of phenoxyacetamide inhibitors of type III secretion on abscess formation in a mouse model of <italic>Pseudomonas aeruginosa</italic> infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e01202-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01202-17</pub-id><?supplied-pmid 28807906?><pub-id pub-id-type="pmid">28807906</pub-id></element-citation></ref><ref id="B35-biomolecules-11-00316"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marteyn</surname><given-names>B.</given-names></name><name><surname>West</surname><given-names>N.P.</given-names></name><name><surname>Browning</surname><given-names>D.F.</given-names></name><name><surname>Cole</surname><given-names>J.A.</given-names></name><name><surname>Shaw</surname><given-names>J.G.</given-names></name><name><surname>Palm</surname><given-names>F.</given-names></name><name><surname>Mounier</surname><given-names>J.</given-names></name><name><surname>Pr&#x000e9;vost</surname><given-names>M.-C.</given-names></name><name><surname>Sansonetti</surname><given-names>P.</given-names></name><name><surname>Tang</surname><given-names>C.M.</given-names></name></person-group><article-title>Modulation of <italic>Shigella</italic> virulence in response to available oxygen in vivo</article-title><source>Nat. Cell Biol.</source><year>2010</year><volume>465</volume><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/nature08970</pub-id></element-citation></ref><ref id="B36-biomolecules-11-00316"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampaio</surname><given-names>S.C.F.</given-names></name><name><surname>Moreira</surname><given-names>F.C.</given-names></name><name><surname>Liberatore</surname><given-names>A.M.A.</given-names></name><name><surname>Vieira</surname><given-names>M.A.M.</given-names></name><name><surname>Knobl</surname><given-names>T.</given-names></name><name><surname>Rom&#x000e3;o</surname><given-names>F.T.</given-names></name><name><surname>Hernandes</surname><given-names>R.T.</given-names></name><name><surname>Ferreira</surname><given-names>C.S.A.</given-names></name><name><surname>Ferreira</surname><given-names>A.P.</given-names></name><name><surname>Felipe-silva</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Analysis of the virulence of an atypical enteropathogenic <italic>Escherichia coli</italic> strain <italic>in vitro</italic> and in vivo and the influence of type three secretion system</article-title><source>Biomed. Res. Int.</source><year>2014</year><volume>2014</volume><pub-id pub-id-type="doi">10.1155/2014/797508</pub-id></element-citation></ref><ref id="B37-biomolecules-11-00316"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>J.R.C.</given-names></name><name><surname>Worrall</surname><given-names>L.J.</given-names></name><name><surname>Sgourakis</surname><given-names>N.G.</given-names></name><name><surname>DiMaio</surname><given-names>F.</given-names></name><name><surname>Pfuetzner</surname><given-names>R.A.</given-names></name><name><surname>Felise</surname><given-names>H.B.</given-names></name><name><surname>Vuckovic</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>A.C.</given-names></name><name><surname>Miller</surname><given-names>S.I.</given-names></name><name><surname>Baker</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A refined model of the prototypical <italic>Salmonella</italic> SPI-1 T3SS basal body reveals the molecular basis for its assembly</article-title><source>PLOS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003307</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003307</pub-id><?supplied-pmid 23633951?><pub-id pub-id-type="pmid">23633951</pub-id></element-citation></ref><ref id="B38-biomolecules-11-00316"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernal</surname><given-names>I.</given-names></name><name><surname>B&#x000f6;rnicke</surname><given-names>J.</given-names></name><name><surname>Heidemann</surname><given-names>J.</given-names></name><name><surname>Svergun</surname><given-names>D.</given-names></name><name><surname>Horstmann</surname><given-names>J.A.</given-names></name><name><surname>Erhardt</surname><given-names>M.</given-names></name><name><surname>Tuukkanen</surname><given-names>A.</given-names></name><name><surname>Uetrecht</surname><given-names>C.</given-names></name><name><surname>Kolbe</surname><given-names>M.</given-names></name></person-group><article-title>Molecular organization of soluble type III secretion system sorting platform complexes</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>3787</fpage><lpage>3803</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.07.004</pub-id><?supplied-pmid 31288030?><pub-id pub-id-type="pmid">31288030</pub-id></element-citation></ref><ref id="B39-biomolecules-11-00316"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>T.C.</given-names></name><name><surname>Ochoa</surname><given-names>C.D.</given-names></name><name><surname>Morrow</surname><given-names>K.A.</given-names></name><name><surname>Robson</surname><given-names>M.J.</given-names></name><name><surname>Prasain</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>D.F.</given-names></name><name><surname>Frank</surname><given-names>D.W.</given-names></name><name><surname>Balczon</surname><given-names>R.</given-names></name><name><surname>Stevens</surname><given-names>T.</given-names></name></person-group><article-title>The <italic>Pseudomonas aeruginosa</italic> exoenzyme Y impairs endothelial cell proliferation and vascular repair following lung injury</article-title><source>Am. J. Physiol. Cell. Mol. Physiol.</source><year>2014</year><volume>306</volume><fpage>L915</fpage><lpage>L924</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00135.2013</pub-id></element-citation></ref><ref id="B40-biomolecules-11-00316"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>M.C.</given-names></name><name><surname>Linington</surname><given-names>R.G.</given-names></name><name><surname>Auerbuch</surname><given-names>V.</given-names></name></person-group><article-title>Chemical inhibitors of the type three secretion system: Disarming bacterial pathogens</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>5433</fpage><lpage>5441</lpage><pub-id pub-id-type="doi">10.1128/AAC.00975-12</pub-id><?supplied-pmid 22850518?><pub-id pub-id-type="pmid">22850518</pub-id></element-citation></ref><ref id="B41-biomolecules-11-00316"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minamino</surname><given-names>T.</given-names></name><name><surname>Kawamoto</surname><given-names>A.</given-names></name><name><surname>Kinoshita</surname><given-names>M.</given-names></name><name><surname>Namba</surname><given-names>K.</given-names></name></person-group><article-title>Molecular organization and assembly of the export apparatus off flagellar type III secretion systems</article-title><source>Curr. Topics Microbiol. Immunol.</source><year>2019</year><volume>427</volume><fpage>91</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/82_2019_170</pub-id></element-citation></ref><ref id="B42-biomolecules-11-00316"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>A.R.</given-names></name></person-group><article-title>The type III secretion system of <italic>Pseudomonas aeruginosa</italic>: Infection by injection</article-title><source>Nat. Rev. Genet.</source><year>2009</year><volume>7</volume><fpage>654</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2199</pub-id></element-citation></ref><ref id="B43-biomolecules-11-00316"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name></person-group><article-title>Common themes in the design and function of bacterial effectors</article-title><source>Cell Host Microbe</source><year>2009</year><volume>5</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.04.008</pub-id><pub-id pub-id-type="pmid">19527884</pub-id></element-citation></ref><ref id="B44-biomolecules-11-00316"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golubeva</surname><given-names>Y.A.</given-names></name><name><surname>Sadik</surname><given-names>A.Y.</given-names></name><name><surname>Ellermeier</surname><given-names>J.R.</given-names></name><name><surname>Slauch</surname><given-names>J.M.</given-names></name></person-group><article-title>Integrating global regulatory input into the <italic>Salmonella</italic> Pathogenicity Island 1 type III secretion system</article-title><source>Genetics</source><year>2012</year><volume>190</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1534/genetics.111.132779</pub-id><?supplied-pmid 22021388?><pub-id pub-id-type="pmid">22021388</pub-id></element-citation></ref><ref id="B45-biomolecules-11-00316"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Shinoda</surname><given-names>N.</given-names></name><name><surname>Hiramatsu</surname><given-names>Y.</given-names></name><name><surname>Ohnishi</surname><given-names>S.</given-names></name><name><surname>Kamitani</surname><given-names>S.</given-names></name><name><surname>Ogura</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Horiguchi</surname><given-names>Y.</given-names></name></person-group><article-title>BspR/BtrA, an anti-&#x003c3; factor, regulates the ability of <italic>Bordetella bronchiseptica</italic> to cause cough in rats</article-title><source>mSphere</source><year>2019</year><volume>4</volume><fpage>e00093-19</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00093-19</pub-id><?supplied-pmid 31019000?><pub-id pub-id-type="pmid">31019000</pub-id></element-citation></ref><ref id="B46-biomolecules-11-00316"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>S.</given-names></name><name><surname>Okada</surname><given-names>R.</given-names></name><name><surname>Tandhavanant</surname><given-names>S.</given-names></name><name><surname>Hiyoshi</surname><given-names>H.</given-names></name><name><surname>Gotoh</surname><given-names>K.</given-names></name><name><surname>Iida</surname><given-names>T.</given-names></name><name><surname>Kodama</surname><given-names>T.</given-names></name></person-group><article-title>Export of a <italic>Vibrio parahaemolyticus</italic> toxin by the Sec and type III secretion machineries in tandem</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0368-y</pub-id><?supplied-pmid 30778145?><pub-id pub-id-type="pmid">30778145</pub-id></element-citation></ref><ref id="B47-biomolecules-11-00316"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>T3DB: An integrated database for bacterial type III secretion system</article-title><source>BMC Bioinform.</source><year>2012</year><volume>13</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-13-66</pub-id></element-citation></ref><ref id="B48-biomolecules-11-00316"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barret</surname><given-names>M.</given-names></name><name><surname>Egan</surname><given-names>F.</given-names></name><name><surname>O&#x02019;Gara</surname><given-names>F.</given-names></name></person-group><article-title>Distribution and diversity of bacterial secretion systems across metagenomic datasets</article-title><source>Environ. Microbiol. Rep.</source><year>2013</year><volume>5</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/j.1758-2229.2012.00394.x</pub-id><pub-id pub-id-type="pmid">23757140</pub-id></element-citation></ref><ref id="B49-biomolecules-11-00316"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>D.</given-names></name><name><surname>Williams</surname><given-names>J.D.</given-names></name><name><surname>Majgier-Baranowska</surname><given-names>H.</given-names></name><name><surname>Patel</surname><given-names>I.</given-names></name><name><surname>Peet</surname><given-names>N.P.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Lory</surname><given-names>S.</given-names></name><name><surname>Bowlin</surname><given-names>T.L.</given-names></name><name><surname>Moir</surname><given-names>D.T.</given-names></name></person-group><article-title>Discovery and characterization of inhibitors of <italic>Pseudomonas aeruginosa</italic> type III secretion</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>1988</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1128/AAC.01598-09</pub-id><?supplied-pmid 20176902?><pub-id pub-id-type="pmid">20176902</pub-id></element-citation></ref><ref id="B50-biomolecules-11-00316"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasciano</surname><given-names>A.C.</given-names></name><name><surname>Shaban</surname><given-names>L.</given-names></name><name><surname>Mecsas</surname><given-names>J.</given-names></name></person-group><article-title>Promises and challenges of the type three secretion system injectisome as an antivirulence target</article-title><source>Protein Secretion in Bacteria</source><year>2019</year><volume>8</volume><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1128/ecosalplus.esp-0032-2018</pub-id></element-citation></ref><ref id="B51-biomolecules-11-00316"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linington</surname><given-names>R.G.</given-names></name><name><surname>Robertson</surname><given-names>M.</given-names></name><name><surname>Gauthier</surname><given-names>A.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name><name><surname>van Soest</surname><given-names>R.</given-names></name><name><surname>Andersen</surname><given-names>R.J.</given-names></name></person-group><article-title>Caminoside A, an antimicrobial glycolipid isolated from the marine sponge <italic>Caminus sphaeroconia</italic></article-title><source>Org. Lett.</source><year>2002</year><volume>4</volume><fpage>4089</fpage><lpage>4092</lpage><pub-id pub-id-type="doi">10.1021/ol0268337</pub-id><pub-id pub-id-type="pmid">12423093</pub-id></element-citation></ref><ref id="B52-biomolecules-11-00316"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>A.E.</given-names></name><name><surname>Khosla</surname><given-names>C.</given-names></name></person-group><article-title>Discovery and mechanism of type III secretion system inhibitors</article-title><source>Isr. J. Chem.</source><year>2013</year><volume>53</volume><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1002/ijch.201300025</pub-id></element-citation></ref><ref id="B53-biomolecules-11-00316"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kol&#x000e1;&#x00159;</surname><given-names>M.</given-names></name><name><surname>Urb&#x000e1;nek</surname><given-names>K.</given-names></name><name><surname>L&#x000e1;tal</surname><given-names>T.</given-names></name></person-group><article-title>Antibiotic selective pressure and development of bacterial resistance</article-title><source>Int. J. Antimicrob. Agents</source><year>2001</year><volume>17</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/S0924-8579(01)00317-X</pub-id><pub-id pub-id-type="pmid">11337221</pub-id></element-citation></ref><ref id="B54-biomolecules-11-00316"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Innovation and application of the type III secretion system inhibitors in plant pathogenic bacteria</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1956</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8121956</pub-id><?supplied-pmid 33317075?><pub-id pub-id-type="pmid">33317075</pub-id></element-citation></ref><ref id="B55-biomolecules-11-00316"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troisfontaines</surname><given-names>P.</given-names></name><name><surname>Cornelis</surname><given-names>G.R.</given-names></name></person-group><article-title>Type III secretion: More systems than you think</article-title><source>Physiology</source><year>2005</year><volume>20</volume><fpage>326</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1152/physiol.00011.2005</pub-id><pub-id pub-id-type="pmid">16174872</pub-id></element-citation></ref><ref id="B56-biomolecules-11-00316"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelis</surname><given-names>G.R.</given-names></name></person-group><article-title>The type III secretion injectisome</article-title><source>Nat. Rev. Genet.</source><year>2006</year><volume>4</volume><fpage>811</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1526</pub-id><?supplied-pmid 17041629?><pub-id pub-id-type="pmid">17041629</pub-id></element-citation></ref><ref id="B57-biomolecules-11-00316"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vishwakarma</surname><given-names>V.</given-names></name><name><surname>Pati</surname><given-names>N.B.</given-names></name><name><surname>Chandel</surname><given-names>H.S.</given-names></name><name><surname>Sahoo</surname><given-names>S.S.</given-names></name><name><surname>Saha</surname><given-names>B.</given-names></name><name><surname>Suar</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of <italic>Salmonella enterica</italic> serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e52043</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0052043</pub-id><?supplied-pmid 23284865?><pub-id pub-id-type="pmid">23284865</pub-id></element-citation></ref><ref id="B58-biomolecules-11-00316"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodou</surname><given-names>A.</given-names></name><name><surname>Ankrah</surname><given-names>D.O.</given-names></name><name><surname>Stathopoulos</surname><given-names>C.</given-names></name></person-group><article-title>Toxins and secretion systems of <italic>Photorhabdus luminescens</italic></article-title><source>Toxins</source><year>2010</year><volume>2</volume><fpage>1250</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.3390/toxins2061250</pub-id><pub-id pub-id-type="pmid">22069636</pub-id></element-citation></ref><ref id="B59-biomolecules-11-00316"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelis</surname><given-names>G.R.</given-names></name></person-group><article-title>The <italic>Yersinia</italic> Ysc&#x02013;Yop &#x0201c;type III&#x0201d; weaponry</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2002</year><volume>3</volume><fpage>742</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1038/nrm932</pub-id><pub-id pub-id-type="pmid">12360191</pub-id></element-citation></ref><ref id="B60-biomolecules-11-00316"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>H.</given-names></name><name><surname>Young</surname><given-names>G.M.</given-names></name></person-group><article-title>Translocated effectors of <italic>Yersinia</italic></article-title><source>Curr. Opin. Microbiol.</source><year>2009</year><volume>12</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2008.12.005</pub-id><?supplied-pmid 19185531?><pub-id pub-id-type="pmid">19185531</pub-id></element-citation></ref><ref id="B61-biomolecules-11-00316"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>C.</given-names></name></person-group><article-title>The insect endosymbiont <italic>Sodalis glossinidius</italic> utilizes a type III secretion system for cell invasion</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>1883</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1073/pnas.98.4.1883</pub-id><pub-id pub-id-type="pmid">11172045</pub-id></element-citation></ref><ref id="B62-biomolecules-11-00316"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winstanley</surname><given-names>C.</given-names></name><name><surname>Hales</surname><given-names>B.A.</given-names></name><name><surname>Hart</surname><given-names>C.A.</given-names></name></person-group><article-title>Evidence for the presence in <italic>Burkholderia pseudomallei</italic> of a type III secretion system-associated gene cluster</article-title><source>J. Med. Microbiol.</source><year>1999</year><volume>48</volume><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1099/00222615-48-7-649</pub-id><pub-id pub-id-type="pmid">10403415</pub-id></element-citation></ref><ref id="B63-biomolecules-11-00316"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>T.</given-names></name><name><surname>Akiba</surname><given-names>K.</given-names></name><name><surname>Iguchi</surname><given-names>M.</given-names></name><name><surname>Danbara</surname><given-names>H.</given-names></name><name><surname>Okada</surname><given-names>N.</given-names></name></person-group><article-title>The <italic>Chromobacterium violaceum</italic> type III effector CopE, a guanine nucleotide exchange factor for Rac1 and Cdc42, is involved in bacterial invasion of epithelial cells and pathogenesis</article-title><source>Mol. Microbiol.</source><year>2011</year><volume>80</volume><fpage>1186</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2011.07637.x</pub-id><pub-id pub-id-type="pmid">21435035</pub-id></element-citation></ref><ref id="B64-biomolecules-11-00316"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniell</surname><given-names>S.J.</given-names></name><name><surname>Kocsis</surname><given-names>E.</given-names></name><name><surname>Morris</surname><given-names>E.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Booy</surname><given-names>F.P.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>3D structure of EspA filaments from enteropathogenic <italic>Escherichia coli</italic></article-title><source>Mol. Microbiol.</source><year>2003</year><volume>49</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03555.x</pub-id><?supplied-pmid 12828630?><pub-id pub-id-type="pmid">12828630</pub-id></element-citation></ref><ref id="B65-biomolecules-11-00316"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McHugh</surname><given-names>R.E.</given-names></name><name><surname>O&#x02019;Boyle</surname><given-names>N.</given-names></name><name><surname>Connolly</surname><given-names>J.P.R.</given-names></name><name><surname>Hoskisson</surname><given-names>P.A.</given-names></name><name><surname>Roe</surname><given-names>A.J.</given-names></name></person-group><article-title>Characterization of the mode of action of aurodox, a type III secretion system inhibitor from <italic>Streptomyces goldiniensis</italic></article-title><source>Infect. Immun.</source><year>2018</year><volume>87</volume><fpage>e00595-18</fpage><pub-id pub-id-type="doi">10.1128/IAI.00595-18</pub-id><?supplied-pmid 30455200?><pub-id pub-id-type="pmid">30455200</pub-id></element-citation></ref><ref id="B66-biomolecules-11-00316"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallen</surname><given-names>M.J.</given-names></name><name><surname>Beatson</surname><given-names>S.A.</given-names></name><name><surname>Bailey</surname><given-names>C.M.</given-names></name></person-group><article-title>Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: A Darwinian perpective</article-title><source>FEMS Microbiol. Rev.</source><year>2005</year><volume>29</volume><fpage>201</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.femsre.2005.01.001</pub-id><?supplied-pmid 15808742?><pub-id pub-id-type="pmid">15808742</pub-id></element-citation></ref><ref id="B67-biomolecules-11-00316"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfano</surname><given-names>J.R.</given-names></name><name><surname>Collmer</surname><given-names>A.</given-names></name></person-group><article-title>Type III secretion system effector proteins: Double agents in bacterial disease and plant defense</article-title><source>Annu. Rev. Phytopathol.</source><year>2004</year><volume>42</volume><fpage>385</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1146/annurev.phyto.42.040103.110731</pub-id><?supplied-pmid 15283671?><pub-id pub-id-type="pmid">15283671</pub-id></element-citation></ref><ref id="B68-biomolecules-11-00316"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfano</surname><given-names>J.R.</given-names></name><name><surname>Collmer</surname><given-names>A.</given-names></name></person-group><article-title>The type III (Hrp) secretion pathway of plant pathogenic bacteria: Trafficking harpins, Avr proteins, and death</article-title><source>J. Bacteriol.</source><year>1997</year><volume>179</volume><fpage>5655</fpage><lpage>5662</lpage><pub-id pub-id-type="doi">10.1128/JB.179.18.5655-5662.1997</pub-id><pub-id pub-id-type="pmid">9294418</pub-id></element-citation></ref><ref id="B69-biomolecules-11-00316"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainbow</surname><given-names>L.</given-names></name><name><surname>Hart</surname><given-names>C.A.</given-names></name><name><surname>Winstanley</surname><given-names>C.</given-names></name></person-group><article-title>Distribution of type III secretion gene clusters in <italic>Burkholderia pseudomallei</italic>, <italic>B. thailandensis</italic> and <italic>B. mallei</italic></article-title><source>J. Med Microbiol.</source><year>2002</year><volume>51</volume><fpage>374</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-51-5-374</pub-id><?supplied-pmid 11990489?><pub-id pub-id-type="pmid">11990489</pub-id></element-citation></ref><ref id="B70-biomolecules-11-00316"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>K.</given-names></name><name><surname>Oshima</surname><given-names>K.</given-names></name><name><surname>Kurokawa</surname><given-names>K.</given-names></name><name><surname>Yokoyama</surname><given-names>K.</given-names></name><name><surname>Uda</surname><given-names>T.</given-names></name><name><surname>Tagomori</surname><given-names>K.</given-names></name><name><surname>Iijima</surname><given-names>Y.</given-names></name><name><surname>Najima</surname><given-names>M.</given-names></name><name><surname>Nakano</surname><given-names>M.</given-names></name><name><surname>Yamashita</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genome sequence of <italic>Vibrio parahaemolyticus</italic>: A pathogenic mechanism distinct from that of <italic>V. cholerae</italic></article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)12659-1</pub-id><pub-id pub-id-type="pmid">12620739</pub-id></element-citation></ref><ref id="B71-biomolecules-11-00316"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>F.</given-names></name><name><surname>Hsu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name></person-group><article-title>Transcriptomic analysis provides insights into the molecular mechanisms of epigallocatechin-3-gallate to attenuate schistosomiasis hepatic fibrosis in mice</article-title><source>Int. J. Agric. Biol.</source><year>2019</year><volume>21</volume><fpage>314</fpage><lpage>324</lpage></element-citation></ref><ref id="B72-biomolecules-11-00316"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marie</surname><given-names>C.</given-names></name><name><surname>Broughton</surname><given-names>W.J.</given-names></name><name><surname>Deakin</surname><given-names>W.J.</given-names></name></person-group><article-title>Rhizobium type III secretion systems: Legume charmers or alarmers?</article-title><source>Curr. Opin. Plant Biol.</source><year>2001</year><volume>4</volume><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S1369-5266(00)00182-5</pub-id><pub-id pub-id-type="pmid">11418344</pub-id></element-citation></ref><ref id="B73-biomolecules-11-00316"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriya</surname><given-names>N.</given-names></name><name><surname>Minamino</surname><given-names>T.</given-names></name><name><surname>Hughes</surname><given-names>K.T.</given-names></name><name><surname>Macnab</surname><given-names>R.M.</given-names></name><name><surname>Namba</surname><given-names>K.</given-names></name></person-group><article-title>The type III flagellar export specificity switch is dependent on FliK ruler and a molecular clock</article-title><source>J. Mol. Biol.</source><year>2006</year><volume>359</volume><fpage>466</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.03.025</pub-id><pub-id pub-id-type="pmid">16630628</pub-id></element-citation></ref><ref id="B74-biomolecules-11-00316"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>J.R.C.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>L.</given-names></name><name><surname>Wasney</surname><given-names>G.A.</given-names></name><name><surname>Vuckovic</surname><given-names>M.</given-names></name><name><surname>Reffuveille</surname><given-names>F.</given-names></name><name><surname>Hancock</surname><given-names>R.E.W.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name></person-group><article-title>The structure of a type 3 secretion system (T3SS) ruler protein suggests a molecular mechanism for needle length sensing</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>1676</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.684423</pub-id><?supplied-pmid 26589798?><pub-id pub-id-type="pmid">26589798</pub-id></element-citation></ref><ref id="B75-biomolecules-11-00316"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sal-Man</surname><given-names>N.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>EscI: A crucial component of the type III secretion system forms the inner rod structure in enteropathogenic <italic>Escherichia coli</italic></article-title><source>Biochem. J.</source><year>2012</year><volume>442</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1042/BJ20111620</pub-id><?supplied-pmid 22087554?><pub-id pub-id-type="pmid">22087554</pub-id></element-citation></ref><ref id="B76-biomolecules-11-00316"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burghout</surname><given-names>P.</given-names></name><name><surname>Van Boxtel</surname><given-names>R.</given-names></name><name><surname>Van Gelder</surname><given-names>P.</given-names></name><name><surname>Ringler</surname><given-names>P.</given-names></name><name><surname>Mu</surname><given-names>S.A.</given-names></name><name><surname>Tommassen</surname><given-names>J.</given-names></name><name><surname>Koster</surname><given-names>M.</given-names></name></person-group><article-title>Structure and electrophysiological properties of the YscC secretin from the type III secretion system of <italic>Yersinia enterocolitica</italic></article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>4645</fpage><lpage>4654</lpage><pub-id pub-id-type="doi">10.1128/JB.186.14.4645-4654.2004</pub-id><?supplied-pmid 15231798?><pub-id pub-id-type="pmid">15231798</pub-id></element-citation></ref><ref id="B77-biomolecules-11-00316"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>K.</given-names></name><name><surname>Ohishi</surname><given-names>M.</given-names></name><name><surname>Ogino</surname><given-names>T.</given-names></name><name><surname>Tamano</surname><given-names>K.</given-names></name><name><surname>Sasakawa</surname><given-names>C.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name></person-group><article-title>Supermolecular structure of the enteropathogenic <italic>Escherichia coli</italic> type III secretion system and its direct interaction with the EspA-sheath-like structure</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>11638</fpage><lpage>11643</lpage><pub-id pub-id-type="doi">10.1073/pnas.191378598</pub-id><?supplied-pmid 11562461?><pub-id pub-id-type="pmid">11562461</pub-id></element-citation></ref><ref id="B78-biomolecules-11-00316"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R.K.</given-names></name><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Daniell</surname><given-names>S.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>Role of EscF, a putative needle complex protein, in the type III protein translocation system of enteropathogenic <italic>Escherichia coli</italic></article-title><source>Cell. Microbiol.</source><year>2001</year><volume>3</volume><fpage>753</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.2001.00159.x</pub-id><?supplied-pmid 11696035?><pub-id pub-id-type="pmid">11696035</pub-id></element-citation></ref><ref id="B79-biomolecules-11-00316"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>C.A.</given-names></name><name><surname>Broz</surname><given-names>P.</given-names></name><name><surname>Cornelis</surname><given-names>G.R.</given-names></name></person-group><article-title>The type III secretion system tip complex and translocon</article-title><source>Mol. Microbiol.</source><year>2008</year><volume>68</volume><fpage>1085</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06237.x</pub-id><?supplied-pmid 18430138?><pub-id pub-id-type="pmid">18430138</pub-id></element-citation></ref><ref id="B80-biomolecules-11-00316"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delahay</surname><given-names>R.M.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Hartland</surname><given-names>E.L.</given-names></name><name><surname>Pallen</surname><given-names>M.J.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>The coiled-coil domain of EspA is essential for the assembly of the type III secretion translocon on the surface of enteropathogenic <italic>Escherichia coli</italic></article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>35969</fpage><lpage>35974</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.50.35969</pub-id><?supplied-pmid 10585486?><pub-id pub-id-type="pmid">10585486</pub-id></element-citation></ref><ref id="B81-biomolecules-11-00316"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Rosenshine</surname><given-names>M.</given-names></name><name><surname>Pallen</surname><given-names>M.J.</given-names></name><name><surname>Nisan</surname><given-names>I.</given-names></name><name><surname>Neves</surname><given-names>B.C.</given-names></name><name><surname>Bain</surname><given-names>C.</given-names></name><name><surname>Wolff</surname><given-names>C.</given-names></name><name><surname>Dougan</surname><given-names>G.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>A novel EspA-associated surface organelle of enteropathogenic <italic>Escherichia coli</italic> involved in protein translocation into epithelial cells</article-title><source>EMBO J.</source><year>1998</year><volume>17</volume><fpage>2166</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.8.2166</pub-id><pub-id pub-id-type="pmid">9545230</pub-id></element-citation></ref><ref id="B82-biomolecules-11-00316"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Daniell</surname><given-names>S.</given-names></name><name><surname>Ebel</surname><given-names>F.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name></person-group><article-title>EspA filament-mediated protein translocation into red blood cells</article-title><source>Cell. Microbiol.</source><year>2001</year><volume>3</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.2001.00105.x</pub-id><?supplied-pmid 11298645?><pub-id pub-id-type="pmid">11298645</pub-id></element-citation></ref><ref id="B83-biomolecules-11-00316"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>T.</given-names></name><name><surname>Laarmann</surname><given-names>S.</given-names></name><name><surname>Greune</surname><given-names>L.</given-names></name><name><surname>Schillers</surname><given-names>H.</given-names></name><name><surname>Oberleithner</surname><given-names>H.</given-names></name><name><surname>Schmidt</surname><given-names>M.A.</given-names></name></person-group><article-title>Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic <italic>Escherichia coli</italic></article-title><source>Cell. Microbiol.</source><year>2001</year><volume>3</volume><fpage>669</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.2001.00146.x</pub-id><?supplied-pmid 11580752?><pub-id pub-id-type="pmid">11580752</pub-id></element-citation></ref><ref id="B84-biomolecules-11-00316"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name></person-group><article-title>Interactions and predicted host membrane topology of the enteropathogenic <italic>Escherichia coli</italic> translocator protein EspB</article-title><source>J. Bacteriol.</source><year>2011</year><volume>193</volume><fpage>2972</fpage><lpage>2980</lpage><pub-id pub-id-type="doi">10.1128/JB.00153-11</pub-id><pub-id pub-id-type="pmid">21498649</pub-id></element-citation></ref><ref id="B85-biomolecules-11-00316"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larz&#x000e1;bal</surname><given-names>M.</given-names></name><name><surname>Baldoni</surname><given-names>H.A.</given-names></name><name><surname>Suvire</surname><given-names>F.D.</given-names></name><name><surname>Curto</surname><given-names>L.M.</given-names></name><name><surname>Gomez</surname><given-names>G.E.</given-names></name><name><surname>Da Silva</surname><given-names>W.M.</given-names></name><name><surname>Giudicessi</surname><given-names>S.L.</given-names></name><name><surname>Camperi</surname><given-names>S.A.</given-names></name><name><surname>Delfino</surname><given-names>J.M.</given-names></name><name><surname>Cataldi</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>An inhibitory mechanism of action of coiled-coil peptides against type three secretion system from enteropathogenic <italic>Escherichia coli</italic></article-title><source>J. Pept. Sci.</source><year>2019</year><volume>25</volume><fpage>e3149</fpage><pub-id pub-id-type="doi">10.1002/psc.3149</pub-id><?supplied-pmid 30746861?><pub-id pub-id-type="pmid">30746861</pub-id></element-citation></ref><ref id="B86-biomolecules-11-00316"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaspar</surname><given-names>A.A.</given-names></name><name><surname>Reichert</surname><given-names>J.M.</given-names></name></person-group><article-title>Future directions for peptide therapeutics development</article-title><source>Drug Discov. Today</source><year>2013</year><volume>18</volume><fpage>807</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.05.011</pub-id><pub-id pub-id-type="pmid">23726889</pub-id></element-citation></ref><ref id="B87-biomolecules-11-00316"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordfelth</surname><given-names>R.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name></person-group><article-title>Small-molecule inhibitors specically targeting type III secretion</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>3104</fpage><lpage>3114</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.5.3104-3114.2005</pub-id><?supplied-pmid 15845518?><pub-id pub-id-type="pmid">15845518</pub-id></element-citation></ref><ref id="B88-biomolecules-11-00316"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muschiol</surname><given-names>S.</given-names></name><name><surname>Bailey</surname><given-names>L.</given-names></name><name><surname>Gylfe</surname><given-names>&#x000c5;.</given-names></name><name><surname>Sundin</surname><given-names>C.</given-names></name><name><surname>Hultenby</surname><given-names>K.</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>S.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name><name><surname>Normark</surname><given-names>S.</given-names></name><name><surname>Henriques-Normark</surname><given-names>B.</given-names></name></person-group><article-title>A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of <italic>Chlamydia trachomatis</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>14566</fpage><lpage>14571</lpage><pub-id pub-id-type="doi">10.1073/pnas.0606412103</pub-id><?supplied-pmid 16973741?><pub-id pub-id-type="pmid">16973741</pub-id></element-citation></ref><ref id="B89-biomolecules-11-00316"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>L.</given-names></name><name><surname>Gylfe</surname><given-names>&#x000c5;.</given-names></name><name><surname>Sundin</surname><given-names>C.</given-names></name><name><surname>Muschiol</surname><given-names>S.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Nordstr&#x000f6;m</surname><given-names>P.</given-names></name><name><surname>Henriques-Normark</surname><given-names>B.</given-names></name><name><surname>Lugert</surname><given-names>R.</given-names></name><name><surname>Waldenstr&#x000f6;m</surname><given-names>A.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Small molecule inhibitors of type III secretion in <italic>Yersinia</italic> block the <italic>Chlamydia pneumoniae</italic> infection cycle</article-title><source>FEBS Lett.</source><year>2007</year><volume>581</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2007.01.013</pub-id><?supplied-pmid 17257594?><pub-id pub-id-type="pmid">17257594</pub-id></element-citation></ref><ref id="B90-biomolecules-11-00316"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>D.L.</given-names></name><name><surname>Layton</surname><given-names>A.N.</given-names></name><name><surname>Field</surname><given-names>T.R.</given-names></name><name><surname>Bowen</surname><given-names>A.J.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Stevens</surname><given-names>M.P.</given-names></name><name><surname>Galyov</surname><given-names>E.E.</given-names></name></person-group><article-title>Inhibition of type III secretion in <italic>Salmonella enterica</italic> serovar Typhimurium by small-molecule inhibitors</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>2631</fpage><lpage>2635</lpage><pub-id pub-id-type="doi">10.1128/AAC.01492-06</pub-id><pub-id pub-id-type="pmid">17502403</pub-id></element-citation></ref><ref id="B91-biomolecules-11-00316"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veenendaal</surname><given-names>A.K.J.</given-names></name><name><surname>Sundin</surname><given-names>C.</given-names></name><name><surname>Blocker</surname><given-names>A.J.</given-names></name></person-group><article-title>Small-molecule type III secretion system inhibitors block assembly of the <italic>Shigella</italic> type III secretion</article-title><source>J. Bacteriol.</source><year>2009</year><volume>191</volume><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1128/JB.01004-08</pub-id><pub-id pub-id-type="pmid">18996990</pub-id></element-citation></ref><ref id="B92-biomolecules-11-00316"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tree</surname><given-names>J.J.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>McInally</surname><given-names>C.</given-names></name><name><surname>Mahajan</surname><given-names>A.</given-names></name><name><surname>Layton</surname><given-names>A.</given-names></name><name><surname>Houghton</surname><given-names>I.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Stevens</surname><given-names>M.P.</given-names></name><name><surname>Gally</surname><given-names>D.L.</given-names></name><name><surname>Roe</surname><given-names>A.J.</given-names></name></person-group><article-title>Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in <italic>Escherichia coli</italic> O157:H7</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>4209</fpage><lpage>4220</lpage><pub-id pub-id-type="doi">10.1128/IAI.00562-09</pub-id><pub-id pub-id-type="pmid">19635828</pub-id></element-citation></ref><ref id="B93-biomolecules-11-00316"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>H.</given-names></name><name><surname>Fan</surname><given-names>S.-S.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.-H.</given-names></name><name><surname>Cui</surname><given-names>Z.-N.</given-names></name></person-group><article-title>Small molecule inhibitors specifically targeting the type III secretion system of <italic>Xanthomonas oryzae</italic> on rice</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>971</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20040971</pub-id><?supplied-pmid 30813400?><pub-id pub-id-type="pmid">30813400</pub-id></element-citation></ref><ref id="B94-biomolecules-11-00316"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Hutchins</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>C.-H.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name></person-group><article-title>Identification of phenolic compounds that suppress the virulence of <italic>Xanthomonas oryzae</italic> on rice via the type III secretion system</article-title><source>Mol. Plant Pathol.</source><year>2016</year><volume>18</volume><fpage>555</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/mpp.12415</pub-id><pub-id pub-id-type="pmid">27084974</pub-id></element-citation></ref><ref id="B95-biomolecules-11-00316"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Korban</surname><given-names>S.S.</given-names></name><name><surname>Pusey</surname><given-names>P.L.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Sundin</surname><given-names>G.W.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Small-molecule inhibitors suppress the expression of both type III secretion and amylovoran biosynthesis genes in <italic>Erwinia amylovora</italic></article-title><source>Mol. Plant Pathol.</source><year>2014</year><volume>15</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/mpp.12064</pub-id><?supplied-pmid 23915008?><pub-id pub-id-type="pmid">23915008</pub-id></element-citation></ref><ref id="B96-biomolecules-11-00316"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowlin</surname><given-names>N.O.</given-names></name><name><surname>Williams</surname><given-names>J.D.</given-names></name><name><surname>Knoten</surname><given-names>C.A.</given-names></name><name><surname>Torhan</surname><given-names>M.C.</given-names></name><name><surname>Tashjian</surname><given-names>T.F.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Aiello</surname><given-names>D.</given-names></name><name><surname>Mecsas</surname><given-names>J.</given-names></name><name><surname>Hauser</surname><given-names>A.R.</given-names></name><name><surname>Peet</surname><given-names>N.P.</given-names></name><etal/></person-group><article-title>Mutations in the <italic>Pseudomonas aeruginosa</italic> needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>2211</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1128/AAC.02795-13</pub-id><?supplied-pmid 24468789?><pub-id pub-id-type="pmid">24468789</pub-id></element-citation></ref><ref id="B97-biomolecules-11-00316"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>M.C.</given-names></name><name><surname>Wong</surname><given-names>W.R.</given-names></name><name><surname>Dupzyk</surname><given-names>A.J.</given-names></name><name><surname>Bray</surname><given-names>W.M.</given-names></name><name><surname>Linington</surname><given-names>R.G.</given-names></name><name><surname>Auerbuch</surname><given-names>V.</given-names></name></person-group><article-title>An NF-&#x003ba;B-based high-throughput screen identifies piericidins as inhibitors of the <italic>Yersinia pseudotuberculosis</italic> type III secretion system</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1118</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1128/AAC.02025-13</pub-id><?supplied-pmid 24295981?><pub-id pub-id-type="pmid">24295981</pub-id></element-citation></ref><ref id="B98-biomolecules-11-00316"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>J.M.</given-names></name><name><surname>Duncan</surname><given-names>M.C.</given-names></name><name><surname>Johnson</surname><given-names>K.S.</given-names></name><name><surname>Diepold</surname><given-names>A.</given-names></name><name><surname>Lam</surname><given-names>H.</given-names></name><name><surname>Dupzyk</surname><given-names>A.J.</given-names></name><name><surname>Martin</surname><given-names>L.R.</given-names></name><name><surname>Wong</surname><given-names>W.R.</given-names></name><name><surname>Armitage</surname><given-names>J.P.</given-names></name><name><surname>Linington</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Piericidin A1 blocks <italic>Yersinia</italic> Ysc type III secretion system needle assembly</article-title><source>mSphere</source><year>2017</year><volume>2</volume><fpage>e00030-17</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00030-17</pub-id><?supplied-pmid 28217742?><pub-id pub-id-type="pmid">28217742</pub-id></element-citation></ref><ref id="B99-biomolecules-11-00316"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auerbuch</surname><given-names>V.</given-names></name><name><surname>Golenbock</surname><given-names>D.T.</given-names></name><name><surname>Isberg</surname><given-names>R.R.</given-names></name></person-group><article-title>Innate immune recognition of <italic>Yersinia pseudotuberculosis</italic> type III secretion</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000686</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000686</pub-id><pub-id pub-id-type="pmid">19997504</pub-id></element-citation></ref><ref id="B100-biomolecules-11-00316"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawa</surname><given-names>T.</given-names></name><name><surname>Kinoshita</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>K.</given-names></name><name><surname>Ohara</surname><given-names>J.</given-names></name><name><surname>Moriyama</surname><given-names>K.</given-names></name></person-group><article-title>Immunoglobulin for treating bacterial infections: One more mechanism of action</article-title><source>Antibodies</source><year>2019</year><volume>8</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3390/antib8040052</pub-id></element-citation></ref><ref id="B101-biomolecules-11-00316"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendergrass</surname><given-names>H.A.</given-names></name><name><surname>May</surname><given-names>A.E.</given-names></name></person-group><article-title>Delivery of heterologous proteins, enzymes, and antigens via the bacterial type III secretion system</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>777</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8050777</pub-id></element-citation></ref><ref id="B102-biomolecules-11-00316"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotinger</surname><given-names>J.A.</given-names></name><name><surname>May</surname><given-names>A.E.</given-names></name></person-group><article-title>Antibodies inhibiting the type III secretion system of Gram-negative pathogenic bacteria</article-title><source>Antibodies</source><year>2020</year><volume>9</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.3390/antib9030035</pub-id></element-citation></ref><ref id="B103-biomolecules-11-00316"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.-M.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Rustandi</surname><given-names>E.</given-names></name><name><surname>Chang</surname><given-names>K.</given-names></name><name><surname>Yusuf-Makagiansar</surname><given-names>H.</given-names></name><name><surname>Ryll</surname><given-names>T.</given-names></name></person-group><article-title>Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment</article-title><source>Biotechnol. Prog.</source><year>2010</year><volume>26</volume><fpage>1400</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1002/btpr.436</pub-id><pub-id pub-id-type="pmid">20945494</pub-id></element-citation></ref><ref id="B104-biomolecules-11-00316"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sittner</surname><given-names>A.</given-names></name><name><surname>Mechaly</surname><given-names>A.</given-names></name><name><surname>Vitner</surname><given-names>E.</given-names></name><name><surname>Aftalion</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>Y.</given-names></name><name><surname>Levy</surname><given-names>H.</given-names></name><name><surname>Mamroud</surname><given-names>E.</given-names></name><name><surname>Fisher</surname><given-names>M.</given-names></name></person-group><article-title>Improved production of monoclonal antibodies against the LcrV antigen of <italic>Yersinia pestis</italic> using FACS-aided hybridoma selection</article-title><source>J. Biol. Methods</source><year>2018</year><volume>5</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.14440/jbm.2018.257</pub-id><?supplied-pmid 31453250?><pub-id pub-id-type="pmid">31453250</pub-id></element-citation></ref><ref id="B105-biomolecules-11-00316"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Embry</surname><given-names>A.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Cantwell</surname><given-names>A.</given-names></name><name><surname>Dube</surname><given-names>P.H.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name></person-group><article-title>Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5331</fpage><lpage>5339</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.088</pub-id><pub-id pub-id-type="pmid">21664218</pub-id></element-citation></ref><ref id="B106-biomolecules-11-00316"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>C.</given-names></name><name><surname>Philipovskiy</surname><given-names>A.V.</given-names></name><name><surname>Wulff-Strobel</surname><given-names>C.R.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Straley</surname><given-names>S.C.</given-names></name></person-group><article-title>Anti-LcrV antibody inhibits delivery of Yops by <italic>Yersinia pestis</italic> KIM5 by directly promoting phagocytosis</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>6127</fpage><lpage>6137</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.9.6127-6137.2005</pub-id><?supplied-pmid 16113334?><pub-id pub-id-type="pmid">16113334</pub-id></element-citation></ref><ref id="B107-biomolecules-11-00316"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>M.</given-names></name><name><surname>Shimizu</surname><given-names>M.</given-names></name><name><surname>Akiyama</surname><given-names>K.</given-names></name><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Moriyama</surname><given-names>K.</given-names></name><name><surname>Sawa</surname><given-names>T.</given-names></name></person-group><article-title>Epidemiological survey of serum titers from adults against various Gram-negative bacterial V-antigens</article-title><source>PLOS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0220924</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0220924</pub-id><?supplied-pmid 32155175?><pub-id pub-id-type="pmid">32155175</pub-id></element-citation></ref><ref id="B108-biomolecules-11-00316"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramov</surname><given-names>V.M.</given-names></name><name><surname>Kosarev</surname><given-names>I.V.</given-names></name><name><surname>Motin</surname><given-names>V.L.</given-names></name><name><surname>Khlebnikov</surname><given-names>V.S.</given-names></name><name><surname>Vasilenko</surname><given-names>R.N.</given-names></name><name><surname>Sakulin</surname><given-names>V.K.</given-names></name><name><surname>Machulin</surname><given-names>A.V.</given-names></name><name><surname>Uversky</surname><given-names>V.N.</given-names></name><name><surname>Karlyshev</surname><given-names>A.V.</given-names></name></person-group><article-title>Binding of LcrV protein from <italic>Yersinia pestis</italic> to human T-cells induces apoptosis, which is completely blocked by specific antibodies</article-title><source>Int. J. Biol. Macromol.</source><year>2019</year><volume>122</volume><fpage>1062</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.09.054</pub-id><pub-id pub-id-type="pmid">30218736</pub-id></element-citation></ref><ref id="B109-biomolecules-11-00316"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawa</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>E.</given-names></name><name><surname>Nguyen</surname><given-names>V.H.</given-names></name><name><surname>Haight</surname><given-names>M.</given-names></name></person-group><article-title>Anti-PcrV antibody strategies against virulent <italic>Pseudomonas aeruginosa</italic></article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>2843</fpage><lpage>2852</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.971641</pub-id></element-citation></ref><ref id="B110-biomolecules-11-00316"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name><surname>Keller</surname><given-names>A.E.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Rainey</surname><given-names>G.J.</given-names></name><name><surname>Warrener</surname><given-names>P.</given-names></name><name><surname>Camara</surname><given-names>M.M.</given-names></name><name><surname>Bonnell</surname><given-names>J.</given-names></name><name><surname>Fleming</surname><given-names>R.</given-names></name><name><surname>Bezabeh</surname><given-names>B.</given-names></name><name><surname>DiMasi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A multifunctional bispecific antibody protects against <italic>Pseudomonas aeruginosa</italic></article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>262ra155</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3009655</pub-id></element-citation></ref><ref id="B111-biomolecules-11-00316"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabor</surname><given-names>D.E.</given-names></name><name><surname>Oganesyan</surname><given-names>V.</given-names></name><name><surname>Keller</surname><given-names>A.E.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>McLaughlin</surname><given-names>R.E.</given-names></name><name><surname>Song</surname><given-names>E.</given-names></name><name><surname>Warrener</surname><given-names>P.</given-names></name><name><surname>Rosenthal</surname><given-names>K.</given-names></name><name><surname>Esser</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title><italic>Pseudomonas aeruginosa</italic> PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>1983</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy438</pub-id><pub-id pub-id-type="pmid">30016475</pub-id></element-citation></ref><ref id="B112-biomolecules-11-00316"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>H.N.</given-names></name><name><surname>Quetz</surname><given-names>J.S.</given-names></name><name><surname>Tran</surname><given-names>V.G.</given-names></name><name><surname>Le</surname><given-names>V.T.M.</given-names></name><name><surname>Aguiar-Alves</surname><given-names>F.</given-names></name><name><surname>Pinheiro</surname><given-names>M.G.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Sellman</surname><given-names>B.R.</given-names></name><name><surname>Stover</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>MEDI3902 Correlates of protection against severe <italic>Pseudomonas aeruginosa</italic> pneumonia in a rabbit acute pneumonia model</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e02565-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.02565-17</pub-id><pub-id pub-id-type="pmid">29483116</pub-id></element-citation></ref><ref id="B113-biomolecules-11-00316"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S.O.</given-names></name><name><surname>Yu</surname><given-names>X.Q.</given-names></name><name><surname>Robbie</surname><given-names>G.J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Shoemaker</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name><surname>Keller</surname><given-names>A.E.</given-names></name><name><surname>Anude</surname><given-names>C.</given-names></name><name><surname>Hernandez-Illas</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase 1 study of MEDI3902, an investigational anti&#x02013;<italic>Pseudomonas aeruginosa</italic> PcrV and Psl bispecific human monoclonal antibody, in healthy adults</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>629.e1</fpage><lpage>629.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2018.08.004</pub-id><?supplied-pmid 30107283?><pub-id pub-id-type="pmid">30107283</pub-id></element-citation></ref><ref id="B114-biomolecules-11-00316"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chastre</surname><given-names>J.</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>B.</given-names></name><name><surname>Bourgeois</surname><given-names>M.</given-names></name><name><surname>Komnos</surname><given-names>A.</given-names></name><name><surname>Ferrer</surname><given-names>R.</given-names></name><name><surname>Rahav</surname><given-names>G.</given-names></name><name><surname>De Schryver</surname><given-names>N.</given-names></name><name><surname>Lepape</surname><given-names>A.</given-names></name><name><surname>Koksal</surname><given-names>I.</given-names></name><name><surname>Luyt</surname><given-names>C.-E.</given-names></name><etal/></person-group><article-title>635. Efficacy, pharmacokinetics (PK), and safety profile of MEDI3902, an anti-<italic>Pseudomonas aeruginosa</italic> bispecific human monoclonal antibody in mechanically ventilated intensive care unit patients; Results of the phase 2 EVADE study conducted by the public-private COMBACTE-MAGNET consortium in the innovative medicines initiative (IMI) program</article-title><source>Open Forum Infect. Dis.</source><year>2020</year><volume>7</volume><fpage>S377</fpage><lpage>S378</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofaa439.829</pub-id></element-citation></ref><ref id="B115-biomolecules-11-00316"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>H.N.</given-names></name><name><surname>Tran</surname><given-names>V.G.</given-names></name><name><surname>Vu</surname><given-names>T.T.T.</given-names></name><name><surname>Gras</surname><given-names>E.</given-names></name><name><surname>Le</surname><given-names>V.T.M.</given-names></name><name><surname>Pinheiro</surname><given-names>M.G.</given-names></name><name><surname>Aguiar-Alves</surname><given-names>F.</given-names></name><name><surname>Schneider-Smith</surname><given-names>E.</given-names></name><name><surname>Carter</surname><given-names>H.C.</given-names></name><name><surname>Sellman</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Treatment efficacy of MEDI3902 in <italic>Pseudomonas aeruginosa</italic> bloodstream infection and acute pneumonia rabbit models</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00710-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.00710-19</pub-id><?supplied-pmid 31160288?><pub-id pub-id-type="pmid">31160288</pub-id></element-citation></ref><ref id="B116-biomolecules-11-00316"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>S.</given-names></name><name><surname>Anbanandam</surname><given-names>A.</given-names></name><name><surname>Mumford</surname><given-names>B.E.</given-names></name><name><surname>De Guzman</surname><given-names>R.N.</given-names></name></person-group><article-title>Characterization of small molecule scaffolds that bind to the <italic>Shigella</italic> type III secretion system protein IpaD</article-title><source>ChemMedChem</source><year>2017</year><volume>12</volume><fpage>1534</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201700348</pub-id><?supplied-pmid 28750143?><pub-id pub-id-type="pmid">28750143</pub-id></element-citation></ref><ref id="B117-biomolecules-11-00316"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barta</surname><given-names>M.L.</given-names></name><name><surname>Guragain</surname><given-names>M.</given-names></name><name><surname>Adam</surname><given-names>P.</given-names></name><name><surname>Dickenson</surname><given-names>N.E.</given-names></name><name><surname>Patil</surname><given-names>M.</given-names></name><name><surname>Geisbrecht</surname><given-names>B.V.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name></person-group><article-title>Identification of the bile salt binding site on ipad from <italic>Shigella flexneri</italic> and the influence of ligand binding on IpaD structure</article-title><source>Proteins Struct. Funct. Bioinform.</source><year>2011</year><volume>80</volume><fpage>935</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1002/prot.23251</pub-id></element-citation></ref><ref id="B118-biomolecules-11-00316"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>N.E.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Epler</surname><given-names>C.R.</given-names></name><name><surname>Adam</surname><given-names>P.R.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name></person-group><article-title>Conformational changes in IpaD from <italic>Shigella flexneri</italic> upon binding bile salts provide insight into the second step of type III secretion</article-title><source>Biochemistry</source><year>2011</year><volume>50</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1021/bi101365f</pub-id><pub-id pub-id-type="pmid">21126091</pub-id></element-citation></ref><ref id="B119-biomolecules-11-00316"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensrud</surname><given-names>K.F.</given-names></name><name><surname>Adam</surname><given-names>P.R.</given-names></name><name><surname>La Mar</surname><given-names>C.D.</given-names></name><name><surname>Olive</surname><given-names>A.J.</given-names></name><name><surname>Lushington</surname><given-names>G.H.</given-names></name><name><surname>Sudharsan</surname><given-names>R.</given-names></name><name><surname>Shelton</surname><given-names>N.L.</given-names></name><name><surname>Givens</surname><given-names>R.S.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name></person-group><article-title>Deoxycholate interacts with IpaD of <italic>Shigella flexneri</italic> in inducing the recruitment of IpaB to the type III secretion apparatus needle tip</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>18646</fpage><lpage>18654</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802799200</pub-id><pub-id pub-id-type="pmid">18450744</pub-id></element-citation></ref><ref id="B120-biomolecules-11-00316"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>N.E.</given-names></name><name><surname>Arizmendi</surname><given-names>O.</given-names></name><name><surname>Patil</surname><given-names>M.K.</given-names></name><name><surname>Toth</surname><given-names>R.T.</given-names></name><name><surname>Middaugh</surname><given-names>C.R.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name></person-group><article-title>N-Terminus of IpaB provides a potential anchor to the <italic>Shigella</italic> type III secretion system tip complex protein IpaD</article-title><source>Biochemistry</source><year>2013</year><volume>52</volume><fpage>8790</fpage><lpage>8799</lpage><pub-id pub-id-type="doi">10.1021/bi400755f</pub-id><pub-id pub-id-type="pmid">24236510</pub-id></element-citation></ref><ref id="B121-biomolecules-11-00316"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zetterstr&#x000f6;m</surname><given-names>C.E.</given-names></name><name><surname>Gabrielsen</surname><given-names>M.</given-names></name><name><surname>Beckham</surname><given-names>K.S.H.</given-names></name><name><surname>Tree</surname><given-names>J.J.</given-names></name><name><surname>Macdonald</surname><given-names>S.E.</given-names></name><name><surname>Byron</surname><given-names>O.</given-names></name><name><surname>Mitchell</surname><given-names>T.J.</given-names></name><name><surname>Gally</surname><given-names>D.L.</given-names></name><name><surname>Herzyk</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>29922</fpage><lpage>29931</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.233858</pub-id><pub-id pub-id-type="pmid">21724850</pub-id></element-citation></ref><ref id="B122-biomolecules-11-00316"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambelloni</surname><given-names>R.</given-names></name><name><surname>Connolly</surname><given-names>J.P.R.</given-names></name><name><surname>Huerta Uribe</surname><given-names>A.</given-names></name><name><surname>Burgess</surname><given-names>K.</given-names></name><name><surname>Marquez</surname><given-names>R.</given-names></name><name><surname>Roe</surname><given-names>A.J.</given-names></name></person-group><article-title>Novel compounds targeting the enterohemorrhagic <italic>Escherichia coli</italic> type three secretion system reveal insights into mechanisms of secretion inhibition</article-title><source>Mol. Microbiol.</source><year>2017</year><volume>105</volume><fpage>606</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1111/mmi.13719</pub-id><pub-id pub-id-type="pmid">28557017</pub-id></element-citation></ref><ref id="B123-biomolecules-11-00316"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd</surname><given-names>S.A.</given-names></name><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>M.</given-names></name><name><surname>Andersson</surname><given-names>S.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name></person-group><article-title>Molecular characterization of type III secretion signals via analysis of synthetic N-terminal amino acid sequences</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>43</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.02738.x</pub-id><pub-id pub-id-type="pmid">11849536</pub-id></element-citation></ref><ref id="B124-biomolecules-11-00316"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbins</surname><given-names>C.E.</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name></person-group><article-title>Maintenance of an unfolded polypeptide by a cognate chaperone in bacterial type III secretion</article-title><source>Nat. Cell Biol.</source><year>2001</year><volume>414</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/35102073</pub-id><?supplied-pmid 11689946?><pub-id pub-id-type="pmid">11689946</pub-id></element-citation></ref><ref id="B125-biomolecules-11-00316"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilharm</surname><given-names>G.</given-names></name><name><surname>Dittmann</surname><given-names>S.</given-names></name><name><surname>Schmid</surname><given-names>A.</given-names></name><name><surname>Heesemann</surname><given-names>J.</given-names></name></person-group><article-title>On the role of specific chaperones, the specific ATPase, and the proton motive force in type III secretion</article-title><source>Int. J. Med. Microbiol.</source><year>2007</year><volume>297</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2006.10.003</pub-id><pub-id pub-id-type="pmid">17126597</pub-id></element-citation></ref><ref id="B126-biomolecules-11-00316"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woestyn</surname><given-names>S.</given-names></name><name><surname>Sory</surname><given-names>M.-P.</given-names></name><name><surname>Boland</surname><given-names>A.</given-names></name><name><surname>Lequenne</surname><given-names>O.</given-names></name><name><surname>Cornelis</surname><given-names>G.R.</given-names></name></person-group><article-title>The cytosolic SycE and SycH chaperones of <italic>Yersinia</italic> protect the region of YopE and YopH involved in translocation across eukaryotic cell membranes</article-title><source>Mol. Microbiol.</source><year>1996</year><volume>20</volume><fpage>1261</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1996.tb02645.x</pub-id><?supplied-pmid 8809777?><pub-id pub-id-type="pmid">8809777</pub-id></element-citation></ref><ref id="B127-biomolecules-11-00316"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>N.A.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Puente</surname><given-names>J.L.</given-names></name><name><surname>Frey</surname><given-names>E.A.</given-names></name><name><surname>Yip</surname><given-names>C.K.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>CesT is a multi-effector chaperone and recruitment factor required for the efficient type III secretion of both LEE- and non-LEE-encoded effectors of enteropathogenic <italic>Escherichia coli</italic></article-title><source>Mol. Microbiol.</source><year>2005</year><volume>57</volume><fpage>1762</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04802.x</pub-id><?supplied-pmid 16135239?><pub-id pub-id-type="pmid">16135239</pub-id></element-citation></ref><ref id="B128-biomolecules-11-00316"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkinshaw</surname><given-names>B.J.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name></person-group><article-title>Assembly and structure of the T3SS</article-title><source>Biochim. Biophys. Acta Bioenerg.</source><year>2014</year><volume>1843</volume><fpage>1649</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.01.035</pub-id></element-citation></ref><ref id="B129-biomolecules-11-00316"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sal-Man</surname><given-names>N.</given-names></name><name><surname>Setiaputra</surname><given-names>D.</given-names></name><name><surname>Scholz</surname><given-names>R.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>A.C.Y.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>EscE and EscG are cochaperones for the type III needle protein EscF of enteropathogenic <italic>Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>2013</year><volume>195</volume><fpage>2481</fpage><lpage>2489</lpage><pub-id pub-id-type="doi">10.1128/JB.00118-13</pub-id><pub-id pub-id-type="pmid">23524615</pub-id></element-citation></ref><ref id="B130-biomolecules-11-00316"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>C.K.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name></person-group><article-title>Structural characterization of a type III secretion system filament protein in complex with its chaperone</article-title><source>Nat. Struct. Mol. Biol.</source><year>2005</year><volume>12</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nsmb879</pub-id><pub-id pub-id-type="pmid">15619638</pub-id></element-citation></ref><ref id="B131-biomolecules-11-00316"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creasey</surname><given-names>E.A.</given-names></name><name><surname>Friedberg</surname><given-names>D.</given-names></name><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Umanski</surname><given-names>T.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Rosenshine</surname><given-names>I.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>CesAB is an enteropathogenic <italic>Escherichia coli</italic> chaperone for the type-III translocator proteins EspA and EspB</article-title><source>Microbiology</source><year>2003</year><volume>149</volume><fpage>3639</fpage><lpage>3647</lpage><pub-id pub-id-type="doi">10.1099/mic.0.26735-0</pub-id><pub-id pub-id-type="pmid">14663095</pub-id></element-citation></ref><ref id="B132-biomolecules-11-00316"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>C.P.</given-names></name><name><surname>Lio</surname><given-names>J.C.W.</given-names></name><name><surname>Wang</surname><given-names>S.H.</given-names></name><name><surname>Lin</surname><given-names>C.N.</given-names></name><name><surname>Syu</surname><given-names>W.J.</given-names></name></person-group><article-title>Identification of a third EspA-binding protein that forms part of the type III secretion system of enterohemorrhagic <italic>Escherichia coli</italic></article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>1686</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807478200</pub-id><?supplied-pmid 19028682?><pub-id pub-id-type="pmid">19028682</pub-id></element-citation></ref><ref id="B133-biomolecules-11-00316"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>S.</given-names></name><name><surname>Roversi</surname><given-names>P.</given-names></name><name><surname>Espina</surname><given-names>M.</given-names></name><name><surname>Olive</surname><given-names>A.</given-names></name><name><surname>Deane</surname><given-names>J.E.</given-names></name><name><surname>Birket</surname><given-names>S.</given-names></name><name><surname>Field</surname><given-names>T.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name><name><surname>Blocker</surname><given-names>A.J.</given-names></name><name><surname>Galyov</surname><given-names>E.E.</given-names></name><etal/></person-group><article-title>Self-chaperoning of the type III secretion system needle tip proteins IpaD and BipD</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>282</volume><fpage>4035</fpage><lpage>4044</lpage><pub-id pub-id-type="doi">10.1074/jbc.M607945200</pub-id><pub-id pub-id-type="pmid">17077085</pub-id></element-citation></ref><ref id="B134-biomolecules-11-00316"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>V.S.</given-names></name><name><surname>Jobichen</surname><given-names>C.</given-names></name><name><surname>Tan</surname><given-names>K.W.</given-names></name><name><surname>Tan</surname><given-names>Y.W.</given-names></name><name><surname>Chan</surname><given-names>S.L.</given-names></name><name><surname>Ramesh</surname><given-names>K.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>Y.</given-names></name><name><surname>Seetharaman</surname><given-names>J.</given-names></name><name><surname>Leung</surname><given-names>K.Y.</given-names></name><etal/></person-group><article-title>Structure of AcrH-AopB chaperone-translocator complex reveals a role for membrane hairpins in type III secretion system translocon assembly</article-title><source>Structure</source><year>2015</year><volume>23</volume><fpage>2022</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.08.014</pub-id><pub-id pub-id-type="pmid">26439768</pub-id></element-citation></ref><ref id="B135-biomolecules-11-00316"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>C.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Chakraborty</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>Y.W.</given-names></name><name><surname>Leung</surname><given-names>K.Y.</given-names></name><name><surname>Sivaraman</surname><given-names>J.</given-names></name><name><surname>Mok</surname><given-names>Y.-K.</given-names></name></person-group><article-title>Crystal structure of the heteromolecular chaperone, AscE-AscG, from the type III secretion system in <italic>Aeromonas hydrophila</italic></article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e19208</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0019208</pub-id><pub-id pub-id-type="pmid">21559439</pub-id></element-citation></ref><ref id="B136-biomolecules-11-00316"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>J.</given-names></name><name><surname>Miletic</surname><given-names>S.</given-names></name><name><surname>Gaildry</surname><given-names>T.</given-names></name><name><surname>Chin-Fatt</surname><given-names>A.</given-names></name><name><surname>Menassa</surname><given-names>R.</given-names></name></person-group><article-title>Co-expression with the type 3 secretion chaperone CesT from enterohemorrhagic <italic>E. coli</italic> increases accumulation of recombinant Tir in plant chloroplasts</article-title><source>Front. Plant Sci.</source><year>2017</year><volume>8</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.3389/fpls.2017.00283</pub-id><pub-id pub-id-type="pmid">28321227</pub-id></element-citation></ref><ref id="B137-biomolecules-11-00316"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wainwright</surname><given-names>L.A.</given-names></name><name><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>EspB and EspD require a specific chaperone for proper secretion from enteropathogenic <italic>Escherichia coil</italic></article-title><source>Mol. Microbiol.</source><year>1998</year><volume>27</volume><fpage>1247</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.00771.x</pub-id><pub-id pub-id-type="pmid">9570409</pub-id></element-citation></ref><ref id="B138-biomolecules-11-00316"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>B.C.</given-names></name><name><surname>Mundy</surname><given-names>R.</given-names></name><name><surname>Petrovska</surname><given-names>L.</given-names></name><name><surname>Dougan</surname><given-names>G.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>CesD2 of Enteropathogenic <italic>Escherichia coli</italic> is a second chaperone for the type III secretion translocator protein EspD</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>2130</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.4.2130-2141.2003</pub-id><?supplied-pmid 12654835?><pub-id pub-id-type="pmid">12654835</pub-id></element-citation></ref><ref id="B139-biomolecules-11-00316"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>M.S.-W.</given-names></name><name><surname>Kao</surname><given-names>H.-C.</given-names></name><name><surname>Lin</surname><given-names>C.-N.</given-names></name><name><surname>Syu</surname><given-names>W.-J.</given-names></name></person-group><article-title>Gene l0017 encodes a second chaperone for EspA of enterohaemorrhagic <italic>Escherichia coli</italic> O157: H7</article-title><source>Microbiology</source><year>2008</year><volume>154</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2007/013946-0</pub-id><pub-id pub-id-type="pmid">18375802</pub-id></element-citation></ref><ref id="B140-biomolecules-11-00316"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiner</surname><given-names>M.</given-names></name><name><surname>Niemann</surname><given-names>H.H.</given-names></name></person-group><article-title>Crystal structure of the <italic>Yersinia enterocolitica</italic> type III secretion chaperone SycD in complex with a peptide of the minor translocator YopD</article-title><source>BMC Struct. Biol.</source><year>2012</year><volume>12</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6807-12-13</pub-id><?supplied-pmid 22708907?><pub-id pub-id-type="pmid">22708907</pub-id></element-citation></ref><ref id="B141-biomolecules-11-00316"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanao</surname><given-names>M.</given-names></name><name><surname>Ricard-Blum</surname><given-names>S.</given-names></name><name><surname>Di Guilmi</surname><given-names>A.M.</given-names></name><name><surname>Lemaire</surname><given-names>D.</given-names></name><name><surname>Lascoux</surname><given-names>D.</given-names></name><name><surname>Chabert</surname><given-names>J.</given-names></name><name><surname>Attree</surname><given-names>I.</given-names></name><name><surname>Dessen</surname><given-names>A.</given-names></name></person-group><article-title>Type III secretion proteins PcrV and PcrG from <italic>Pseudomonas aeruginosa</italic> form a 1:1 complex through high affinity interactions</article-title><source>BMC Microbiol.</source><year>2003</year><volume>3</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-3-21</pub-id><?supplied-pmid 14565848?><pub-id pub-id-type="pmid">14565848</pub-id></element-citation></ref><ref id="B142-biomolecules-11-00316"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pl&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Job</surname><given-names>V.</given-names></name><name><surname>Dessen</surname><given-names>A.</given-names></name><name><surname>Attree</surname><given-names>I.</given-names></name></person-group><article-title>Cochaperone interactions in export of the type III needle component PscF of <italic>Pseudomonas aeruginosa</italic></article-title><source>J. Bacteriol.</source><year>2010</year><volume>192</volume><fpage>3801</fpage><lpage>3808</lpage><pub-id pub-id-type="doi">10.1128/JB.00117-10</pub-id><?supplied-pmid 20494986?><pub-id pub-id-type="pmid">20494986</pub-id></element-citation></ref><ref id="B143-biomolecules-11-00316"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darwin</surname><given-names>K.H.</given-names></name><name><surname>Miller</surname><given-names>V.L.</given-names></name></person-group><article-title>The putative invasion protein chaperone SicA acts together with InvF to activate the expression of <italic>Salmonella</italic> typhimurium virulence genes</article-title><source>Mol. Microbiol.</source><year>2000</year><volume>35</volume><fpage>949</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.01772.x</pub-id><pub-id pub-id-type="pmid">10692170</pub-id></element-citation></ref><ref id="B144-biomolecules-11-00316"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>K.</given-names></name><name><surname>Chatterjee</surname><given-names>S.</given-names></name><name><surname>De Guzman</surname><given-names>R.N.</given-names></name></person-group><article-title>Characterization of the <italic>Shigella</italic> and <italic>Salmonella</italic> type III secretion system tip-translocon protein-protein interaction by paramagnetic relaxation enhancement</article-title><source>ChemBioChem</source><year>2016</year><volume>17</volume><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1002/cbic.201500556</pub-id><?supplied-pmid 26749041?><pub-id pub-id-type="pmid">26749041</pub-id></element-citation></ref><ref id="B145-biomolecules-11-00316"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>Y.</given-names></name><name><surname>Miki</surname><given-names>T.</given-names></name><name><surname>Ono</surname><given-names>S.</given-names></name><name><surname>Haneda</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Okada</surname><given-names>N.</given-names></name></person-group><article-title>Functional characterization of the type III secretion ATPase SsaN encoded by <italic>Salmonella</italic> Pathogenicity Island 2</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e94347</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094347</pub-id><pub-id pub-id-type="pmid">24722491</pub-id></element-citation></ref><ref id="B146-biomolecules-11-00316"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurawski</surname><given-names>D.V.</given-names></name><name><surname>Stein</surname><given-names>M.A.</given-names></name></person-group><article-title>SseA acts as the chaperone for the SseB component of the <italic>Salmonella</italic> Pathogenicity Island 2 translocon</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>47</volume><fpage>1341</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03373.x</pub-id><pub-id pub-id-type="pmid">12603739</pub-id></element-citation></ref><ref id="B147-biomolecules-11-00316"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname><given-names>A.</given-names></name><name><surname>Takeda</surname><given-names>H.</given-names></name><name><surname>Tashiro</surname><given-names>S.</given-names></name><name><surname>Kawashima</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name></person-group><article-title>Chaperone-mediated secretion switching from early to middle substrates in the type III secretion system encoded by <italic>Salmonella</italic> pathogenicity island 2</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>3783</fpage><lpage>3793</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.005072</pub-id><?supplied-pmid 30651351?><pub-id pub-id-type="pmid">30651351</pub-id></element-citation></ref><ref id="B148-biomolecules-11-00316"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Becerra</surname><given-names>F.J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Dickenson</surname><given-names>N.E.</given-names></name><name><surname>Choudhari</surname><given-names>S.P.</given-names></name><name><surname>Harrison</surname><given-names>K.</given-names></name><name><surname>Clements</surname><given-names>J.D.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name><name><surname>Van De Verg</surname><given-names>L.L.</given-names></name><name><surname>Walker</surname><given-names>R.I.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name></person-group><article-title>Characterization of a novel fusion protein from IpaB and IpaD of <italic>Shigella</italic> spp. and its potential as a pan-<italic>Shigella</italic> vaccine</article-title><source>Infect. Immun.</source><year>2013</year><volume>81</volume><fpage>4470</fpage><lpage>4477</lpage><pub-id pub-id-type="doi">10.1128/IAI.00859-13</pub-id><pub-id pub-id-type="pmid">24060976</pub-id></element-citation></ref><ref id="B149-biomolecules-11-00316"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherradi</surname><given-names>Y.</given-names></name><name><surname>Hachani</surname><given-names>A.</given-names></name><name><surname>Allaoui</surname><given-names>A.</given-names></name></person-group><article-title>Spa13 of <italic>Shigella flexneri</italic> has a dual role: Chaperone escort and export gate-activator switch of the type III secretion system</article-title><source>Microbiology</source><year>2014</year><volume>160</volume><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1099/mic.0.071712-0</pub-id><?supplied-pmid 24126350?><pub-id pub-id-type="pmid">24126350</pub-id></element-citation></ref><ref id="B150-biomolecules-11-00316"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukerjea</surname><given-names>R.</given-names></name><name><surname>Ghosh</surname><given-names>P.</given-names></name></person-group><article-title>Functionally essential interaction between <italic>Yersinia</italic> YscO and the T3S4 domain of YscP</article-title><source>J. Bacteriol.</source><year>2013</year><volume>195</volume><fpage>4631</fpage><lpage>4638</lpage><pub-id pub-id-type="doi">10.1128/JB.00876-13</pub-id><pub-id pub-id-type="pmid">23935040</pub-id></element-citation></ref><ref id="B151-biomolecules-11-00316"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhury</surname><given-names>S.</given-names></name><name><surname>Souza</surname><given-names>C.A.</given-names></name><name><surname>Plano</surname><given-names>G.V.</given-names></name><name><surname>De Guzman</surname><given-names>R.N.</given-names></name></person-group><article-title>The LcrG tip chaperone protein of the <italic>Yersinia pestis</italic> type III secretion system is partially folded</article-title><source>J. Mol. Biol.</source><year>2015</year><volume>427</volume><fpage>3096</fpage><lpage>3109</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2015.07.024</pub-id><?supplied-pmid 26259880?><pub-id pub-id-type="pmid">26259880</pub-id></element-citation></ref><ref id="B152-biomolecules-11-00316"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>C.D.A.</given-names></name><name><surname>Richards</surname><given-names>K.L.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Schwartz</surname><given-names>M.</given-names></name><name><surname>Garcia</surname><given-names>J.T.</given-names></name><name><surname>Bartra</surname><given-names>S.S.</given-names></name><name><surname>Plano</surname><given-names>G.V.</given-names></name></person-group><article-title>The YscE/YscG chaperone and YscF N-terminal sequences target YscF to the <italic>Yersinia pestis</italic> type III secretion apparatus</article-title><source>Microbiology</source><year>2018</year><volume>164</volume><fpage>338</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1099/mic.0.000610</pub-id><pub-id pub-id-type="pmid">29458689</pub-id></element-citation></ref><ref id="B153-biomolecules-11-00316"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>M.S.</given-names></name><name><surname>Lloyd</surname><given-names>S.A.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name></person-group><article-title>The type III secretion chaperone LcrH co-operates with YopD to establish a negative, regulatory loop for control of Yop synthesis in <italic>Yersinia pseudotuberculosis</italic></article-title><source>Mol. Microbiol.</source><year>2001</year><volume>42</volume><fpage>1075</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2001.02702.x</pub-id><?supplied-pmid 11737648?><pub-id pub-id-type="pmid">11737648</pub-id></element-citation></ref><ref id="B154-biomolecules-11-00316"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>T.D.</given-names></name><name><surname>Pl&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Barette</surname><given-names>C.</given-names></name><name><surname>Fortun&#x000e9;</surname><given-names>A.</given-names></name><name><surname>Bouzidi</surname><given-names>Y.</given-names></name><name><surname>Fauvarque</surname><given-names>M.-O.</given-names></name><name><surname>de Freitas</surname><given-names>R.P.</given-names></name><name><surname>Hil&#x000e1;rio</surname><given-names>F.F.</given-names></name><name><surname>Attr&#x000e9;e</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Chimeric protein&#x02013;protein interface inhibitors allow efficient inhibition of type III secretion machinery and <italic>Pseudomonas aeruginosa</italic> virulence</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>1843</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00154</pub-id><?supplied-pmid 31525902?><pub-id pub-id-type="pmid">31525902</pub-id></element-citation></ref><ref id="B155-biomolecules-11-00316"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diepold</surname><given-names>A.</given-names></name><name><surname>Armitage</surname><given-names>J.P.</given-names></name></person-group><article-title>Type III secretion systems: The bacterial flagellum and the injectisome</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2015</year><volume>370</volume><fpage>20150020</fpage><pub-id pub-id-type="doi">10.1098/rstb.2015.0020</pub-id><?supplied-pmid 26370933?><pub-id pub-id-type="pmid">26370933</pub-id></element-citation></ref><ref id="B156-biomolecules-11-00316"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abby</surname><given-names>S.S.</given-names></name><name><surname>Rocha</surname><given-names>E.P.C.</given-names></name></person-group><article-title>The non-flagellar type III secretion system evolved from the bacterial flagellum and diversified into host-cell adapted systems</article-title><source>PLoS Genet.</source><year>2012</year><volume>8</volume><elocation-id>e1002983</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002983</pub-id><?supplied-pmid 23028376?><pub-id pub-id-type="pmid">23028376</pub-id></element-citation></ref><ref id="B157-biomolecules-11-00316"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>W.R.</given-names></name></person-group><article-title>An introduction to sequence similarity (&#x0201c;homology&#x0201d;) searching</article-title><source>Curr. Protoc. Bioinform.</source><year>2013</year><volume>42</volume><fpage>3.1.1</fpage><lpage>3.1.8</lpage><pub-id pub-id-type="doi">10.1002/0471250953.bi0301s42</pub-id></element-citation></ref><ref id="B158-biomolecules-11-00316"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotkov</surname><given-names>K.V.</given-names></name><name><surname>Gonen</surname><given-names>T.</given-names></name><name><surname>Hol</surname><given-names>W.G.J.</given-names></name></person-group><article-title>Secretins: Dynamic channels for protein transport across membranes</article-title><source>Trends Biochem. Sci.</source><year>2011</year><volume>36</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2011.04.002</pub-id><pub-id pub-id-type="pmid">21565514</pub-id></element-citation></ref><ref id="B159-biomolecules-11-00316"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>A.</given-names></name><name><surname>Puente</surname><given-names>J.L.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Secretin of the enteropathogenic <italic>Escherichia coli</italic> type III secretion system requires components of the type III apparatus for assembly and localization</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3310</fpage><lpage>3319</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.6.3310-3319.2003</pub-id><pub-id pub-id-type="pmid">12761113</pub-id></element-citation></ref><ref id="B160-biomolecules-11-00316"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauppi</surname><given-names>A.M.</given-names></name><name><surname>Nordfelth</surname><given-names>R.</given-names></name><name><surname>Uvell</surname><given-names>H.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name></person-group><article-title>Targeting bacterial virulence: Inhibitors of type III secretion in <italic>Yersinia</italic></article-title><source>Chem. Biol.</source><year>2003</year><volume>10</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(03)00046-2</pub-id><pub-id pub-id-type="pmid">12670538</pub-id></element-citation></ref><ref id="B161-biomolecules-11-00316"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negrea</surname><given-names>A.</given-names></name><name><surname>Bjur</surname><given-names>E.</given-names></name><name><surname>Ygberg</surname><given-names>S.E.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Wolf-Watz</surname><given-names>H.</given-names></name><name><surname>Rhen</surname><given-names>M.</given-names></name></person-group><article-title>Salicylidene acylhydrazides that affect type III protein secretion in <italic>Salmonella enterica</italic> serovar Typhimurium</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>2867</fpage><lpage>2876</lpage><pub-id pub-id-type="doi">10.1128/AAC.00223-07</pub-id><pub-id pub-id-type="pmid">17548496</pub-id></element-citation></ref><ref id="B162-biomolecules-11-00316"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Argudo</surname><given-names>I.</given-names></name><name><surname>Veenendaal</surname><given-names>A.K.J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Roehrich</surname><given-names>A.D.</given-names></name><name><surname>Ronessen</surname><given-names>M.C.</given-names></name><name><surname>Franzoni</surname><given-names>G.</given-names></name><name><surname>van Rietschoten</surname><given-names>K.N.</given-names></name><name><surname>Morimoto</surname><given-names>Y.V.</given-names></name><name><surname>Saijo-Hamano</surname><given-names>Y.</given-names></name><name><surname>Avison</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>Isolation of <italic>Salmonella</italic> mutants resistant to the inhibitory effect of salicylidene acylhydrazides on flagella-mediated motility</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e52179</elocation-id><pub-id pub-id-type="pmid">23300965</pub-id></element-citation></ref><ref id="B163-biomolecules-11-00316"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Grin</surname><given-names>I.</given-names></name><name><surname>Malmsheimer</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Torres-Vargas</surname><given-names>C.E.</given-names></name><name><surname>Westerhausen</surname><given-names>S.</given-names></name></person-group><article-title>Bacterial type III secretion systems: A complex device for the delivery of bacterial effector proteins into eukaryotic host cells</article-title><source>FEMS Microbiol. Lett.</source><year>2018</year><volume>365</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.1093/femsle/fny201</pub-id><?supplied-pmid 30107569?><pub-id pub-id-type="pmid">30107569</pub-id></element-citation></ref><ref id="B164-biomolecules-11-00316"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseytin</surname><given-names>I.</given-names></name><name><surname>Madar</surname><given-names>A.</given-names></name><name><surname>Mitrovic</surname><given-names>B.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name><name><surname>Sal-Man</surname><given-names>N.</given-names></name></person-group><article-title>The third transmembrane domain of EscR is critical for function of the enteropathogenic <italic>Escherichia coli</italic> type III secretion system</article-title><source>mSphere</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1128/mSphere.00162-18</pub-id></element-citation></ref><ref id="B165-biomolecules-11-00316"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>S.J.</given-names></name><name><surname>Wainwright</surname><given-names>L.A.</given-names></name><name><surname>McDaniel</surname><given-names>T.K.</given-names></name><name><surname>Jarvis</surname><given-names>K.G.</given-names></name><name><surname>Deng</surname><given-names>Y.K.</given-names></name><name><surname>Lai</surname><given-names>L.C.</given-names></name><name><surname>McNamara</surname><given-names>B.P.</given-names></name><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name><name><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic <italic>Escherichia coli</italic> E2348/69</article-title><source>Mol. Microbiol.</source><year>1998</year><volume>28</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.00783.x</pub-id><pub-id pub-id-type="pmid">9593291</pub-id></element-citation></ref><ref id="B166-biomolecules-11-00316"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseytin</surname><given-names>I.</given-names></name><name><surname>Mitrovic</surname><given-names>B.</given-names></name><name><surname>David</surname><given-names>N.</given-names></name><name><surname>Langenfeld</surname><given-names>K.</given-names></name><name><surname>Zarivach</surname><given-names>R.</given-names></name><name><surname>Diepold</surname><given-names>A.</given-names></name><name><surname>Sal-Man</surname><given-names>N.</given-names></name></person-group><article-title>The role of the small export apparatus protein, SctS, in the activity of the type III secretion system</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>2551</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.02551</pub-id><?supplied-pmid 31798543?><pub-id pub-id-type="pmid">31798543</pub-id></element-citation></ref><ref id="B167-biomolecules-11-00316"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomassin</surname><given-names>J.-L.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Thomas</surname><given-names>N.A.</given-names></name></person-group><article-title>Role of EscU auto-cleavage in promoting type III effector translocation into host cells by enteropathogenic <italic>Escherichia coli</italic></article-title><source>BMC Microbiol.</source><year>2011</year><volume>11</volume><elocation-id>205</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-11-205</pub-id><?supplied-pmid 21933418?><pub-id pub-id-type="pmid">21933418</pub-id></element-citation></ref><ref id="B168-biomolecules-11-00316"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minamino</surname><given-names>T.</given-names></name><name><surname>Morimoto</surname><given-names>Y.V.</given-names></name><name><surname>Hara</surname><given-names>N.</given-names></name><name><surname>Aldridge</surname><given-names>P.D.</given-names></name><name><surname>Namba</surname><given-names>K.</given-names></name></person-group><article-title>The bacterial flagellar type III export gate complex is a dual fuel engine that can use both H+ and Na+ for flagellar protein export</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005495</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005495</pub-id><pub-id pub-id-type="pmid">26943926</pub-id></element-citation></ref><ref id="B169-biomolecules-11-00316"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majewski</surname><given-names>D.D.</given-names></name><name><surname>Worrall</surname><given-names>L.J.</given-names></name><name><surname>Hong</surname><given-names>C.</given-names></name><name><surname>Atkinson</surname><given-names>C.E.</given-names></name><name><surname>Vuckovic</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>N.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name></person-group><article-title>Cryo-EM structure of the homohexameric T3SS ATPase-central stalk complex reveals rotary ATPase-like asymmetry</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>626</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08477-7</pub-id><?supplied-pmid 30733444?><pub-id pub-id-type="pmid">30733444</pub-id></element-citation></ref><ref id="B170-biomolecules-11-00316"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biemans-Oldehinkel</surname><given-names>E.</given-names></name><name><surname>Sal-Man</surname><given-names>N.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Foster</surname><given-names>L.J.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Quantitative proteomic analysis reveals formation of an EscL-EscQ-EscN type III complex in enteropathogenic <italic>Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>2011</year><volume>193</volume><fpage>5514</fpage><lpage>5519</lpage><pub-id pub-id-type="doi">10.1128/JB.05235-11</pub-id><?supplied-pmid 21804003?><pub-id pub-id-type="pmid">21804003</pub-id></element-citation></ref><ref id="B171-biomolecules-11-00316"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>E.</given-names></name><name><surname>Espinosa</surname><given-names>N.</given-names></name><name><surname>D&#x000ed;az-Guerrero</surname><given-names>M.</given-names></name><name><surname>Gayt&#x000e1;n</surname><given-names>M.O.</given-names></name><name><surname>Puente</surname><given-names>J.L.</given-names></name><name><surname>Gonz&#x000e1;lez-Pedrajo</surname><given-names>B.</given-names></name></person-group><article-title>Functional Characterization of EscK (Orf4), a sorting platform component of the enteropathogenic <italic>Escherichia coli</italic> injectisome</article-title><source>J. Bacteriol.</source><year>2016</year><volume>61</volume><fpage>e00538-16</fpage><pub-id pub-id-type="doi">10.1128/JB.00538-16</pub-id><?supplied-pmid 27795324?><pub-id pub-id-type="pmid">27795324</pub-id></element-citation></ref><ref id="B172-biomolecules-11-00316"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadouloglou</surname><given-names>V.E.</given-names></name><name><surname>Tampakaki</surname><given-names>A.P.</given-names></name><name><surname>Glykos</surname><given-names>N.M.</given-names></name><name><surname>Bastaki</surname><given-names>M.N.</given-names></name><name><surname>Hadden</surname><given-names>J.M.</given-names></name><name><surname>Phillips</surname><given-names>S.E.</given-names></name><name><surname>Panopoulos</surname><given-names>N.J.</given-names></name><name><surname>Kokkinidis</surname><given-names>M.</given-names></name></person-group><article-title>Structure of HrcQB-C, a conserved component of the bacterial type III secretion systems</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>101</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1073/pnas.0304579101</pub-id><?supplied-pmid 14694203?><pub-id pub-id-type="pmid">14694203</pub-id></element-citation></ref><ref id="B173-biomolecules-11-00316"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseytin</surname><given-names>I.</given-names></name><name><surname>Dagan</surname><given-names>A.</given-names></name><name><surname>Oren</surname><given-names>S.</given-names></name><name><surname>Sal-Man</surname><given-names>N.</given-names></name></person-group><article-title>The role of EscD in supporting EscC polymerization in the type III secretion system of enteropathogenic <italic>Escherichia coli</italic></article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2018</year><volume>1860</volume><fpage>384</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2017.10.001</pub-id><pub-id pub-id-type="pmid">28988128</pub-id></element-citation></ref><ref id="B174-biomolecules-11-00316"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-G&#x000f3;mez</surname><given-names>E.</given-names></name><name><surname>Espinosa</surname><given-names>N.</given-names></name><name><surname>De La Mora</surname><given-names>J.</given-names></name><name><surname>Dreyfus</surname><given-names>G.</given-names></name><name><surname>G&#x000f3;nzalez-Pedrajo</surname><given-names>B.</given-names></name></person-group><article-title>The muramidase EtgA from enteropathogenic <italic>Escherichia coli</italic> is required for efficient type III secretion</article-title><source>Microbiology</source><year>2011</year><volume>157</volume><fpage>1145</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1099/mic.0.045617-0</pub-id><pub-id pub-id-type="pmid">21233160</pub-id></element-citation></ref><ref id="B175-biomolecules-11-00316"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Wagner</surname><given-names>S.</given-names></name></person-group><article-title>Investigating the assembly of the bacterial type III secretion system injectisome by in vivo photocrosslinking</article-title><source>Int. J. Med. Microbiol.</source><year>2019</year><volume>309</volume><fpage>151331</fpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2019.151331</pub-id><?supplied-pmid 31375411?><pub-id pub-id-type="pmid">31375411</pub-id></element-citation></ref><ref id="B176-biomolecules-11-00316"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diepold</surname><given-names>A.</given-names></name><name><surname>Wagner</surname><given-names>S.</given-names></name></person-group><article-title>Assembly of the bacterial type III secretion machinery</article-title><source>FEMS Microbiol. Rev.</source><year>2014</year><volume>38</volume><fpage>802</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1111/1574-6976.12061</pub-id><pub-id pub-id-type="pmid">24484471</pub-id></element-citation></ref><ref id="B177-biomolecules-11-00316"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Worrall</surname><given-names>L.J.</given-names></name><name><surname>Vuckovic</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Atkinson</surname><given-names>C.E.</given-names></name><name><surname>Brett Finlay</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.J.</given-names></name></person-group><article-title>T3S injectisome needle complex structures in four distinct states reveal the basis of membrane coupling and assembly</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>2010</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0545-z</pub-id><pub-id pub-id-type="pmid">31427728</pub-id></element-citation></ref><ref id="B178-biomolecules-11-00316"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felise</surname><given-names>H.B.</given-names></name><name><surname>Nguyen</surname><given-names>H.V.</given-names></name><name><surname>Pfuetzner</surname><given-names>R.A.</given-names></name><name><surname>Barry</surname><given-names>K.C.</given-names></name><name><surname>Jackson</surname><given-names>S.R.</given-names></name><name><surname>Blanc</surname><given-names>M.-P.</given-names></name><name><surname>Bronstein</surname><given-names>P.A.</given-names></name><name><surname>Kline</surname><given-names>T.</given-names></name><name><surname>Miller</surname><given-names>S.I.</given-names></name></person-group><article-title>An inhibitor of Gram-negative bacterial virulence protein secretion</article-title><source>Cell Host Microbe</source><year>2008</year><volume>4</volume><fpage>325</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2008.08.001</pub-id><?supplied-pmid 18854237?><pub-id pub-id-type="pmid">18854237</pub-id></element-citation></ref><ref id="B179-biomolecules-11-00316"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kline</surname><given-names>T.</given-names></name><name><surname>Barry</surname><given-names>K.C.</given-names></name><name><surname>Jackson</surname><given-names>S.R.</given-names></name><name><surname>Felise</surname><given-names>H.B.</given-names></name><name><surname>Nguyen</surname><given-names>H.V.</given-names></name><name><surname>Miller</surname><given-names>S.I.</given-names></name></person-group><article-title>Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2009</year><volume>19</volume><fpage>1340</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.01.047</pub-id><?supplied-pmid 19195888?><pub-id pub-id-type="pmid">19195888</pub-id></element-citation></ref><ref id="B180-biomolecules-11-00316"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>H.B.</given-names></name><name><surname>Dickenson</surname><given-names>N.E.</given-names></name></person-group><article-title>Kinetic characterization of the <italic>Shigella</italic> type three secretion system ATPase Spa47 using &#x003b1;-32P ATP</article-title><source>Bio-Protocol</source><year>2018</year><volume>8</volume><fpage>e3074</fpage><pub-id pub-id-type="doi">10.21769/BioProtoc.3074</pub-id><?supplied-pmid 30474049?><pub-id pub-id-type="pmid">30474049</pub-id></element-citation></ref><ref id="B181-biomolecules-11-00316"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akeda</surname><given-names>Y.</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name></person-group><article-title>Chaperone release and unfolding of substrates in type III secretion</article-title><source>Nat. Cell Biol.</source><year>2005</year><volume>437</volume><fpage>911</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/nature03992</pub-id></element-citation></ref><ref id="B182-biomolecules-11-00316"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>K.</given-names></name><name><surname>Erhardt</surname><given-names>M.</given-names></name><name><surname>Hirano</surname><given-names>T.</given-names></name><name><surname>Blair</surname><given-names>D.F.</given-names></name><name><surname>Hughes</surname><given-names>K.T.</given-names></name></person-group><article-title>Energy source of flagellar type III secretion</article-title><source>Nat. Cell Biol.</source><year>2008</year><volume>451</volume><fpage>489</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nature06497</pub-id><?supplied-pmid 18216859?><pub-id pub-id-type="pmid">18216859</pub-id></element-citation></ref><ref id="B183-biomolecules-11-00316"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>J.M.</given-names></name><name><surname>Waldor</surname><given-names>M.K.</given-names></name></person-group><article-title>The locus of enterocyte effacement-encoded effector proteins all promote enterohemorrhagic <italic>Escherichia coli</italic> pathogenicity in infant rabbits</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>1466</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.3.1466-1474.2005</pub-id><?supplied-pmid 15731044?><pub-id pub-id-type="pmid">15731044</pub-id></element-citation></ref><ref id="B184-biomolecules-11-00316"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swietnicki</surname><given-names>W.</given-names></name><name><surname>Carmany</surname><given-names>D.</given-names></name><name><surname>Retford</surname><given-names>M.</given-names></name><name><surname>Guelta</surname><given-names>M.</given-names></name><name><surname>Dorsey</surname><given-names>R.</given-names></name><name><surname>Bozue</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Olson</surname><given-names>M.A.</given-names></name></person-group><article-title>Identification of small-molecule inhibitors of <italic>Yersinia pestis</italic> type III secretion system YscN ATPase</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e19716</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0019716</pub-id><pub-id pub-id-type="pmid">21611119</pub-id></element-citation></ref><ref id="B185-biomolecules-11-00316"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozue</surname><given-names>J.</given-names></name><name><surname>Cote</surname><given-names>C.K.</given-names></name><name><surname>Webster</surname><given-names>W.</given-names></name><name><surname>Bassett</surname><given-names>A.</given-names></name><name><surname>Tobery</surname><given-names>S.</given-names></name><name><surname>Little</surname><given-names>S.</given-names></name><name><surname>Swietnicki</surname><given-names>W.</given-names></name></person-group><article-title>A <italic>Yersinia pestis</italic> YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice</article-title><source>FEMS Microbiol. Lett.</source><year>2012</year><volume>332</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2012.02583.x</pub-id><?supplied-pmid 22537022?><pub-id pub-id-type="pmid">22537022</pub-id></element-citation></ref><ref id="B186-biomolecules-11-00316"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinaud</surname><given-names>M.</given-names></name><name><surname>Pl&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Job</surname><given-names>V.</given-names></name><name><surname>Contreras-Martel</surname><given-names>C.</given-names></name><name><surname>Simorre</surname><given-names>J.-P.</given-names></name><name><surname>Attree</surname><given-names>I.</given-names></name><name><surname>Dessen</surname><given-names>A.</given-names></name></person-group><article-title>Structure of the heterotrimeric complex that regulates type III secretion needle formation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>7803</fpage><lpage>7808</lpage><pub-id pub-id-type="doi">10.1073/pnas.0610098104</pub-id><pub-id pub-id-type="pmid">17470796</pub-id></element-citation></ref><ref id="B187-biomolecules-11-00316"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Lai</surname><given-names>S.-C.</given-names></name><name><surname>Treerat</surname><given-names>P.</given-names></name><name><surname>Prescott</surname><given-names>M.</given-names></name><name><surname>Adler</surname><given-names>B.</given-names></name><name><surname>Boyce</surname><given-names>J.D.</given-names></name><name><surname>Devenish</surname><given-names>R.J.</given-names></name></person-group><article-title><italic>Burkholderia pseudomallei</italic> type III secretion system cluster 3 ATPase BsaS, a chemotherapeutic target for small-molecule ATPase inhibitors</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>1276</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1128/IAI.03070-14</pub-id><pub-id pub-id-type="pmid">25605762</pub-id></element-citation></ref><ref id="B188-biomolecules-11-00316"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grishin</surname><given-names>A.V.</given-names></name><name><surname>Luyksaar</surname><given-names>S.I.</given-names></name><name><surname>Kapotina</surname><given-names>L.N.</given-names></name><name><surname>Kirsanov</surname><given-names>D.D.</given-names></name><name><surname>Zayakin</surname><given-names>E.S.</given-names></name><name><surname>Karyagina</surname><given-names>A.S.</given-names></name><name><surname>Zigangirova</surname><given-names>N.A.</given-names></name></person-group><article-title>Identification of chlamydial T3SS inhibitors through virtual screening against T3SS ATPase</article-title><source>Chem. Biol. Drug Des.</source><year>2018</year><volume>91</volume><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1111/cbdd.13130</pub-id><pub-id pub-id-type="pmid">29068165</pub-id></element-citation></ref><ref id="B189-biomolecules-11-00316"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>C.B.</given-names></name><name><surname>Bulir</surname><given-names>D.C.</given-names></name><name><surname>Emdin</surname><given-names>C.A.</given-names></name><name><surname>Pirie</surname><given-names>R.M.</given-names></name><name><surname>Porfilio</surname><given-names>E.A.</given-names></name><name><surname>Slootstra</surname><given-names>J.W.</given-names></name><name><surname>Mahony</surname><given-names>J.B.</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae</italic> CdsL regulates CdsN ATPase activity, and disruption with a peptide mimetic prevents bacterial invasion</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2011.00021</pub-id><pub-id pub-id-type="pmid">21687413</pub-id></element-citation></ref><ref id="B190-biomolecules-11-00316"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bzdzion</surname><given-names>L.</given-names></name><name><surname>Krezel</surname><given-names>H.</given-names></name><name><surname>Wrzeszcz</surname><given-names>K.</given-names></name><name><surname>Grzegorek</surname><given-names>I.</given-names></name><name><surname>Nowinska</surname><given-names>K.</given-names></name><name><surname>Chodaczek</surname><given-names>G.</given-names></name><name><surname>Swietnicki</surname><given-names>W.</given-names></name></person-group><article-title>Design of small molecule inhibitors of type III secretion system ATPase EscN from enteropathogenic <italic>Escherichia coli</italic></article-title><source>Acta Biochim. Pol.</source><year>2017</year><volume>64</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.18388/abp.2016_1265</pub-id><pub-id pub-id-type="pmid">27864920</pub-id></element-citation></ref><ref id="B191-biomolecules-11-00316"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anantharajah</surname><given-names>A.</given-names></name><name><surname>Buyck</surname><given-names>J.M.</given-names></name><name><surname>Sundin</surname><given-names>C.</given-names></name><name><surname>Tulkens</surname><given-names>P.M.</given-names></name><name><surname>Mingeot-Leclercq</surname><given-names>M.-P.</given-names></name><name><surname>Van Bambeke</surname><given-names>F.</given-names></name></person-group><article-title>Salicylidene acylhydrazides and hydroxyquinolines act as inhibitors of type three secretion systems in <italic>Pseudomonas aeruginosa</italic> by distinct mechanisms</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e02566-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.02566-16</pub-id><?supplied-pmid 28396545?><pub-id pub-id-type="pmid">28396545</pub-id></element-citation></ref><ref id="B192-biomolecules-11-00316"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerboneschi</surname><given-names>M.</given-names></name><name><surname>Decorosi</surname><given-names>F.</given-names></name><name><surname>Biancalani</surname><given-names>C.</given-names></name><name><surname>Ortenzi</surname><given-names>M.V.</given-names></name><name><surname>Macconi</surname><given-names>S.</given-names></name><name><surname>Giovannetti</surname><given-names>L.</given-names></name><name><surname>Viti</surname><given-names>C.</given-names></name><name><surname>Campanella</surname><given-names>B.</given-names></name><name><surname>Onor</surname><given-names>M.</given-names></name><name><surname>Bramanti</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Indole-3-acetic acid in plant&#x02013;pathogen interactions: A key molecule for in planta bacterial virulence and fitness</article-title><source>Res. Microbiol.</source><year>2016</year><volume>167</volume><fpage>774</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2016.09.002</pub-id><pub-id pub-id-type="pmid">27637152</pub-id></element-citation></ref><ref id="B193-biomolecules-11-00316"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enquist</surname><given-names>P.A.</given-names></name><name><surname>Gylfe</surname><given-names>&#x000c5;.</given-names></name><name><surname>H&#x000e4;gglund</surname><given-names>U.</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>P.</given-names></name><name><surname>Norberg-Scherman</surname><given-names>H.</given-names></name><name><surname>Sundin</surname><given-names>C.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name></person-group><article-title>Derivatives of 8-hydroxyquinoline - Antibacterial agents that target intra- and extracellular Gram-negative pathogens</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>3550</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.03.096</pub-id></element-citation></ref><ref id="B194-biomolecules-11-00316"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>H.B.</given-names></name><name><surname>Mattock</surname><given-names>D.S.</given-names></name><name><surname>Dickenson</surname><given-names>N.E.</given-names></name></person-group><article-title>Shutting down <italic>Shigella</italic> secretion: Characterizing small molecule type three secretion system ATPase inhibitors</article-title><source>Biochemistry</source><year>2018</year><volume>57</volume><fpage>6906</fpage><lpage>6916</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b01077</pub-id><pub-id pub-id-type="pmid">30460850</pub-id></element-citation></ref><ref id="B195-biomolecules-11-00316"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachiyama</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Muthuramalingam</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Barta</surname><given-names>M.L.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name></person-group><article-title>The cytoplasmic domain of MxiG interacts with MxiK and directs assembly of the sorting platform in the <italic>Shigella</italic> type III secretion system</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>19184</fpage><lpage>19196</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.009125</pub-id><pub-id pub-id-type="pmid">31699894</pub-id></element-citation></ref><ref id="B196-biomolecules-11-00316"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swietnicki</surname><given-names>W.</given-names></name><name><surname>Czarny</surname><given-names>A.</given-names></name><name><surname>Antkowiak</surname><given-names>L.</given-names></name><name><surname>Zaczynska</surname><given-names>E.</given-names></name><name><surname>Kolodziejczak</surname><given-names>M.</given-names></name><name><surname>Sycz</surname><given-names>J.</given-names></name><name><surname>Stachowicz</surname><given-names>L.</given-names></name><name><surname>Alicka</surname><given-names>M.</given-names></name><name><surname>Marycz</surname><given-names>K.</given-names></name></person-group><article-title>Identification of a potent inhibitor of type II secretion system from <italic>Pseudomonas aeruginosa</italic></article-title><source>Biochem. Biophys. Res. Commun.</source><year>2019</year><volume>513</volume><fpage>688</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.04.055</pub-id><pub-id pub-id-type="pmid">30987825</pub-id></element-citation></ref><ref id="B197-biomolecules-11-00316"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B.W.</given-names></name><name><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>46</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B198-biomolecules-11-00316"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>J.</given-names></name><name><surname>Balachandran</surname><given-names>P.</given-names></name></person-group><article-title>Role of <italic>Pseudomonas aeruginosa</italic> type III effectors in disease</article-title><source>Curr. Opin. Microbiol.</source><year>2009</year><volume>12</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2008.12.007</pub-id><pub-id pub-id-type="pmid">19168385</pub-id></element-citation></ref><ref id="B199-biomolecules-11-00316"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaver</surname><given-names>C.M.</given-names></name><name><surname>Hauser</surname><given-names>A.R.</given-names></name></person-group><article-title>Relative contributions of <italic>Pseudomonas aeruginosa</italic> ExoU, ExoS, and ExoT</article-title><source>Society</source><year>2004</year><volume>72</volume><fpage>6969</fpage><lpage>6977</lpage></element-citation></ref><ref id="B200-biomolecules-11-00316"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>D.M.</given-names></name><name><surname>McLean</surname><given-names>K.</given-names></name><name><surname>Haneef</surname><given-names>A.S.</given-names></name><name><surname>Fernig</surname><given-names>D.G.</given-names></name><name><surname>Winstanley</surname><given-names>C.</given-names></name><name><surname>Berry</surname><given-names>N.</given-names></name><name><surname>Kaye</surname><given-names>S.B.</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> toxin ExoU as a therapeutic target in the treatment of bacterial infections</article-title><source>Microorganisms</source><year>2019</year><volume>7</volume><elocation-id>707</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms7120707</pub-id></element-citation></ref><ref id="B201-biomolecules-11-00316"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>V.T.</given-names></name><name><surname>Pukatzki</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Kikawada</surname><given-names>E.</given-names></name><name><surname>Kazimirova</surname><given-names>A.A.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Arm</surname><given-names>J.P.</given-names></name><name><surname>Frank</surname><given-names>D.W.</given-names></name><name><surname>Lory</surname><given-names>S.</given-names></name></person-group><article-title>Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of <italic>Pseudomonas aeruginosa</italic> cytotoxin ExoU</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1128/IAI.01184-06</pub-id><pub-id pub-id-type="pmid">17178785</pub-id></element-citation></ref><ref id="B202-biomolecules-11-00316"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Baek</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Byeon</surname><given-names>H.</given-names></name><name><surname>Min</surname><given-names>H.</given-names></name><name><surname>Min</surname><given-names>K.H.</given-names></name></person-group><article-title>Identification of arylsulfonamides as ExoU inhibitors</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2014</year><volume>24</volume><fpage>3823</fpage><lpage>3825</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2014.06.064</pub-id></element-citation></ref><ref id="B203-biomolecules-11-00316"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vareechon</surname><given-names>C.</given-names></name><name><surname>Zmina</surname><given-names>S.E.</given-names></name><name><surname>Karmakar</surname><given-names>M.</given-names></name><name><surname>Pearlman</surname><given-names>E.</given-names></name><name><surname>Rietsch</surname><given-names>A.</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> effector ExoS inhibits ROS production in human neutrophils</article-title><source>Cell Host Microbe</source><year>2017</year><volume>21</volume><fpage>611.e5</fpage><lpage>618.e5</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.04.001</pub-id><pub-id pub-id-type="pmid">28494242</pub-id></element-citation></ref><ref id="B204-biomolecules-11-00316"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnoldo</surname><given-names>A.</given-names></name><name><surname>Curak</surname><given-names>J.</given-names></name><name><surname>Kittanakom</surname><given-names>S.</given-names></name><name><surname>Chevelev</surname><given-names>I.</given-names></name><name><surname>Lee</surname><given-names>V.T.</given-names></name><name><surname>Sahebol-Amri</surname><given-names>M.</given-names></name><name><surname>Koscik</surname><given-names>B.</given-names></name><name><surname>Ljuma</surname><given-names>L.</given-names></name><name><surname>Roy</surname><given-names>P.J.</given-names></name><name><surname>Bedalov</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Identification of small molecule inhibitors of <italic>Pseudomonas aeruginosa</italic> exoenzyme S using a yeast phenotypic screen</article-title><source>PLoS Genet.</source><year>2008</year><volume>4</volume><elocation-id>e1000005</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/76d35829-07a2-479f-bbc1-cce6755b6d8c</pub-id><pub-id pub-id-type="pmid">18454192</pub-id></element-citation></ref><ref id="B205-biomolecules-11-00316"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanifar</surname><given-names>J.</given-names></name><name><surname>Hosseini</surname><given-names>R.H.</given-names></name><name><surname>Kazemi</surname><given-names>R.</given-names></name><name><surname>Ramandi</surname><given-names>M.F.</given-names></name><name><surname>Amani</surname><given-names>J.</given-names></name><name><surname>Salmanian</surname><given-names>A.H.</given-names></name></person-group><article-title>Prevention of EHEC infection by chitosan nano-structure coupled with synthetic recombinant antigen</article-title><source>J. Microbiol. Methods</source><year>2019</year><volume>157</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2019.01.002</pub-id><pub-id pub-id-type="pmid">30633949</pub-id></element-citation></ref><ref id="B206-biomolecules-11-00316"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>X.</given-names></name><name><surname>Quan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>A small-molecule norspermidine and norspermidine-hosting polyelectrolyte coatings inhibit biofilm formation by multi-species wastewater culture</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2015</year><volume>99</volume><fpage>10861</fpage><lpage>10870</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-6943-0</pub-id><pub-id pub-id-type="pmid">26350146</pub-id></element-citation></ref><ref id="B207-biomolecules-11-00316"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alnaqdy</surname><given-names>A.</given-names></name><name><surname>Al-Jabri</surname><given-names>A.</given-names></name><name><surname>Al Mahrooqi</surname><given-names>Z.</given-names></name><name><surname>Nzeako</surname><given-names>B.</given-names></name><name><surname>Nsanze</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition effect of honey on the adherence of <italic>Salmonella</italic> to intestinal epithelial cells in vitro</article-title><source>Int. J. Food Microbiol.</source><year>2005</year><volume>103</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2004.11.042</pub-id><pub-id pub-id-type="pmid">16099316</pub-id></element-citation></ref><ref id="B208-biomolecules-11-00316"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ur-Rehman</surname><given-names>T.</given-names></name><name><surname>Slepenkin</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Blomgren</surname><given-names>A.</given-names></name><name><surname>Dahlgren</surname><given-names>M.K.</given-names></name><name><surname>Zetterstr&#x000f6;m</surname><given-names>C.E.</given-names></name><name><surname>Peterson</surname><given-names>E.M.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Gylfe</surname><given-names>&#x000c5;.</given-names></name></person-group><article-title>Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion</article-title><source>J. Antibiot.</source><year>2012</year><volume>65</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/ja.2012.43</pub-id><?supplied-pmid 22669447?><pub-id pub-id-type="pmid">22669447</pub-id></element-citation></ref><ref id="B209-biomolecules-11-00316"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlgren</surname><given-names>M.K.</given-names></name><name><surname>Kauppi</surname><given-names>A.M.</given-names></name><name><surname>Olsson</surname><given-names>I.-M.</given-names></name><name><surname>Linusson</surname><given-names>A.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name></person-group><article-title>Design, synthesis, and multivariate quantitative structure&#x02212;activity relationship of salicylanilides potent inhibitors of type III secretion in <italic>Yersinia</italic></article-title><source>J. Med. Chem.</source><year>2007</year><volume>50</volume><fpage>6177</fpage><lpage>6188</lpage><pub-id pub-id-type="doi">10.1021/jm070741b</pub-id><?supplied-pmid 17975903?><pub-id pub-id-type="pmid">17975903</pub-id></element-citation></ref><ref id="B210-biomolecules-11-00316"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita-Konishi</surname><given-names>Y.</given-names></name><name><surname>Sakanaka</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>K.</given-names></name><name><surname>Juneja</surname><given-names>L.R.</given-names></name><name><surname>Noda</surname><given-names>T.</given-names></name><name><surname>Amano</surname><given-names>F.</given-names></name></person-group><article-title>Inhibition of bacterial adhesion and <italic>Salmonella</italic> infection in BALB/c mice by sialyloligosaccharides and their derivatives from chicken egg yolk</article-title><source>J. Agric. Food Chem.</source><year>2002</year><volume>50</volume><fpage>3607</fpage><lpage>3613</lpage><pub-id pub-id-type="doi">10.1021/jf0116451</pub-id><pub-id pub-id-type="pmid">12033837</pub-id></element-citation></ref><ref id="B211-biomolecules-11-00316"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichert</surname><given-names>S.</given-names></name><name><surname>Jennewein</surname><given-names>S.</given-names></name><name><surname>H&#x000fc;fner</surname><given-names>E.</given-names></name><name><surname>Weiss</surname><given-names>C.</given-names></name><name><surname>Borkowski</surname><given-names>J.</given-names></name><name><surname>Putze</surname><given-names>J.</given-names></name><name><surname>Schroten</surname><given-names>H.</given-names></name></person-group><article-title>Bioengineered 2&#x02032;-fucosyllactose and 3-fucosyllactose inhibit the adhesion of <italic>Pseudomonas aeruginosa</italic> and enteric pathogens to human intestinal and respiratory cell lines</article-title><source>Nutr. Res.</source><year>2013</year><volume>33</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2013.07.009</pub-id><pub-id pub-id-type="pmid">24074741</pub-id></element-citation></ref><ref id="B212-biomolecules-11-00316"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Vallance</surname><given-names>B.A.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Locus of enterocyte effacement from <italic>Citrobacter rodentium</italic>: Sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>6323</fpage><lpage>6335</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.10.6323-6335.2001</pub-id><pub-id pub-id-type="pmid">11553577</pub-id></element-citation></ref><ref id="B213-biomolecules-11-00316"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>Y.</given-names></name><name><surname>Rosenshine</surname><given-names>I.</given-names></name><name><surname>Leong</surname><given-names>J.M.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>Intimate host attachment: Enteropathogenic and enterohaemorrhagic <italic>Escherichia coli</italic></article-title><source>Cell. Microbiol.</source><year>2013</year><volume>15</volume><fpage>1796</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1111/cmi.12179</pub-id><pub-id pub-id-type="pmid">23927593</pub-id></element-citation></ref><ref id="B214-biomolecules-11-00316"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVinney</surname><given-names>R.</given-names></name><name><surname>Stein</surname><given-names>M.</given-names></name><name><surname>Reinscheid</surname><given-names>D.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>Ruschkowski</surname><given-names>S.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Enterohemorrhagic <italic>Escherichia coli</italic> O157:H7 Produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated</article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>2389</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.5.2389-2398.1999</pub-id><pub-id pub-id-type="pmid">10225900</pub-id></element-citation></ref><ref id="B215-biomolecules-11-00316"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>B.</given-names></name></person-group><article-title>Phosphorylation of tyrosine 474 of the enteropathogenic <italic>Escherichia coli</italic> (EPEC) Tir receptor molecule is essential for actin nucleating activity and is preceded by additional host modifications</article-title><source>Mol. Microbiol.</source><year>1999</year><volume>31</volume><fpage>1229</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01265.x</pub-id><pub-id pub-id-type="pmid">10096089</pub-id></element-citation></ref><ref id="B216-biomolecules-11-00316"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name><name><surname>Tzipori</surname><given-names>S.</given-names></name><name><surname>Mckee</surname><given-names>M.L.</given-names></name><name><surname>O &#x02019;brien</surname><given-names>A.D.</given-names></name><name><surname>Alroy</surname><given-names>J.</given-names></name><name><surname>Kapert</surname><given-names>J.B.</given-names></name></person-group><article-title>The role of the <italic>eae</italic> gene of enterohemorrhagic <italic>Escherichia coli</italic> in intimate attachment <italic>in vitro</italic> and in a porcine model</article-title><source>Clin. Investig.</source><year>1993</year><volume>92</volume><fpage>1418</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1172/JCI116718</pub-id><?supplied-pmid 8376595?><pub-id pub-id-type="pmid">8376595</pub-id></element-citation></ref><ref id="B217-biomolecules-11-00316"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goosney</surname><given-names>D.L.</given-names></name><name><surname>DeVinney</surname><given-names>R.</given-names></name><name><surname>Pfuetzner</surname><given-names>R.A.</given-names></name><name><surname>Frey</surname><given-names>E.A.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name><name><surname>Finlay</surname><given-names>B.</given-names></name></person-group><article-title>Enteropathogenic <italic>E. coli</italic> translocated intimin receptor, Tir, interacts directly with &#x003b1;-actinin</article-title><source>Curr. Biol.</source><year>2000</year><volume>10</volume><fpage>735</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(00)00543-1</pub-id><pub-id pub-id-type="pmid">10873808</pub-id></element-citation></ref><ref id="B218-biomolecules-11-00316"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>N.L.</given-names></name><name><surname>Zurawski</surname><given-names>D.V.</given-names></name><name><surname>Chowrashi</surname><given-names>P.</given-names></name><name><surname>Ayoob</surname><given-names>J.C.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Mittal</surname><given-names>B.</given-names></name><name><surname>Sanger</surname><given-names>J.M.</given-names></name><name><surname>Sanger</surname><given-names>J.W.</given-names></name></person-group><article-title>Interaction of the enteropathogenic <italic>Escherichia coli</italic> protein, translocated intimin receptor (Tir), with focal adhesion proteins</article-title><source>Cell Motil. Cytoskelet.</source><year>2000</year><volume>47</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1002/1097-0169(200012)47:4&#x0003c;307::AID-CM5&#x0003e;3.0.CO;2-Q</pub-id></element-citation></ref><ref id="B219-biomolecules-11-00316"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garmendia</surname><given-names>J.</given-names></name><name><surname>Phillips</surname><given-names>A.D.</given-names></name><name><surname>Carlier</surname><given-names>M.-F.</given-names></name><name><surname>Chong</surname><given-names>Y.</given-names></name><name><surname>Schuller</surname><given-names>S.</given-names></name><name><surname>Marches</surname><given-names>O.</given-names></name><name><surname>Dahan</surname><given-names>S.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><etal/></person-group><article-title>TccP is an enterohaemorrhagic <italic>Escherichia coli</italic> O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton</article-title><source>Cell. Microbiol.</source><year>2004</year><volume>6</volume><fpage>1167</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2004.00459.x</pub-id><?supplied-pmid 15527496?><pub-id pub-id-type="pmid">15527496</pub-id></element-citation></ref><ref id="B220-biomolecules-11-00316"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruenheid</surname><given-names>S.</given-names></name><name><surname>DeVinney</surname><given-names>R.</given-names></name><name><surname>Bladt</surname><given-names>F.</given-names></name><name><surname>Goosney</surname><given-names>D.L.</given-names></name><name><surname>Gelkop</surname><given-names>S.</given-names></name><name><surname>Gish</surname><given-names>G.D.</given-names></name><name><surname>Pawson</surname><given-names>T.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Enteropathogenic <italic>E. coli</italic> Tir binds Nck to initiate actin pedestal formation in host cells</article-title><source>Nat. Cell Biol.</source><year>2001</year><volume>3</volume><fpage>856</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1038/ncb0901-856</pub-id><pub-id pub-id-type="pmid">11533668</pub-id></element-citation></ref><ref id="B221-biomolecules-11-00316"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batchelor</surname><given-names>M.</given-names></name><name><surname>Guignot</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Cummings</surname><given-names>N.</given-names></name><name><surname>Cleary</surname><given-names>J.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Holden</surname><given-names>D.W.</given-names></name><name><surname>Connerton</surname><given-names>I.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>Involvement of the intermediate filament protein cytokeratin-18 in actin pedestal formation during EPEC infection</article-title><source>EMBO Rep.</source><year>2004</year><volume>5</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400038</pub-id><pub-id pub-id-type="pmid">14710194</pub-id></element-citation></ref><ref id="B222-biomolecules-11-00316"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodin</surname><given-names>J.L.</given-names></name><name><surname>Raab</surname><given-names>R.W.</given-names></name><name><surname>McKown</surname><given-names>R.L.</given-names></name><name><surname>Coffman</surname><given-names>G.L.</given-names></name><name><surname>Powell</surname><given-names>B.S.</given-names></name><name><surname>Enama</surname><given-names>J.T.</given-names></name><name><surname>Ligon</surname><given-names>J.A.</given-names></name><name><surname>Andrews</surname><given-names>G.P.</given-names></name></person-group><article-title><italic>Yersinia pestis</italic> outer membrane type III secretion protein YscC: Expression, purification, characterization, and induction of specific antiserum</article-title><source>Protein Expr. Purif.</source><year>2005</year><volume>40</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2004.11.001</pub-id><pub-id pub-id-type="pmid">15721783</pub-id></element-citation></ref><ref id="B223-biomolecules-11-00316"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>S.V.</given-names></name><name><surname>Flanagan</surname><given-names>J.L.</given-names></name><name><surname>Sawa</surname><given-names>T.</given-names></name><name><surname>Fang</surname><given-names>A.</given-names></name><name><surname>Baek</surname><given-names>M.S.</given-names></name><name><surname>Rubio-Mills</surname><given-names>A.</given-names></name><name><surname>Ajayi</surname><given-names>T.</given-names></name><name><surname>Yanagihara</surname><given-names>K.</given-names></name><name><surname>Hirakata</surname><given-names>Y.</given-names></name><name><surname>Kohno</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Polymorphisms in the <italic>Pseudomonas</italic> aeruginosa type III secretion protein, PcrV &#x02013; Implications for anti-PcrV immunotherapy</article-title><source>Microb. Pathog.</source><year>2010</year><volume>48</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2010.02.008</pub-id><pub-id pub-id-type="pmid">20211240</pub-id></element-citation></ref><ref id="B224-biomolecules-11-00316"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilf</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>V.L.</given-names></name><name><surname>Sharp</surname><given-names>J.</given-names></name><name><surname>Zuravleff</surname><given-names>J.J.</given-names></name><name><surname>Korvick</surname><given-names>J.A.</given-names></name><name><surname>Muder</surname><given-names>R.R.</given-names></name></person-group><article-title>Antibiotic therapy for <italic>Pseudomonas aeruginosa</italic> bacteremia: Outcome correlations in a prospective study of 200 patients</article-title><source>Am. J. Med.</source><year>1989</year><volume>87</volume><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(89)80611-4</pub-id><pub-id pub-id-type="pmid">2816969</pub-id></element-citation></ref><ref id="B225-biomolecules-11-00316"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saberianfar</surname><given-names>R.</given-names></name><name><surname>Chin-Fatt</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>A.</given-names></name><name><surname>Henry</surname><given-names>K.A.</given-names></name><name><surname>Topp</surname><given-names>E.</given-names></name><name><surname>Menassa</surname><given-names>R.</given-names></name></person-group><article-title>Plant-produced chimeric V<sub>H</sub>H-sIgA against enterohemorrhagic <italic>E. coli</italic> intimin shows cross-serotype inhibition of bacterial adhesion to epithelial cells</article-title><source>Front. Plant Sci.</source><year>2019</year><volume>10</volume><fpage>270</fpage><pub-id pub-id-type="doi">10.3389/fpls.2019.00270</pub-id><pub-id pub-id-type="pmid">30972081</pub-id></element-citation></ref><ref id="B226-biomolecules-11-00316"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Ragione</surname><given-names>R.M.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Maddison</surname><given-names>B.</given-names></name><name><surname>Woodward</surname><given-names>M.J.</given-names></name><name><surname>Best</surname><given-names>A.</given-names></name><name><surname>Whitelam</surname><given-names>G.C.</given-names></name><name><surname>Gough</surname><given-names>K.C.</given-names></name></person-group><article-title>Recombinant anti-EspA antibodies block <italic>Escherichia coli</italic> O157:H7-induced attaching and effacing lesions <italic>in vitro</italic></article-title><source>Microbes Infect.</source><year>2006</year><volume>8</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.07.009</pub-id><pub-id pub-id-type="pmid">16298154</pub-id></element-citation></ref><ref id="B227-biomolecules-11-00316"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selma</surname><given-names>M.V.</given-names></name><name><surname>Larrosa</surname><given-names>M.</given-names></name><name><surname>Beltr&#x000e1;n</surname><given-names>D.</given-names></name><name><surname>Lucas</surname><given-names>R.</given-names></name><name><surname>Morales</surname><given-names>J.C.</given-names></name><name><surname>Tom&#x000e1;s-Barber&#x000e1;n</surname><given-names>F.</given-names></name><name><surname>Esp&#x000ed;n</surname><given-names>J.C.</given-names></name></person-group><article-title>Resveratrol and some glucosyl, glucosylacyl, and glucuronide derivatives reduce <italic>Escherichia coli</italic> O157:H7, <italic>Salmonella</italic> typhimurium, and <italic>Listeria monocytogenes</italic> Scott A adhesion to colonic epithelial cell lines</article-title><source>J. Agric. Food Chem.</source><year>2012</year><volume>60</volume><fpage>7367</fpage><lpage>7374</lpage><pub-id pub-id-type="doi">10.1021/jf203967u</pub-id><?supplied-pmid 22762450?><pub-id pub-id-type="pmid">22762450</pub-id></element-citation></ref><ref id="B228-biomolecules-11-00316"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>J.-X.</given-names></name><name><surname>Pan</surname><given-names>W.-G.</given-names></name><name><surname>Yang</surname><given-names>W.-Z.</given-names></name><name><surname>Yu</surname><given-names>Z.-J.</given-names></name><name><surname>Deng</surname><given-names>Q.-W.</given-names></name></person-group><article-title>Inhibition of adhesion of enteropathogenic <italic>Escherichia coli</italic> to HEp-2 cells by binding of a novel peptide to EspB protein</article-title><source>Curr. Microbiol.</source><year>2016</year><volume>73</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1007/s00284-016-1070-4</pub-id><?supplied-pmid 27246497?><pub-id pub-id-type="pmid">27246497</pub-id></element-citation></ref><ref id="B229-biomolecules-11-00316"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>Y.-L.</given-names></name><name><surname>Zen</surname><given-names>K.</given-names></name></person-group><article-title>Heparin blocks the adhesion of <italic>E. coli</italic> O157:H7 to human colonic epithelial cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2008</year><volume>369</volume><fpage>1061</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.02.160</pub-id><pub-id pub-id-type="pmid">18342623</pub-id></element-citation></ref><ref id="B230-biomolecules-11-00316"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Inhibition of adhesion of intestinal pathogens (<italic>Escherichia coli</italic>, <italic>Vibrio cholerae</italic>, <italic>Campylobacter jejuni</italic>, and <italic>Salmonella</italic> Typhimurium) by common oligosaccharides</article-title><source>Foodborne Pathog. Dis.</source><year>2015</year><volume>12</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1089/fpd.2014.1835</pub-id><pub-id pub-id-type="pmid">25692734</pub-id></element-citation></ref><ref id="B231-biomolecules-11-00316"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruano-Gallego</surname><given-names>D.</given-names></name><name><surname>Yara</surname><given-names>D.A.</given-names></name><name><surname>Di Ianni</surname><given-names>L.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name><name><surname>Sch&#x000fc;ller</surname><given-names>S.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>L.&#x000c1;.</given-names></name></person-group><article-title>A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic <italic>E. coli</italic> to human colonic mucosa</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1003081</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008031</pub-id></element-citation></ref><ref id="B232-biomolecules-11-00316"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>M.J.</given-names></name></person-group><article-title>Quercetin prevents <italic>Escherichia coli</italic> O157:H7 adhesion to epithelial cells via suppressing focal adhesions</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>3278</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.03278</pub-id></element-citation></ref><ref id="B233-biomolecules-11-00316"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>R.</given-names></name><name><surname>Piao</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name></person-group><article-title>Dietary quercetin increases colonic microbial diversity and attenuates colitis severity in <italic>Citrobacter rodentium</italic>-infected mice</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1092</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01092</pub-id><pub-id pub-id-type="pmid">31156598</pub-id></element-citation></ref><ref id="B234-biomolecules-11-00316"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>G.W.</given-names></name><name><surname>Richardson</surname><given-names>L.A.</given-names></name></person-group><article-title>The attachment to, and invasion of HeLa cells by <italic>Salmonella</italic> Typhimurium: The contribution of mannose-sensitive and mannose-resistant haemagglutinating activities</article-title><source>J. Gen. Microbiol.</source><year>1981</year><volume>127</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1099/00221287-127-2-361</pub-id><?supplied-pmid 6123544?><pub-id pub-id-type="pmid">6123544</pub-id></element-citation></ref><ref id="B235-biomolecules-11-00316"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golberg</surname><given-names>D.</given-names></name><name><surname>Kroupitski</surname><given-names>Y.</given-names></name><name><surname>Belausov</surname><given-names>E.</given-names></name><name><surname>Pinto</surname><given-names>R.</given-names></name><name><surname>Sela</surname><given-names>S.</given-names></name></person-group><article-title><italic>Salmonella</italic> Typhimurium internalization is variable in leafy vegetables and fresh herbs</article-title><source>Int. J. Food Microbiol.</source><year>2011</year><volume>145</volume><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2010.12.031</pub-id><?supplied-pmid 21262550?><pub-id pub-id-type="pmid">21262550</pub-id></element-citation></ref><ref id="B236-biomolecules-11-00316"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Lian</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>Overexpression of Toll-like receptor 4 enhances LPS-induced inflammatory response and inhibits <italic>Salmonella</italic> Typhimurium growth in ovine macrophages</article-title><source>Eur. J. Cell Biol.</source><year>2019</year><volume>98</volume><fpage>36</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2018.11.004</pub-id><pub-id pub-id-type="pmid">30522781</pub-id></element-citation></ref><ref id="B237-biomolecules-11-00316"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Riba</surname><given-names>A.</given-names></name><name><surname>Nietschke</surname><given-names>M.</given-names></name><name><surname>Torow</surname><given-names>N.</given-names></name><name><surname>Repnik</surname><given-names>U.</given-names></name><name><surname>P&#x000fc;tz</surname><given-names>A.</given-names></name><name><surname>Fulde</surname><given-names>M.</given-names></name><name><surname>Dupont</surname><given-names>A.</given-names></name><name><surname>Hensel</surname><given-names>M.</given-names></name><name><surname>Hornef</surname><given-names>M.</given-names></name></person-group><article-title>Minimal SPI1-T3SS effector requirement for <italic>Salmonella</italic> enterocyte invasion and intracellular proliferation in vivo</article-title><source>PLOS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1006925</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006925</pub-id><pub-id pub-id-type="pmid">29522566</pub-id></element-citation></ref><ref id="B238-biomolecules-11-00316"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>K.T.</given-names></name><name><surname>Casanova</surname><given-names>J.E.</given-names></name></person-group><article-title>Mechanisms of <italic>Salmonella</italic> entry into host cells</article-title><source>Cell. Microbiol.</source><year>2007</year><volume>9</volume><fpage>2103</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.00992.x</pub-id><pub-id pub-id-type="pmid">17593246</pub-id></element-citation></ref><ref id="B239-biomolecules-11-00316"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlumberger</surname><given-names>M.C.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>A.J.</given-names></name><name><surname>Ehrbar</surname><given-names>K.</given-names></name><name><surname>Winnen</surname><given-names>B.</given-names></name><name><surname>Duss</surname><given-names>I.</given-names></name><name><surname>Stecher</surname><given-names>B.</given-names></name><name><surname>Hardt</surname><given-names>W.D.</given-names></name></person-group><article-title>Real-time imaging of type III secretion: <italic>Salmonella</italic> SipA injection into host cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>12548</fpage><lpage>12553</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503407102</pub-id><pub-id pub-id-type="pmid">16107539</pub-id></element-citation></ref><ref id="B240-biomolecules-11-00316"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffatellu</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>R.P.</given-names></name><name><surname>Chessa</surname><given-names>D.</given-names></name><name><surname>Andrews-polymenis</surname><given-names>H.</given-names></name><name><surname>Tran</surname><given-names>Q.T.</given-names></name><name><surname>Lawhon</surname><given-names>S.</given-names></name><name><surname>Khare</surname><given-names>S.</given-names></name><name><surname>Adams</surname><given-names>L.G.</given-names></name><name><surname>Ba</surname><given-names>A.J.</given-names></name></person-group><article-title>SipA, SopA, SopB, SopD, and SopE2 contribute to <italic>Salmonella enterica</italic> serotype Typhimurium invasion of epithelial cells</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.1.146-154.2005</pub-id><pub-id pub-id-type="pmid">15618149</pub-id></element-citation></ref><ref id="B241-biomolecules-11-00316"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Mooseker</surname><given-names>M.S.</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name></person-group><article-title>Role of the <italic>S</italic>. Typhimurium actin-binding protein SipA in bacterial internalization</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>2092</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1126/science.283.5410.2092</pub-id><pub-id pub-id-type="pmid">10092234</pub-id></element-citation></ref><ref id="B242-biomolecules-11-00316"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>A.</given-names></name><name><surname>Meikle</surname><given-names>L.M.</given-names></name><name><surname>Ormsby</surname><given-names>M.J.</given-names></name><name><surname>McCormick</surname><given-names>B.A.</given-names></name><name><surname>Christie</surname><given-names>J.M.</given-names></name><name><surname>Brewer</surname><given-names>J.M.</given-names></name><name><surname>Roberts</surname><given-names>M.</given-names></name><name><surname>Wall</surname><given-names>D.M.</given-names></name></person-group><article-title>SipA Activation of caspase-3 is a decisive mediator of host cell survival at early stages of <italic>Salmonella enterica</italic> serovar Typhimurium infection</article-title><source>Infect. Immun.</source><year>2017</year><volume>85</volume><fpage>e00393-17</fpage><pub-id pub-id-type="doi">10.1128/IAI.00393-17</pub-id><pub-id pub-id-type="pmid">28630067</pub-id></element-citation></ref><ref id="B243-biomolecules-11-00316"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osiecki</surname><given-names>J.C.</given-names></name><name><surname>Barker</surname><given-names>J.</given-names></name><name><surname>Picking</surname><given-names>W.L.</given-names></name><name><surname>Serfis</surname><given-names>A.B.</given-names></name><name><surname>Berring</surname><given-names>E.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Harrington</surname><given-names>A.</given-names></name><name><surname>Picking</surname><given-names>W.D.</given-names></name></person-group><article-title>IpaC from <italic>Shigella</italic> and SipC from <italic>Salmonella</italic> possess similar biochemical properties but are functionally distinct</article-title><source>Mol. Microbiol.</source><year>2001</year><volume>42</volume><fpage>469</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2001.02654.x</pub-id><?supplied-pmid 11703668?><pub-id pub-id-type="pmid">11703668</pub-id></element-citation></ref><ref id="B244-biomolecules-11-00316"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavolos</surname><given-names>M.H.</given-names></name><name><surname>Wilson</surname><given-names>M.</given-names></name><name><surname>Henderson</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.J.</given-names></name><name><surname>Khan</surname><given-names>C.M.A.</given-names></name></person-group><article-title>Type III secretion of the <italic>Salmonella</italic> effector protein SopE is mediated <italic>via</italic> an N-terminal amino acid signal and not an mRNA sequence</article-title><source>J. Bacteriol.</source><year>2005</year><volume>187</volume><fpage>1559</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1128/JB.187.5.1559-1567.2005</pub-id><pub-id pub-id-type="pmid">15716426</pub-id></element-citation></ref><ref id="B245-biomolecules-11-00316"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebl</surname><given-names>D.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Zhe</surname><given-names>Y.</given-names></name><name><surname>Barnett</surname><given-names>T.C.</given-names></name><name><surname>Teasdale</surname><given-names>R.D.</given-names></name></person-group><article-title>SopB-mediated recruitment of SNX18 facilitates <italic>Salmonella</italic> Typhimurium internalization by the host cell</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2017</year><volume>7</volume><fpage>257</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00257</pub-id><pub-id pub-id-type="pmid">28664153</pub-id></element-citation></ref><ref id="B246-biomolecules-11-00316"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacomodonato</surname><given-names>M.N.</given-names></name><name><surname>Sarnacki</surname><given-names>H.</given-names></name><name><surname>Llana</surname><given-names>N.</given-names></name><name><surname>Cerquetti</surname><given-names>C.</given-names></name></person-group><article-title>SopB effector protein of <italic>Salmonella</italic> Typhimurium is translocated in mesenteric lymph nodes during murine salmonellosis</article-title><source>FEMS Microbiol. Lett.</source><year>2011</year><volume>317</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2011.02217.x</pub-id><pub-id pub-id-type="pmid">21241360</pub-id></element-citation></ref><ref id="B247-biomolecules-11-00316"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>F.</given-names></name><name><surname>Kawashima</surname><given-names>Y.</given-names></name><name><surname>Takeuchi</surname><given-names>S.</given-names></name><name><surname>Okimori</surname><given-names>K.</given-names></name><name><surname>Inobe</surname><given-names>E.</given-names></name><name><surname>Oosawa</surname><given-names>K.</given-names></name></person-group><article-title>SptP106&#x02013;136plays a role in the complex formation with SptP-specific chaperone SicP</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2014</year><volume>78</volume><fpage>1560</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1080/09168451.2014.921552</pub-id><pub-id pub-id-type="pmid">25209503</pub-id></element-citation></ref><ref id="B248-biomolecules-11-00316"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R.</given-names></name><name><surname>Byrne</surname><given-names>A.</given-names></name><name><surname>Berger</surname><given-names>C.N.</given-names></name><name><surname>Klemm</surname><given-names>E.</given-names></name><name><surname>Crepin</surname><given-names>V.F.</given-names></name><name><surname>Dougan</surname><given-names>G.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>The type III secretion system effector SptP of <italic>Salmonella enterica</italic> serovar Typhi</article-title><source>J. Bacteriol.</source><year>2017</year><volume>199</volume><fpage>e00647-16</fpage><pub-id pub-id-type="doi">10.1128/JB.00647-16</pub-id><pub-id pub-id-type="pmid">27920299</pub-id></element-citation></ref><ref id="B249-biomolecules-11-00316"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>R.</given-names></name><name><surname>Grimaldi</surname><given-names>E.</given-names></name><name><surname>Donnarumma</surname><given-names>G.</given-names></name><name><surname>Greco</surname><given-names>R.</given-names></name><name><surname>Auricchio</surname><given-names>L.</given-names></name><name><surname>De Filippis</surname><given-names>A.</given-names></name><name><surname>Tufano</surname><given-names>M.A.</given-names></name></person-group><article-title>Quinine sulfate inhibits invasion of <italic>Salmonella</italic> typhimurium and <italic>Shigella flexneri</italic>: A preliminary study</article-title><source>J. Travel Med.</source><year>2006</year><volume>12</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.2310/7060.2005.12608</pub-id><?supplied-pmid 16343387?><pub-id pub-id-type="pmid">16343387</pub-id></element-citation></ref><ref id="B250-biomolecules-11-00316"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharal</surname><given-names>S.A.</given-names></name><name><surname>Hussain</surname><given-names>Q.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name></person-group><article-title>Fakhuruddin Quinine is bactericidal</article-title><source>J. Pak. Med. Assoc.</source><year>2009</year><volume>59</volume><fpage>208</fpage><lpage>211</lpage><?supplied-pmid 19402279?><pub-id pub-id-type="pmid">19402279</pub-id></element-citation></ref><ref id="B251-biomolecules-11-00316"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakasone</surname><given-names>N.</given-names></name><name><surname>Higa</surname><given-names>N.</given-names></name><name><surname>Toma</surname><given-names>C.</given-names></name><name><surname>Ogura</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Yamashiro</surname><given-names>T.</given-names></name></person-group><article-title>Epigallocatechin gallate inhibits the type III secretion system of Gram-negative enteropathogenic bacteria under model conditions</article-title><source>FEMS Microbiol. Lett.</source><year>2017</year><volume>364</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/femsle/fnx111</pub-id></element-citation></ref><ref id="B252-biomolecules-11-00316"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>L.K.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group><article-title>Epigallocatechin-3-gallate inhibits bacterial virulence and invasion of host cells</article-title><source>Bioorganic Med. Chem.</source><year>2017</year><volume>25</volume><fpage>2883</fpage><lpage>2887</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.03.023</pub-id><?supplied-pmid 28325635?><pub-id pub-id-type="pmid">28325635</pub-id></element-citation></ref><ref id="B253-biomolecules-11-00316"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runte</surname><given-names>C.S.</given-names></name><name><surname>Jain</surname><given-names>U.</given-names></name><name><surname>Getz</surname><given-names>L.J.</given-names></name><name><surname>Secord</surname><given-names>S.</given-names></name><name><surname>Kuwae</surname><given-names>A.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>LeBlanc</surname><given-names>J.J.</given-names></name><name><surname>Stadnyk</surname><given-names>A.W.</given-names></name><name><surname>Kaper</surname><given-names>J.B.</given-names></name><name><surname>Hansen</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Tandem tyrosine phosphosites in the enteropathogenic <italic>Escherichia coli</italic> chaperone CesT are required for differential type III effector translocation and virulence</article-title><source>Mol. Microbiol.</source><year>2018</year><volume>108</volume><fpage>536</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1111/mmi.13948</pub-id><pub-id pub-id-type="pmid">29509331</pub-id></element-citation></ref><ref id="B254-biomolecules-11-00316"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castiblanco</surname><given-names>L.F.</given-names></name><name><surname>Triplett</surname><given-names>L.R.</given-names></name><name><surname>Sundin</surname><given-names>G.W.</given-names></name></person-group><article-title>Regulation of effector delivery by type III secretion chaperone proteins in <italic>Erwinia amylovora</italic></article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>146</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00146</pub-id><pub-id pub-id-type="pmid">29472907</pub-id></element-citation></ref><ref id="B255-biomolecules-11-00316"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>D.J.</given-names></name><name><surname>Coombes</surname><given-names>B.K.</given-names></name></person-group><article-title>Molecular basis for CesT recognition of type III secretion effectors in enteropathogenic <italic>Escherichia coli</italic></article-title><source>PLOS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1007224</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007224</pub-id><?supplied-pmid 30118511?><pub-id pub-id-type="pmid">30118511</pub-id></element-citation></ref><ref id="B256-biomolecules-11-00316"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaz</surname><given-names>N.</given-names></name><name><surname>Socol</surname><given-names>Y.</given-names></name><name><surname>Katsowich</surname><given-names>N.</given-names></name><name><surname>Rosenshine</surname><given-names>I.</given-names></name></person-group><article-title>Control of type III secretion system effector/chaperone ratio fosters pathogen adaptation to host-adherent lifestyle</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e02074-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.02074-19</pub-id><?supplied-pmid 31530678?><pub-id pub-id-type="pmid">31530678</pub-id></element-citation></ref><ref id="B257-biomolecules-11-00316"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramu</surname><given-names>T.</given-names></name><name><surname>Prasad</surname><given-names>M.E.</given-names></name><name><surname>Connors</surname><given-names>E.</given-names></name><name><surname>Mishra</surname><given-names>A.</given-names></name><name><surname>Thomassin</surname><given-names>J.L.</given-names></name><name><surname>Leblanc</surname><given-names>J.</given-names></name><name><surname>Rainey</surname><given-names>J.K.</given-names></name><name><surname>Thomas</surname><given-names>N.A.</given-names></name></person-group><article-title>A novel C-terminal region within the multicargo type III secretion chaperone CesT contributes to effector secretion</article-title><source>J. Bacteriol.</source><year>1999</year><volume>195</volume><fpage>740</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1128/JB.01967-12</pub-id></element-citation></ref><ref id="B258-biomolecules-11-00316"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>S.J.</given-names></name><name><surname>Hutcheson</surname><given-names>S.W.</given-names></name><name><surname>Dubois</surname><given-names>M.S.</given-names></name><name><surname>Mellies</surname><given-names>J.L.</given-names></name><name><surname>Wainwright</surname><given-names>L.A.</given-names></name><name><surname>Batchelor</surname><given-names>M.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>Identification of CesT, a chaperone for the type III secretion of Tir in enteropathogenic <italic>Escherichia coli</italic></article-title><source>Mol. Microbiol.</source><year>1999</year><volume>33</volume><fpage>1176</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01559.x</pub-id><pub-id pub-id-type="pmid">10510232</pub-id></element-citation></ref><ref id="B259-biomolecules-11-00316"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creasey</surname><given-names>E.A.</given-names></name><name><surname>Delahay</surname><given-names>R.M.</given-names></name><name><surname>Bishop</surname><given-names>A.A.</given-names></name><name><surname>Shaw</surname><given-names>R.K.</given-names></name><name><surname>Kenny</surname><given-names>B.</given-names></name><name><surname>Knutton</surname><given-names>S.</given-names></name><name><surname>Frankel</surname><given-names>G.</given-names></name></person-group><article-title>CesT is a bivalent enteropathogenic <italic>Escherichia coli</italic> chaperone required for translocation of both Tir and Map</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>47</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03290.x</pub-id><pub-id pub-id-type="pmid">12492865</pub-id></element-citation></ref><ref id="B260-biomolecules-11-00316"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>A.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Translocated intimin receptor and its chaperone interact with ATPase of the type III secretion apparatus of enteropathogenic <italic>Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>2003</year><volume>185</volume><fpage>6747</fpage><lpage>6755</lpage><pub-id pub-id-type="doi">10.1128/JB.185.23.6747-6755.2003</pub-id><pub-id pub-id-type="pmid">14617638</pub-id></element-citation></ref><ref id="B261-biomolecules-11-00316"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tr&#x000fc;lzsch</surname><given-names>K.</given-names></name><name><surname>Roggenkamp</surname><given-names>A.</given-names></name><name><surname>Aepfelbacher</surname><given-names>M.</given-names></name><name><surname>Wilharm</surname><given-names>G.</given-names></name><name><surname>Ruckdeschel</surname><given-names>K.</given-names></name><name><surname>Heesemann</surname><given-names>J.</given-names></name></person-group><article-title>Analysis of chaperone-dependent Yop secretion/translocation and effector function using a mini-virulence plasmid of <italic>Yersinia enterocolitica</italic></article-title><source>Int. J. Med. Microbiol.</source><year>2003</year><volume>293</volume><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1078/1438-4221-00251</pub-id><?supplied-pmid 12868653?><pub-id pub-id-type="pmid">12868653</pub-id></element-citation></ref><ref id="B262-biomolecules-11-00316"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerschen</surname><given-names>E.J.</given-names></name><name><surname>Cohen</surname><given-names>D.A.</given-names></name><name><surname>Kaplan</surname><given-names>A.M.</given-names></name><name><surname>Straley</surname><given-names>S.C.</given-names></name></person-group><article-title>The plague virulence protein YopM targets the innate immune response by causing a global depletion of NK cells</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>4589</fpage><lpage>4602</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.8.4589-4602.2004</pub-id><pub-id pub-id-type="pmid">15271919</pub-id></element-citation></ref><ref id="B263-biomolecules-11-00316"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evdokimov</surname><given-names>A.G.</given-names></name><name><surname>Anderson</surname><given-names>D.E.</given-names></name><name><surname>Routzahn</surname><given-names>K.M.</given-names></name><name><surname>Waugh</surname><given-names>D.S.</given-names></name></person-group><article-title>Unusual molecular architecture of the <italic>Yersinia pestis</italic> cytotoxin YopM: A leucine-rich repeat protein with the shortest repeating unit</article-title><source>J. Mol. Biol.</source><year>2001</year><volume>312</volume><fpage>807</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2001.4973</pub-id><?supplied-pmid 11575934?><pub-id pub-id-type="pmid">11575934</pub-id></element-citation></ref><ref id="B264-biomolecules-11-00316"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name></person-group><article-title>Attenuation of <italic>Pseudomonas aeruginosa</italic> infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis</article-title><source>Virulence</source><year>2020</year><volume>11</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1080/21505594.2020.1776979</pub-id><?supplied-pmid 32507000?><pub-id pub-id-type="pmid">32507000</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="biomolecules-11-00316-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The general structure of the T3SS. <bold>Left</bold>: Cross-section of a prototypical T3SS with color-coded and labeled sections. <bold>Right</bold>: Table of unified names of T3SS structural components by section [<xref rid="B23-biomolecules-11-00316" ref-type="bibr">23</xref>].</p></caption><graphic xlink:href="biomolecules-11-00316-g001"/></fig><fig id="biomolecules-11-00316-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The 5 main groups of T3SS needles. (<bold>A</bold>) Ysc Group; (<bold>B</bold>) Inv-Mxi-Spa Group; (<bold>C</bold>) Esc-Ssa Group; (<bold>D</bold>) Hrp1 Group; (<bold>E</bold>) Hrp2 Group. Modified from [<xref rid="B59-biomolecules-11-00316" ref-type="bibr">59</xref>]. Abbreviations: SPI1, <italic>Salmonella</italic> pathogenicity island; SPI2, <italic>Salmonella</italic> pathogenicity island 2; OM, bacterial outer membrane; PG, bacterial peptidoglycan layer; IM, bacterial inner membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g002"/></fig><fig id="biomolecules-11-00316-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Ruler protein measuring the length of T3SS needle polymerization. (<bold>A</bold>) SS interacts with SctC to signal needle component secretion (SctF, yellow). Ruler protein (SctP, blue) assisting in SctF polymerization. SS acts as a cap to the needle and LS interacts with SctU (orange) as it is threaded through the export apparatus. SctP reaches the full length and SctF polymerization halts; (<bold>B</bold>) LS is released from SctU and SctP is secreted. SctU has a conformational change that activates the injectisome to switch to middle secretion, including the needle tip (green). Modified from [<xref rid="B74-biomolecules-11-00316" ref-type="bibr">74</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g003"/></fig><fig id="biomolecules-11-00316-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Structures of MBX 2359 and piericidin A.</p></caption><graphic xlink:href="biomolecules-11-00316-g004"/></fig><fig id="biomolecules-11-00316-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Inhibitors interacting with the T3SS needle tip. (<bold>A</bold>) Antibody inhibitors; <bold>Left</bold>: Antibody binding to the needle tip preventing binding to the translocon; <bold>Right</bold>: Antibody binding and physically preventing the secretion of effectors; (<bold>B</bold>) Small molecule inhibitors; <bold>Left</bold>: Translocation blockade caused by the inhibitor binding to the needle tip; <bold>Middle</bold>: Small molecule binding and physically preventing effector secretion; <bold>Right</bold>: Conformational change of needle tip protein caused by small-molecule binding. Image modified from [<xref rid="B102-biomolecules-11-00316" ref-type="bibr">102</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane; HCM, host cell membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g005"/></fig><fig id="biomolecules-11-00316-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Structures of Dey 1-4 and CmpdD.</p></caption><graphic xlink:href="biomolecules-11-00316-g006"/></fig><fig id="biomolecules-11-00316-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Structures of salicylidene acylhydrazides MED055, RC12, and RC20.</p></caption><graphic xlink:href="biomolecules-11-00316-g007"/></fig><fig id="biomolecules-11-00316-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Structure of 12(4,6) and 12(6,4).</p></caption><graphic xlink:href="biomolecules-11-00316-g008"/></fig><fig id="biomolecules-11-00316-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Structure of the T3SS basal body, export apparatus, and cytoplasmic complex with a list of unified protein names and functions. (<bold>A</bold>) Vertical section of the T3SS basal body and sorting platform. (<bold>B</bold>) A bottom-up view of the T3SS sorting platform. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane. *Degree of similarity between flagellar and injectisome components in <italic>Y. enterocolitica</italic>: high, <italic>E</italic> &#x0003c; 10<sup>&#x02212;5</sup>; medium, 10<sup>&#x02212;5</sup> &#x0003c; <italic>E</italic> &#x0003c; 0.01; low, <italic>E</italic> &#x0003e; 0.01 [<xref rid="B155-biomolecules-11-00316" ref-type="bibr">155</xref>].</p></caption><graphic xlink:href="biomolecules-11-00316-g009"/></fig><fig id="biomolecules-11-00316-f010" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Assembly of the injectisome base. Protein names are abbreviated by their conserved name while omitting &#x0201c;Sct&#x0201d; from the beginning. (<bold>A</bold>) Independent formation of the export apparatus within the bacterial IM; (<bold>B</bold>) Formation of the cytoplasmic complex; (<bold>C</bold>) Basal body formation around the export apparatus and connection of cytoplasmic complex. Image modified from [<xref rid="B163-biomolecules-11-00316" ref-type="bibr">163</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g010"/></fig><fig id="biomolecules-11-00316-f011" orientation="portrait" position="float"><label>Figure 11</label><caption><p>Structure of SA inhibitors INP0404 and INP0405.</p></caption><graphic xlink:href="biomolecules-11-00316-g011"/></fig><fig id="biomolecules-11-00316-f012" orientation="portrait" position="float"><label>Figure 12</label><caption><p>Periplasmic gate conformational states. (<bold>A</bold>) Closed gate state; (<bold>B</bold>) Unlocked gate state; (<bold>C</bold>) Open gate state. Image modified from [<xref rid="B177-biomolecules-11-00316" ref-type="bibr">177</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g012"/></fig><fig id="biomolecules-11-00316-f013" orientation="portrait" position="float"><label>Figure 13</label><caption><p>Structure of SA INP0010 and thiazolidinone HBF1.</p></caption><graphic xlink:href="biomolecules-11-00316-g013"/></fig><fig id="biomolecules-11-00316-f014" orientation="portrait" position="float"><label>Figure 14</label><caption><p>ATPase hexamer cycle of dephosphorylation. The tilt of the hexamer causes unfolded proteins to be &#x0201c;screwed&#x0201d; upwards through the channel and into the needle. Modified from [<xref rid="B186-biomolecules-11-00316" ref-type="bibr">186</xref>].</p></caption><graphic xlink:href="biomolecules-11-00316-g014"/></fig><fig id="biomolecules-11-00316-f015" orientation="portrait" position="float"><label>Figure 15</label><caption><p>Structures of INP1750, compound 7146, and compound 1504.</p></caption><graphic xlink:href="biomolecules-11-00316-g015"/></fig><fig id="biomolecules-11-00316-f016" orientation="portrait" position="float"><label>Figure 16</label><caption><p>Structures of Compound <bold>54</bold>, WEN03-05, W1227933, and W1774182.</p></caption><graphic xlink:href="biomolecules-11-00316-g016"/></fig><fig id="biomolecules-11-00316-f017" orientation="portrait" position="float"><label>Figure 17</label><caption><p>Structure of pseudolipasin A and exosin.</p></caption><graphic xlink:href="biomolecules-11-00316-g017"/></fig><fig id="biomolecules-11-00316-f018" orientation="portrait" position="float"><label>Figure 18</label><caption><p>Process of intimate adhesion via Tir-intimin binding in pathogenic <italic>E. coli</italic>. (<bold>A</bold>) Pathogen contacts the host cell via T3SS and secretes effectors (red), including Tir; (<bold>B</bold>) Tir incorporates into the host membrane and binds to intimin on the bacterial membrane. The N-terminus of Tir binds to focal adhesion proteins within the host. Tir&#x02019;s C-terminus interacts with multiple host factors (blue) to cause actin rearrangement; (<bold>C</bold>) Actin rearrangement causes the formation of the characteristic actin pedestal around the bacterial cell. Modified from [<xref rid="B213-biomolecules-11-00316" ref-type="bibr">213</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane; HCM, host cell membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g018"/></fig><fig id="biomolecules-11-00316-f019" orientation="portrait" position="float"><label>Figure 19</label><caption><p>Structure of Quercetin.</p></caption><graphic xlink:href="biomolecules-11-00316-g019"/></fig><fig id="biomolecules-11-00316-f020" orientation="portrait" position="float"><label>Figure 20</label><caption><p>Process of T3SS-1-related trigger internalization in <italic>S. enterica</italic>. (<bold>A</bold>) Pathogen contacts the host cell via T3SS-1 and secretes effectors, including SipA, SopE, SopE2, SopB, and SptP; (<bold>B</bold>) These effectors (red) interact with numerous host factors (blue) that lead to actin rearrangement and polymerization. SipC acts as a nucleus for actin filaments, with growth outwards from the pore; (<bold>C</bold>) Actin rearrangement causes the formation of membrane ruffling that then engulfs the bacterial cell; (<bold>D</bold>) Once within the SCV, it expresses T3SS-2 and begins proliferation. Multiple bacterial cells can be internalized within a single host cell. Modified from [<xref rid="B238-biomolecules-11-00316" ref-type="bibr">238</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane; HCM, host cell membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g020"/></fig><fig id="biomolecules-11-00316-f021" orientation="portrait" position="float"><label>Figure 21</label><caption><p>Structure of quinine and (-)-epigallocatechin gallate (EGCG).</p></caption><graphic xlink:href="biomolecules-11-00316-g021"/></fig><fig id="biomolecules-11-00316-f022" orientation="portrait" position="float"><label>Figure 22</label><caption><p>T3SS chaperone protein function. (<bold>A</bold>) Class IB chaperone protein (green) assisting effectors (orange and red) in secretion. (<bold>B</bold>) Without the chaperone, the substrate effectors cannot be secreted. There are some effectors (Effector 3, pink) that do not require chaperones and will be secreted. Modified from [<xref rid="B58-biomolecules-11-00316" ref-type="bibr">58</xref>]. Abbreviations: OM, outer membrane; PG, peptidoglycan; IM, inner membrane; HCM, host cell membrane.</p></caption><graphic xlink:href="biomolecules-11-00316-g022"/></fig><table-wrap id="biomolecules-11-00316-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">biomolecules-11-00316-t001_Table 1</object-id><label>Table 1</label><caption><p>Sequences of effectors and synthesized coiled-coil peptides. Red residues were changed to increase solubility. Greyed sequences are original to the protein.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">EspA</td><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">KANNLTTTVNNSQLEIQQMSNTLNLLTSARSDMQSLQYRTISGI</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil A</td><td align="center" valign="middle" rowspan="1" colspan="1">LTTTVNNSQLEIQQM</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil B</td><td align="center" valign="middle" rowspan="1" colspan="1">MSNTLNLLTSARSDM</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil AB1</td><td align="center" valign="middle" rowspan="1" colspan="1">K<styled-content style="color:red">M</styled-content>NNLTT<styled-content style="color:red">K</styled-content>VNN<styled-content style="color:red">L</styled-content>QLE<styled-content style="color:red">L</styled-content>Q<styled-content style="color:red">E</styled-content>M<styled-content style="color:red">R</styled-content>NTL<styled-content style="color:red">KR</styled-content>L<styled-content style="color:red">K</styled-content>SA<styled-content style="color:red">MRR</styled-content>MQ</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil AB2</td><td align="center" valign="middle" rowspan="1" colspan="1">K<styled-content style="color:red">I</styled-content>NNLTT<styled-content style="color:red">K</styled-content>VNN<styled-content style="color:red">L</styled-content>QLE<styled-content style="color:red">L</styled-content>Q<styled-content style="color:red">E</styled-content>M<styled-content style="color:red">R</styled-content>NTL<styled-content style="color:red">KR</styled-content>LK<styled-content style="color:red">S</styled-content>A<styled-content style="color:red">MRR</styled-content>MQ</td></tr><tr><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">EscF</td><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">LSDSVPELLNSTDLVNDPEKMLELQFAVQ</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil C</td><td align="center" valign="middle" rowspan="1" colspan="1">LSDSVPELLNSTDLV</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coil D</td><td align="center" valign="middle" rowspan="1" colspan="1">VNDPEKMLELQFAVQ</td></tr><tr><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">CesA</td><td align="center" valign="middle" style="background:#A5A5A5" rowspan="1" colspan="1">IVSQTRNKELLDKKIRSEIEAIKKIIAEFDVVKESVNELSEKAK</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ces A1</td><td align="center" valign="middle" rowspan="1" colspan="1">IVSQTRNKELLDKKIRSEIEA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ces A2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IKKIIAEFDVVKESVNELSEK</td></tr></tbody></table></table-wrap><table-wrap id="biomolecules-11-00316-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">biomolecules-11-00316-t002_Table 2</object-id><label>Table 2</label><caption><p>Select class II and III chaperones.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species (T3SS)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chaperone </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Binding Partner</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PDB/REF</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Aeromonas</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">AcrH</td><td align="center" valign="middle" rowspan="1" colspan="1">AopB &#x00026; AopD</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">3WXX [<xref rid="B134-biomolecules-11-00316" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AscE/AscG</td><td align="center" valign="middle" rowspan="1" colspan="1">AscF</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">3PH0 [<xref rid="B135-biomolecules-11-00316" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EPEC/EHEC</td><td align="center" valign="middle" rowspan="1" colspan="1">CesD</td><td align="center" valign="middle" rowspan="1" colspan="1">EspB &#x00026; EspD</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B136-biomolecules-11-00316" ref-type="bibr">136</xref>,<xref rid="B137-biomolecules-11-00316" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">CesD2</td><td align="center" valign="middle" rowspan="1" colspan="1">EspD </td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B138-biomolecules-11-00316" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">EscE/EscG</td><td align="center" valign="middle" rowspan="1" colspan="1">EscF</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-biomolecules-11-00316" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">CesA (CesAB)</td><td align="center" valign="middle" rowspan="1" colspan="1">EspA</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1XOU (2M1N) [<xref rid="B130-biomolecules-11-00316" ref-type="bibr">130</xref>,<xref rid="B131-biomolecules-11-00316" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">EscG/CesA2</td><td align="center" valign="middle" rowspan="1" colspan="1">EscF &#x00026; EspA </td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-biomolecules-11-00316" ref-type="bibr">129</xref>,<xref rid="B130-biomolecules-11-00316" ref-type="bibr">130</xref>,<xref rid="B139-biomolecules-11-00316" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Pseudomonas</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">PcrH</td><td align="center" valign="middle" rowspan="1" colspan="1">PopB &#x00026; PopD</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">2XCC, 2XCB [<xref rid="B140-biomolecules-11-00316" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PcrG</td><td align="center" valign="middle" rowspan="1" colspan="1">PcrV</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B141-biomolecules-11-00316" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PscE/PscG</td><td align="center" valign="middle" rowspan="1" colspan="1">PscF</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">2UWJ [<xref rid="B142-biomolecules-11-00316" ref-type="bibr">142</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><italic>Salmonella</italic> spp. (SPI1)</td><td align="center" valign="middle" rowspan="1" colspan="1">SicA</td><td align="center" valign="middle" rowspan="1" colspan="1">SipB &#x00026; SipC</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B143-biomolecules-11-00316" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SipD</td><td align="center" valign="middle" rowspan="1" colspan="1">PrgI</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">3ZQB [<xref rid="B144-biomolecules-11-00316" ref-type="bibr">144</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1"><italic>Salmonella</italic> spp. (SPI2)</td><td align="center" valign="middle" rowspan="1" colspan="1">SseA</td><td align="center" valign="middle" rowspan="1" colspan="1">SseC &#x00026; SseD</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B145-biomolecules-11-00316" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SseA</td><td align="center" valign="middle" rowspan="1" colspan="1">SseB</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B146-biomolecules-11-00316" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SsaH/SsaE</td><td align="center" valign="middle" rowspan="1" colspan="1">SsaG</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B147-biomolecules-11-00316" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Shigella</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">IpgC</td><td align="center" valign="middle" rowspan="1" colspan="1">IpaB &#x00026; IpaC</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">3GYZ [<xref rid="B148-biomolecules-11-00316" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Spa13</td><td align="center" valign="middle" rowspan="1" colspan="1">MxiH</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B149-biomolecules-11-00316" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Yersinia</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">SycD</td><td align="center" valign="middle" rowspan="1" colspan="1">YopD &#x00026; YscO</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">4AM9 [<xref rid="B150-biomolecules-11-00316" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">LcrG</td><td align="center" valign="middle" rowspan="1" colspan="1">LcrV</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B151-biomolecules-11-00316" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YscE/YscG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YscF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2P58 [<xref rid="B152-biomolecules-11-00316" ref-type="bibr">152</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>